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Mankind’s greatest attribute is the capability of higher order intellect being applied to
prolonging life and improving one’s overall health. Modern medicine and the research therein has
created opportunities to understand and combat disease at incredible levels. Yet, some of the most
befuddling diseases are ones that our own bodies inheritably produce. Autoimmune disease is a
condition in which the body’s own defense mechanisms begin to target healthy cells as if they
were foreign threats. Cancer is a condition in which abnormal cell growth can spread throughout
the body and begin to shut down vital bodily functions. Medicinal chemistry has difficulty
combating and understanding such diseases due to the fact that intervention targets of the disorders
are derived from human anatomy. The research presented within aims to aid in the scientific
understanding of the two diseases discussed.
Part I: Lipids isolated for Porphyromonas gingivalis have been recently implicated in
possible development and/or progression of multiple sclerosis. The lipids are produced in bacteria,
which are found throughout the GI track, and are shown to invade into the body. First, this study
is intended as a structural proof and stereochemical elucidation of the proposed lipid compounds
labeled lipid 430 and 654. Second, synthesis of stereochemically pure material is needed for further
biological testing to establish a greater understanding of disease implications. We present

Christopher James Dietz, Ph.D.
University of Connecticut 2017
the details of the convergent synthesis of lipids 430 and 654, which confirm the proposed structure
of P. gingivalis lipid 654 to be (3R and 3S)-L-serine. The bis(fatty acid) (3R)-L-serine 2 was
prepared as well as the synthetic precursor, serine dipeptide mono-fatty acid (3R)-L-serine 1,
which is the structure of lipid 430. We also synthesized the (3S)-L-serine diastereomer 2 as well
as (3S)-L-serine 1. Using these synthetic standards, we confirmed that phospholipase A2 (PLA2)mediated hydrolysis of lipid 654 is enantioselective in that only the (3R)-L-serine 2, but not (3S)L-serine

2 is enzymatically hydrolyzed.

Part II: Cancerous tumors have been shown to have a hypoxic microenvironment that
creates resistance to radiation therapy and ineffectiveness of common chemotherapy drugs. There
is a need for improved noninvasive imaging techniques that detect hypoxic tumors and monitor
the effects of administered cancer treatments. To do this we have synthesized hypoxic targeting
fluorescence probes derived from FDA approved Indocyanine green dye to be used for optical
imaging. Extending our previous work with 2-nitroimidazole-piperazine-indocyanine dyeconjugate 3, we prepared the 4-nitroimidazole-piperazine-indocyanine derivative 12. We also
prepared imidazole derivative 14 as a control. We compared the in vivo hypoxia targeting
performance of both with the previously tested 2-nitro dye conjugate, and the 4-nitro derivative
showed a higher fluorescent intensity after 15 min post-injection. All findings were supported with
fluorescence images of histological sections of tumor samples an immunohistochemistry technique
for tumor hypoxia. New generations of the dyes are being created to increase the efficiency of the
imaging technique.
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Convergent Total Synthesis of Bioactive Dipeptide–Lipids Isolated
from Porphyromonas gingivalis: Possible Biomarker for Multiple
Sclerosis
1.1 Introduction
1.1.1 Disease, introducing the human microbiome
Chemistry, the study of matter, and biology, the study of life, can be linked in a number of ways.

Medicinal chemistry is the nexus of modern chemistry and biology. Today, nothing is more
important than the collaboration between the two sciences and how this plays in the development,
progression, and regression of human disease.
Disease is classified as a disorder in the structure or function of a living organism. The
causes of such conditions are seemingly endless. However, the vast majority of diseases are caused
by either viruses or bacteria. Viruses, often with extremely complicated pathology, are seemingly
simple to understand as to how they can cause disease. They infect human cells and force their
exponential reproduction. The chemistry behind this can be extremely complex, but the underlying
fact that the infecting agent is on the inside of the cell gives almost definite cause to why or how
a viral disease can exist. On the other hand, bacteria produce disease through a wider group of
pathogenic mechanisms, some of which are progressively being studied and befuddling
researchers as to how they can interact with the human body and its anatomy.
It is easy to understand how a disease can develop from a bacterial infection including
invasion and proliferation within the human body. It is like an invader behind enemy lines. On the
contrary, the human microbiome, "the ecological community of commensal, symbiotic and
pathogenic microorganisms that literally share our body space", has begun to grasp the attention
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of scientists due to the extreme complexity of the relationship between the human body and its
symbiotic partners.1 For this reason, the human microbiome has become an area of utmost interest
in disease relations over the past few decades.
The Human Microbiome Project (NMP) can be looked at as a continuation of the Human
Genome Project. Its Goals include: (1) characterize the human microbiome and (2) Determine the
relationship between heath/disease and changes in the biome.2 The ratio of bacteria to human cells
of an average human has been estimated to 1.3. The vast majority reside on internal and external
surfaces of the human body including the; gastrointestinal track, urinary track, skin, saliva, oral
mucosa, and conjunctiva.3 This microbial community has been associated with the heath and
disease of host multicellular organisms with roles in physiology, metabolism, immunodeficiency,
and hypersensitivity.4

1.1.2 Multiple Sclerosis (MS)
Autoimmune disorders incorporate nearly 80 different diseases and are considered a
leading cause of death and disability, with nearly 24 million reported cases in Americans.5 This
number could be much higher due to the number of undiagnosed patients. Such disorders are a
result of the human immune system becoming unable to recognize self from non-self. Normally
the immune system responds to foreign materials and has built in safe ways to avoid attacking its
own tissues.6 When this mechanism breaks down, the body begins to combat healthy cells/tissues
of various organs including the pancreatic beta cells in diabetes, the joint synovia in rheumatoid
arthritis and the central nervous system in multiple sclerosis, resulting in autoimmune disease.

2

Multiple sclerosis (MS) is one of the more severe autoimmune diseases, as it affects more
than 2.3 million people worldwide. The disorder is considered chronic as symptoms range from
blurred vision or poor coordination, to more severe effects such as paralysis or blindness. The
symptoms differ in every patient, can be permanent or episodic, and often worsen overtime. The
disease is found in patients of all ethnicities and can be diagnosed at any age as symptoms develop.7
One of the most significant problems with MS is the difficultly of diagnosing the disease.
To date, no single laboratory test is available for disease identification. This is extremely
problematic because most common treatments aim to suppress the body’s immune system which
can drastically increase the risk of further illness and infection. Instead of testing for the MS, one
is evaluated for common symptoms and cross examined to rule out any other possibile
explanations of causality. Physicians test mental functions, movement mobility, and vision for
insight into the disease. When significant abnormal neurological findings are apparent, the use of
magnetic resonance imaging (MRI) and invasive techniques are used to provide confirmatory
evidence that MS is the cause. In 2010, the Revised McDonald Criteria was published by the
international panel on diagnosis of multiple sclerosis.8 This gives the most accurate test to date, as
it gives strict guidelines for using the
MRI to speed up the process of diagnosis.
However it is far from a positive test, as
it simply aims to visualize damage that
may be the result of MS.
Within the human body, Multiple
Sclerosis is characterized as the immune
system

producing

an

inflammatory

Figure 1. Example of myelin destruction resulting from
autoimmune disease.63
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response within the central nervous system.9 This causes damage to cells that make up the signaling
pathways of this delicate system. Though there is many theories discussed, the onset and
progression of the process remains poorly understood. The universally accepted belief is that MS
results from the body’s self-produced T cells, a subclass of white blood cells, attack the CNS
myelin surrounding nerve cells.10 The biochemistry for the inflammatory response is unknown but
can be facilitated by a number of factors, including environmental factors.
The causes of MS are not exactly established, however researchers have suggested several
possibilities of factors that could contribute to disease progression. Genetic factors are thought to
play a small roll but there is evidence that the illness isn’t directly inherited.11 Habits and
environment are thought to play a larger roll. Populations further from the equator have increased
frequencies of MS and attribute this to vitamin D deficiencies. Cigarette smoking has also proven
to increase the possibility of developing symptoms of the disease. In totality, the disease is thought
to be contributed to 4 causes: immunology, genetics, environmental, and infection factors.
Understanding the reason for the autoimmune response could shed light onto the prevention,
treatment, and/or detection of the disease.12 Reading further will shift focus towards the role that
human microbiome might play in the pathology of the disease and what evidence this might
suggest.

1.1.3 Porphyromonas gingivalis
Inflammatory periodontal disease in adults is initiated with the accumulation of specific
bacteria in the sulcus around the teeth, followed by a chronic inflammatory reaction by the host
against the colonizing microorganisms. Periodontitis is labeled as an oral inflammatory gum
disease that effects the tissues needed to support the teeth.13 Often, progression of periodontitis
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leads to loss of bone in the jaw and eventually tooth loss. The disease is proceeded by certain forms
of gingivitis that may be directly caused from bacterial biofilms, or plaques, that buildup on tooth
surfaces. Several microorganisms are associated with gingivitis/periodontitis, but substantial
studies have implicated Porphyromonas gingivalis as a major pathogen in the destructive form of
periodontal disease.14
P. gingivalis is an anaerobic, rod-shaped, non-motile, Gram-negative bacteria found in the
oral cavity and the digestive track.15 Expanding upon the implications P. gingivalis displays in
dental disease, evidence has suggested that this bacterium may play a role in autoimmune
disorders.16 Rheumatoid arthritis is another such autoimmune disease associated with periodontal
disease. P. gingivalis has been shown to contain an enzyme arginine deiminase (ADI) that can
modify protein amino acid arginine to citrulline.18 This transformation is called citrullination.
Citrullinated proteins are recognized/attacked by the immune system and can be considered a
direct cause of autoimmune diseases that result from the body trying to defend itself from its own
proteins.
Several studies have reported findings of P. gingivalis’ role in pathogenesis of the central
nervous systems inflammatory response, leading to the aggravation of MS.18 It is not understood
exactly how or why this happens, but it has been shown that peripheral bacteria in the
gastrointestinal track can trigger autoimmune reactivity. This is thought to be the result of the body
recognizing agonists that are produced by the bacteria, not necessarily bacterial infection per se.
These agonists can be bound to receptors of external tissue cells. Our work leads to the idea that
P. gingivalis activates in the innate immune system and in such a way to lead to multiple scleroses.
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1.1.4 Toll-Like Receptors (TLRs)
The innate immune system, or non-specific immune system, is an important part of the
overall immune system. It protects the body from developing infection from microorganisms.
Sentinel cells are the body’s first line of defense verses pathogens derived from microorganisms
that pose potential threats. There is a class of receptor proteins that are embedded in the sentinel
cell’s membranes that are designed to recognize such structural molecules. The general receptor
class is known as Toll-like receptors (TLRs).19 Their mode of action is triggered by binding
pathogen’s, small molecules, located on the exterior of the bacteria and are produced by a wide
range of microbes. The interaction with these stimuli cause a cascade of signaling pathways inside
tissues to activate the innate immune system to fight the foreign invading microbes.20
A total of 13 TLRs are known to exist, conveniently labeled TLR1- TLR13, with the first
11 being found in humans. Each receptor has the ability to recognize certain aspects of structurally
similar molecules that are shared by a broad range of pathogens. A recent study has shown that
TLR2 and TLR4 can play a direct role in CNS damage associated with multiple sclerosis.21
Ligation to these receptors causes a cascade effect in the immune system that ultimately leads to
leukocyte migration across the blood-brain barrier. This is problematic to the nervous system as
white blood cells begin to destroy the protective coating, myelin, of nerve cells. Worse yet, through
a similar mechanism, differentiation of regulatory T cells is inhibited. The regulatory T cells play
an important role in suppressing CNS autoimmunity.22
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Figure 2. Toll-like receptors in Multiple Sclerosis.
Ligation of TLR2 and TLR4 induces the production of IL1, IL6 and IL12, which induce the differentiation of naïve T
cells into Th1 and Th17 cells. Th17 and Th1 cells secrete IL17 and INFγ respectively. IL17/INFγ-producing cells
facilitate leukocyte migration across the blood-brain barrier and contribute to CNS damage. IL1 and IL6 also inhibit
the differentiation of induced regulatory T cells (iTregs). Tregs are a major source of IL10, a cytokine that plays a
critical role in suppressing CNS autoimmunity. Activation of TLR3, TLR7 and/or TLR9 can lead to the production of
IFNβ, which activates T suppressor cells and inhibits the production of IL17 and IL23. 21
Reprinted directly from Miranda-Hernandez, S.; Baxter, A. G. Am. J. Clin. Exp. Immunol. 2013, 2, 75-93.

Toll-like receptor 2 (TLR2) is known to recognize a broad class of structures from micro
bacteria. Many of the substrates that do this closely resemble lipoproteins or fatty acids.23 A recent
report revealed that the lipid extract from P. gingivalis promotes activation of mouse dendritic
7

cells and inhibits osteoblast-mediated bone deposition through engagement of TLR2.24 Studies
originally claimed that Porphyromonas gingivalis lipoprotein, lipopolysaccharide (LPS), and
ﬁmbriae were the cause for TLR2 activation.25 However, the extent these products mediate such
reactions is disputed.26 Upon further investigation, specific serine containing lipids isolated from
P. gingivalis were structurally characterized and proven to be TLR2 ligands.27

1.1.5 Potential Serum Biomarker for MS
The role that P. gingivalis plays in the progression of gingivitis and periodontal disease
can be directly correlated to the ligation of the bacteria’s pathogens to TLR2. Inflammation of the
gums is a major part of the disease. However, as stated earlier, P. gingivalis and similar commensal
bacteria may be contributing to the inflammatory response of the central nervous system in MS.
This potential etiologic environmental factor can give definite evidence towards a mechanism or
causality. But the study of the bacteria populating the GI tract could lead to a diagnostic aid,
progression predictor, and/or possible target for therapeutic intervention for multiple sclerosis.
Recently, lipidomic work done by Clark et al at the University of Connecticut Health
Center, showed that one of the serine lipids of P. Gingivalis, Lipid 654 (2), is detectable in the
blood serum of all individuals.28 This was done using multiple-reaction-monitoring (MRM) mass
spectrometry. The most important finding in this work was that this lipid was found at significantly
lower levels in patients diagnosed with MS. This was compared to the serum of healthy individuals
and patients with Alzheimer’s disease. This result, along with the involvement the serine lipids
have in TLR activation, create a need for structural validation and stereochemical elucidation

8

1.1.6 Serine Lipid Targets

Lipid 1 and 2 are the hypothesized structures of the bioactive ligands responsible for TLR2
activation and are commonly observed in chronically inflamed human tissues.27 They were
deduced using nuclear magnetic resonance (NMR) and tandem mass spectroscopy (MS/MS). The
lipids are composed of a serine glycine dipeptide in an amide linkage to a 3-OH isobranched (iso)
C17:0 fatty acid. This base compound is labeled lipid 430 (1) which is indicative of its mass. The
3-OH iso-C17:0 fatty acid moiety may form a 3-OH ester linkage to a saturated fatty acid, most
frequently to iso-C15:0. This esterified lipid is labeled lipid 654 (2).
A search of the literature indicated that this structure was originally proposed for a serine
lipid product isolated from a limited number of Flavobacteria and was termed flavolipin.29-32 We
have also observed that lipid 430 was produced by enzymatic hydrolysis of lipid 654 and was,
therefore, a logical synthetic precursor. Other fatty acids can substitute into these lipid classes, but
they are less abundant relative to branched C15:0 and 3-OH iso C17:0.33 Both of the serine dipeptide
lipids, lipid 430 and lipid 654, are recovered in lipid extracts of P. gingivalis, but lipid 430 is
recovered in low levels compared with lipid 654. Chiral GC-MS analysis showed that the serine
lipids only contained L-serine stereochemistry. The absolute configuration of the β carbon of 3OH iso C17:0 fatty acid portion of the lipids was not as easy to elucidate. To do this the lipids would
need a high level of quantification and difficult derivations to run 2D NMR experiments.
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1.1.7 Phospolidase A2
Previously, catalytic deesterification of P. gingivalis derived lipid 654 to lipid 430 was
observed using commercially available preparations of phospholipase A2 (PLA2).33 PLA2 is an
important enzyme in the release of arachidonic acid from glycerol-based phospholipids and levels
of this enzyme are increased in chronically inflamed tissues. However, it was noted that a portion
of lipid 654 isolated from P. gingivalis was not hydrolyzed by PLA2. Chiral fractionations show
about 10-15% of one isoform and 85-90% of the other 654 isoform. In the P. gingivalis derived
654, recent HPLC analysis with direct infusion into the mass spectrometer suggest that the one
isoform is less than 10%. These results suggest that enzymatic hydrolysis is stereospecific.
Identification of the stereochemistry of 1 and 2, as well as confirmation of which isoform is
selectively hydrolyzed, required verification by total synthesis for enzymatic hydrolysis studies.

1.1.8 Literature Synthetic Approaches to Target Lipids
This investigation aimed to prepared both (3R) and (3S)-L-serine-lipid 430 and thereby
both (3R) and (3S)-L-serine-lipid 654 and to ascertain if only one diastereomeric form of synthetic
lipid 654 was susceptible to PLA2 enzymatic hydrolysis. If selective hydrolysis is observed, the
diastereospecificity of the partial hydrolysis of P. gingivalis lipid 654 by PLA2 would be
confirmed. This could be accompanied by the role that the diastereomers play in TLR2 ligation.
The biological activity associated with lipid 654 and lipid 430 is sufficiently important that
synthesis is a priority for structural verification, the accumulation of synthetic standards, and the
preparation of each lipid in sufficient quantity for further biological evaluation.
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Structure 2 has been reported as an isolate from several natural products. Uchida and
coworkers isolated dipeptide lipids from Flavobacterium sp. No. 3559, and the compound labeled
WB-3559 D.29 In this work, WD-3559 D was shown to be a platelet aggregation inhibitor, and
stimulated mouse plasma euglobulin clot lysis time. Kawai and coworkers identified a serinecontaining lipid along with ornithine containing lipids from extractable cellular lipids in
Flavabacterium meningosepticum and F. indologes, which are opportunistic pathogens.30 The
serine-containing lipid was identified and shown to be an immunoactivator that exhibited
immuomodulator activity, and it was also identified as a blocking agent against endotoxemia.31
Finally, Andoh and coworkers isolated a dipeptide lipid from strain B-572 of Flexibacter
topostinus sp. nov. and it was named topostin D640.32 Topostins are inhibitors of mammalian DNA
topoisomerase I (topo I). All of these isolated compounds were deduced a structure of what we
call lipid 654 (2). To date, these biological results have led to three synthetic strategies for
structural validation and stereochemical correlation of the lipid.

Scheme 1. Synthesis from Uchida et al.34

Uchida and coworkers were the first to isolate and synthesize Lipid 654 (2).29,34 Their
synthetic strategy started with aldehyde 3, (3aR,5S,6aR)-2,2dimethyltetrahydrofuro[2,3d][1,3]dioxole-5-carbaldehyde, functionalized from D-glucose in 10 steps.35 The isobranched lipid
chain was built into the complexity of the molecule via Wittig reaction with separately prepared
11

11-methyl dodecyltriphenyl- phosphorane to produce olefin 4. Hydrogenation over Adam’s
catalyst and cleavage of the isopropylidene ketal, afforded the cyclic diol that was cleaved with
sodium periodate and oxidized to produce (3R)-hydroxy-15-methylhexadecanal (5R). This
sequence of reactions led to an overall yield as high as 41% in 7 synthetic steps.
Uchida and coworkers then reported a linear synthesis of lipid 654 from the crucial
intermediate 5R.

Glycine benzyl ester and 13-methyltetradecanoic acid were coupled via

amidation using N-hydroxy succinimide to activate the acid moiety and simple acid chloride
acylation of the β hydroxy group respectively. The stepwise elongation was finished by hydrolysis
deprotection of the benzyl ester and similar acid activation coupling with L-serine. From the steps
that were reported, lipid 2R was produced in 27% yield over 13 steps, from complex starting
material 3.

Scheme 2. Synthesis from Shiozaki et al.36

Shiozaki and coworkers prepared β hydroxy acid 5S in 7 steps from the same aldehyde (3)
as Uchida, however this was done in a different schematic manner.36 Reduction of the aldehyde
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and benzyl protection led to compound 6. This 3-deoxy-pentose derivative was deprotected to the
hemiacetal before treatment with sodium borohydride to open the ring between the oxygen and
carbon 1 to produce the triol backbone for compound 7. Protection of this triol ultimately yielded
7. Sequential silyl ether cleavage, followed by Swern oxidation and a Wittig reaction with prepared
11-methyldodecyltriphenylphosphorane gave olefin 8. This produced the scaffold for isobranched
lipid chain in a similar manor as the previous synthesis, but utilized the oxygen atoms in a different
orientation to produce the opposite enantiomer.
Compound 8 was subjected to hydrogenation conditions, reduction of the alkene and a
global deprotection. Then the vicinal diol was cleaved with sodium periodate before ultimately
being oxidized to β hydroxy fatty acid 3S. The acid was esterified with diphenyl diazomethane,
the hydroxyl group was acylated with 13-methyltetradecanioic acid, then hydrogenolysis yielded
acid 9. Tandem coupling/hydrogenolysis of glycine benzyl ester and then L-serine benzyl ester
respectively, yielded lipid 2S. The 19 step synthesis from D-glucose produced the product lipid in
a reported 4% overall yield.

Scheme 3. Synthesis from Shioiri et al.37
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Shioiri and coworkers synthesized lipid 2R from economically friendly 1,10-decanediol.37
Starting by stoichemetric benzylation followed by Swern oxidation of the free alcohol, allowed for
the production of olefin 10 via Wittig reaction with isoamyltriphenylphosphonium bromide.
Therefore the isobranched lipid chain was built into the molecule very efficiently. Catalytic
hydrogenation over palladium-carbon would result in the reduction of the alkene and deprotection
of the benzylated alcohol. Then oxidation to the carboxylic acid proceeded a magnesium enolate
anion coupling of ethyl hydrogen malonate to afforded β keto ester 11.38 Asymmetric
hydrogenation via ruthenium (II) catalyst system with (R)-BINAP as a ligand produced β hydroxy
acid 5R after saponification.
Much like the other syntheses, the final steps utilized a stepwise elongation of the molecule.
First, condensation with glycine tert-butyl ester and O-acylaation with 13-methyltetradecanoic
acid. Then, acid deprotection of the tert-butyl ester before coupling with L-serine benzyl ester and
sequential deprotection, yielded lipid 2R. This was the most efficient and nearly enantiomerically
pure synthesis, achieved in 13 steps in a linear sequence that utilized asymmetric hydrogenation
of a β-keto ester intermediate in an overall yield of about 11%. It also should be noted that this
procedure is the only one that could yield both enantiomers of 5 with identical procedures.
Each synthesis incorporated unique and creative transitions throughout. The major goal
was to produce intermediate 5 as efficiently and stereospecifically as possible. Chiral starting
materials allow for the production of this lipid chain enantiomerically pure. However
stereospecific production in the later stage of shiori’s work, allowed for the production of both
enantiomers. All three strategies chose to build the tagets in a stepwise elongation from the
produced lipid chain. Since the β-hydroxy acid 5 is valuable material, a convergent synthesis could
be utilized to increase yields, as it would carry material through less synthetic steps.
14

1.1.9 Retro Synthesis of Target Lipids
The synthetic goal was to verify the structural identity of lipid 654 (2), which would
correlate with the previously identified and synthesized flavolipin. The previous syntheses
produced hydroxy acid 5, which could be converted to serine-glycine derivative 1, which we
believed to be lipid 430. While the stereochemistry of our lipid 430 and lipid 654 were unknown,
our previous work indicated that the serine dipeptide lipids of P. gingivalis are primarily
constituted with L-serine. This assumption is also consistent with previous reports of 2 by Uchida,
Shiozaki, and Shioiri.

Scheme 4. Retro synthesis of L-serine lipids

Our retrosynthesis began with cleavage of the labile ester linkage from the putative
structure for lipid 654 (2), which generated the putative structure of lipid 430 (1) and 13-
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methyltetradecanoic acid (16). Disconnection of the peptide linkage to the β-hydroxy fatty acid
moiety in 12 gave the L-serine-glycine dipeptide 14 and β-hydroxy acid derivative 11. We therefore
envisioned a convergent strategy that utilized elements of our previous work that would take
advantage of the previously published syntheses to prepare 1 and then 2 using a protected L-serineglycine dipeptide 14.

We believed that this approach would allow us to generate both

diastereomers of L-serine 1 and of L-serine 2, and in a shorter linear synthesis than previously
reported.
Disconnection of 11 led to an acetate surrogate and 13-methyltetradecanal, 15.
Disconnection of 14 led to protected serine and glycine derivatives 17 and 18. Aldehyde 15 can
be prepared from 13-methyltetadean-1-ol (16) using previously published coupling of the Grignard
reagent prepared from 1-bromo-2-methylpropane with 11-bromoundecan-1-ol.39 We planned a
coupling reaction of ethyl diazoacetate with 15 to give a β-keto ester 11.40 Subsequent reduction
of the ketone, followed by saponification, would generate the racemic β-hydroxy acid, 5. One
approach could use the asymmetric hydrogenation procedure reported by Shioiri.37 Alternatively,
a classical resolution of this β-hydroxy fatty acid would yield each enantioenriched product.
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1.2 Results and Discussion
1.2.1 Synthesis of Lipid 430 and Lipid 654
The initial steps of the synthesis focused on the fatty acid portion of the targeted lipids and
the preparation of 16, based on our published synthesis of dihydroceramides isolated from P.
gingivalis.41 The Grignard reagent prepared from 1-bromo-2-methylpropane was coupled to 11bromoundecanol, in the presence of a lithium tetrachlorocuprate complex. A large excess of
Grignard reagent was used to convert the alcohol to an alkoxide in situ, thus avoiding the use of a
protecting group. The use of excess reagent can be avoided if 11-bromoundecanol is protected
prior to the coupling reaction and additives are incorporated. In the latter case, however, there was
a decrease in overall yield mainly attributed to the handling over the three steps. The fact that 2methylbromopropane is much cheaper than the other reagents led us to use the unprotected alcohol
in the coupling step. Oxidation of alcohol 16 with an oxoammonium reagent “Bobbitt’s salt” (4acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl) yielded aldehyde 15 with no over-oxidation to
the acid.42 Upon exposure to air at ambient temperature, this aldehyde proved to be rather unstable,
with rapid oxidation to the carboxylic acid 13. If aldehyde 15 was maintained in wet THF solution
until needed, the yield was near quantitative for the oxidation step and 91% from starting material
11-bromoundecanol.
The β–Keto ester 11 was prepared by the reaction of 16 with ethyl diazoacetate in the
presence of catalytic tin (II) chloride, using the protocol developed by Roskamp et al.40 Under
these conditions, ester 11 was obtained in 80-90% yield under very mild conditions, although small
amounts of carboxylic acid 13 were also observed. Reduction of the ketone moiety with sodium
borohydride generated racemic β–hydroxy ester 19. Saponification using lithium hydroxide
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yielded racemic β-hydroxy acid 20 in an overall yield of 62% from starting material 11bromoundecanol.

Scheme 5. Synthesis of β-hydroxy acids.

Our first attempt to generate enantiopure or enantioenriched β-hydroxy acid relied on an
enzymatic resolution of racemic 20. Sugai and Ohta reported the use of a Pseudomonas lipase with
vinyl acetate for the enzymatic transesterification of 2-hydroxytetracosanoic acid.43 Mori and
coworkers used lipase PS and vinyl acetate to resolve 3-hydroxy-15-methylhexadecanoic acid
(20), and used the (3R)-hydroxy-15-methylhexadecanoic acid provided by this procedure in a
synthesis of sulfobactin.44 We applied this enzymatic resolution technique to compound 20, using
commercially available Amano lipase PS. After several attempts, our best result provided (3R)18

20 in about 77% ee and (3S)-20 in about 79% ee, based on the conversion to the respective
Mosher’s ester followed by 1H NMR analysis that showed a 84R:15S mixture and a 11R:89S
mixture.45 We modified the exposure time of racemic 20 to the lipase, but we observed no
improvement in enantiomeric enrichment.
A traditional resolution of the acid using brucine was also attempted. Racemic β-hydroxy
acid 20 was heated at reflux with brucine in different polar solvents (methanol, ethanol, acetone,
and chloroform). We obtained crystals from the reaction in chloroform, but all attempts to separate
the diastereomeric salts failed because the resolving agent co-crystallized with both diastereomers
under all conditions examined. We therefore abandoned this approach.
We obtained 20 in high enantiopurity using the asymmetric hydrogenation approach
reported by Shioiri with β–keto ester 11.37 Catalytic hydrogenation of the ketone moiety in 11
using ruthenium catalyst complexed with (S)-BINAP or (R)-BINAP as chiral ligands led to βhydroxy esters (3S)-19 and (3R)-19 respectively. The specific rotation of each β-hydroxy acid
21

21

revealed [α] 𝐷 +14.5 and [α] 𝐷 –10.5 (c 1.0, CHCl3) for the (R) and (S) enantiomers respectively.
Shioiri reported the specific rotation of (3R)-10 to be [α]

21
𝐷

–12.5° (c 1.02, CHCl3).37 To confirm

our results, we prepared Mosher’s esters of these compounds, and 1H NMR analysis indicated that
(3R)-19 was formed in 98 % ee and (3S)-19 was formed in 98 %ee.45 These samples were
subjected to the LiOH saponification conditions to yield (3R)-20 in 68 % and (3S)-20 in 70 %,
respectively, over 5 steps from 11-bromoundecanol.
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Scheme 6. Synthesis protected serine-glycine dipeptide.

The glycine-serine dipeptide portion of lipid 654 was prepared using standard
methodology. The amino group of glycine was protected as the benzyl carbamate to produce amino
acid derivative 18. Both the carboxylic acid and alcohol moieties of L-serine required protection
to avoid undesired byproducts in the planned couplings. The reaction of L-serine with thionyl
chloride in methanol gave the L-serine methyl ester, which reacted with tert-butyldimethylsilyl
chloride to give the protected derivative 17. Dipeptide 14 was prepared by coupling the amino
portion of 17 to the carboxyl group of 18 using DCC, where HOBt was used to generate the needed
activated ester.
The coupling reaction of deprotected 14 and 20 proved challenging. Peptides with free
amines, especially ones containing glycine, are known to undergo cyclisation to form a
diketopiperazine derivative.46 Dipeptides substituted with an amine at one terminus and an ester at
the other can spontaneously cyclize to form a 2,5-DKP at a range of pH. Deprotection of the amino
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moiety by hydrogenation of dipeptide 14 using a palladium catalyst gave almost exclusively the
DKP product and little coupling to give 12. Formation of this unwanted product could be partially
suppressed with the addition of methanolic HCl to protonate the amine, but we were unable to
isolate 14 free of DKP. Attempts to couple the HCl salt of 14 with β–hydroxy acid 20 failed and
coupling was only observed upon neutralization of the amine salt. The addition of a stoichiometric
amount of base led to the DKP and the yield of our coupling product was only 30-40%.
Methodology developed by Shute and Rich for the coupling of dipeptides to tetrapeptides
provided a solution to the coupling problem Activation of acid 20 with N-hydroxysuccinimide
formed the reactive ester and this crude product was added to the hydrogenolysis reaction of
dipeptide 14.47 The presence of the activated ester gives a competitive reaction against the
formation of undesired DKP product and facilitated the production of (Rac)-12. When 12 was
obtained, deprotection with TBAF followed by LiOH saponification gave (Rac)-1 (75% yield).
Using an identical procedure beginning with (3R)-20, we obtained (3R)-1 in 68% yield, and using
(3S)-20 in the sequence gave (3S)-1 in 71% yield. Spectroscopic evaluation demonstrated that 1
correlates with the proposed structure of lipid 430 and the biological evaluation confirmed this
conclusion.
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Scheme 7. Synthesis of Lipid 430 and 654.

The final synthetic step was esterification of the alcohol moiety in (Rac)-12 with fatty acid
13. A DCC mediated coupling gave product (Rac)-22 in > 90% yield. The use of EDC did prove
to make the ease of purification easier but did lower yields of the transformation. The sensitivity
of the ester linkage in the lipid 654 derivatives led to deprotection of 12 and 22 using two different
methods. First, the silyl ether was removed using tetrabutylammonium fluoride to liberate the
hydroxyl derivative of the serine moiety. The desilylation of lipid derivative 22 was done in the
same manner as before but a different hydrolysis of the methyl ester was used because
22

saponification of the fatty acid occurred under basic conditions. After treatment with TBAF,
reaction with potassium trimethylsilanolate led to (Rac)-2.48 This SN2 type of deprotection was
successful, but the yield was lower over the two steps, giving 66% of (Rac)-2. In an identical
manner, (3R)-22 gave (3R)-2 (58%) and (3S)-22 gave (3S)-2 (67%). Spectroscopic analysis of
(3R)-L-serine-2 showed that it correlates structurally with lipid 654.

1.2.2 Synthesis of Deuterium Labeled Lipids
In order to implicate this lipid class in human disease, accurate quantification of Lipid 654
requires supplementing biological samples with a stable isotope internal standard for subsequent
quantification using conventional mass spectrometric approaches. For this reason the preparation
of a deuterated serine lipid internal standard (25) for use in quantifying 2 in biological samples.
In addition to quantifying the bacterial lipid 2 in biological samples, the deuterated lipid standard
24 can also be used for the evaluation of enzymatic hydrolysis of the parent lipid by known
esterases as well as peptidases. In addition, the deuterated lipid 25 can be used for evaluation of
metabolic breakdown of 2 by cells important in chronic inflammatory disease processes associated
with the accumulation of bacterial serine dipeptide lipids.
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Deuterium labeled serine dipeptide lipid was successfully prepared for use in the analysis
of biological samples. The first step was to prepare the non-deuterated straight chain fatty ester
dipeptide via procedures that mimic the convergent synthesis of lipids 430 and 654 mentioned
previously.49 The straight chain non-deuterated lipids 26 and 27 were used as a control to correlate
the spectral data for the production of deuterated lipids. We first protected the commercially
available 11-bromoundecanol as the dimethyl(t-butyl)silyl derivative, 28, in 61% yield. The
Grignard reagent prepared from 1-bromobutane was coupled to 28, in the presence of a lithium
cuprate complex with N-methylpyrrolidone (NMP) as an additive. The use of NMP as well as a
catalytic amount of lithium tetrachlorocuprate is an alteration to the previous synthesis and will be
elaborated upon in the deuterium labeled production. Deprotection of 28 and oxidation with the
oxoammonium salt known as Bobbitt’s reagent provided pentadecanal 31 in 80% yield. Coupling
with ethyl diazoacetate gave 32 (89.6%), using our standard methodology and reduction with
NaBH4, followed by deprotection with LiOH, afforded β-hydroxy acid 34 in 65% yield. Coupling
of 34 and the previously prepared protected dipeptide 14 using N-hydroxy succinimide activated
ester in the presence of hydrolysis of the N-Cbz group by catalytic hydrogenation, gave 35 in 67%
yield. Deprotection of the ester of serine protecting groups afforded 26 in 68% yield, whereas
esterification with 13-methyltetradecanoic acid gave 36 in 63.4% yield. Deprotection gave 27 in
50% yield. The overall conversion for the linear sequence of 9 steps to 26 was 6% overall yield,
whereas the linear sequence of 11 steps gave 27 in 3% overall yield.
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Scheme 8. Synthesis of non-deuterated straight chain lipid 654.

Reagents: (a) TBDMSCl, imidazole, 97.7%; (b) (i) 1-bromobutane, Mg0, THF (ii) CuCl2, LiCl, NMP, 93%; (c) TBAF,
87.4%; (d) Bobbitt’s salt, SiO2, 90.8%; (e) SnCl2, ethyl diazoacetate, 89.6%; (f) NaBH4, 77.6%; (g) LiOH, 83.6%; (h)
(i) NHS, EDC, DMAP (ii) Pd/C, H2, 67%; (i) (i) TBAF, 80.5% (ii) LiOH, 84%; (j) 13-methylpentadecanoic acid,
EDC, DMAP, 63.4%; (k) (i) TBAF, 76.1% (ii) KOSi(CH) 3, 65%.

Following a similar synthetic methodology, the synthesis of deuterated lipids initially
focused on the fatty acid portion of the lipid and the preparation of 42. To avoid undesired
reactivity of expensive deuterated Grignard reagent with the acidic hydroxy proton, commercially
available 11-bromoundecan-1-ol was protected with tert-butyl dimethyl silyl chloride to form silyl
ether 28. This was coupled with the Grignard derivative of 37, prepared by bromination of the
commercially available d9-butan-1-ol, in the presence of a lithium tetrachlorocuprate complex with
N-methylpyrrolidone (NMP) as an additive.50 The use of NMP as well as a catalytic amount of
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lithium tetrachlorocuprate insured that a minimum amount of d9-1-bromobutane was used to
produce deuterated silyl ether 37. Deprotection using tetrabutylammonium fluoride generated
alcohol 38. Oxidation of the alcohol with the oxoammonium reagent Bobbitt’s salt yielded
aldehyde 39 with no over-oxidation to the acid and in excellent yield. β–keto ester 40 was prepared
by the reaction of the aldehyde with ethyl diazoacetate in the presence of catalytic tin (II) chloride.
Selective reduction of the ketone moiety with sodium borohydride generated racemic β–hydroxy
ester 41. Saponification of this ester using lithium hydroxide yielded racemic β-hydroxy acid 42
in an overall yield of 42% from 11-bromoundecanol.

Scheme 9. Synthesis of deuterated L-serine lipid 654
Reagents: (a) TBDMSCl, imidazole, 97.7%; (b) (i) d9-1-bromobutane, Mg0, THF (ii) CuCl2, LiCl, NMP, 98.3%; (c)
TBAF, 99.1%; (d) Bobbitt’s salt, SiO2, 75.6%; (e) SnCl2, ethyl diazoacetate, 80.6%; (f) NaBH4, 79.7%; (g) LiOH,
89.3% (h) (i) 10, NHS, EDC, DMAP (ii) Pd/C, H2, 78.2%; (i) (i) TBAF, 85.1% (ii) LiOH, 73%; (j) 13methylpentadecanoic acid, EDC, DMAP, 79.6%; (k) (i) TBAF, 85.1% (ii) KOSi(CH) 3, 58%.
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With d9-β-hydroxy acid 42 prepared, the convergent synthesis proceeded by amidation
coupling with protected dipeptide 10. Activation of the acid with N-hydroxysuccinimide combined
with the hydrogenolysis product from the dipeptide facilitated the protected lipid 43. Subsequent
deprotection with TBAF followed by LiOH saponification gave d9-lipid 24 in 49% yield from the
C17 fatty acid.
The other targeted lipid utilized esterification of the alcohol moiety of 43 with 13methylpentadecanoic acid.

An EDC/DMAP mediated coupling gave d9-protected lipid 44.

Deprotection proceeded via removal of the silyl ether using tetrabutylammonium fluoride to
liberate the serine hydroxyl group. The sensitivity of the ester linkage in the lipid led to liberation
of the methyl ester in a different method. Reaction with potassium trimethylsilanolate led to 25.
This SN2 type of deprotection was successful, but the yield was lower over the two steps, giving
27% from synthetic fragments 42 and 14.

1.2.3 MS/MS Fragmentation of Synthetic Lipids
The analysis via MS/MS of synthetic lipids was correlated with isolated lipid 654 from P.
gingivalis to confirm proposed structure (Figure 3). The fragmentation pattern of L-serine (rac)654-(2) matched identically and proved the hypothesized structure of bioactive compounds. Both
diastereomers, (R)-2 and (S)-2, were also evaluated by MS/MS. The diastermically enriched lipids
showed identical fragmentation patterns. Therefore, no stereoisomer-specific precursor-tofragment transitions available for differential quantitation of the (R) and (S) isoforms by MRM
MS. That is not an unexpected result, however it is disappointing since the stereochemistry of
future isolated lipid batches cannot determined solely by mass spectrometry. The deuterated lipid
27

25 showed the same MS/MS spectrum as the parent lipid 2 and indicating that it is a viable internal
standard for accurate quantitation of L-serine-Lipid 654 stereoisomers.

Figure 3. MS/MS spectrum of synthetic lipids.
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1.2.4 Enzymatic Hydrolysis of Synthetic Lipid 654 (2).

Figure 4. Hydrolysis of (3R)-L-serine-2 and (3S)-L-serine -2 by PLA2 enzyme preparations.
Each lipid preparation was aliquoted (250 ng/sample) and were dried. Samples were processed as described in the
text. Multiple Reaction Monitoring (MRM) was performed using a Sciex QTrap 4000. The 654.3-381.3 or 430.3382.3 m/z transitions were used to calculate the lipid 430/lipid 654 ratios.

HPLC purified synthetic (3R)-L-serine-2 and (3S)-L-serine-2 were subjected to enzymatic
hydrolysis using commercially available PLA2 preparations. Approximately 250 ng of each
synthetic lipid was sonicated in Tris buffer (10 mM, pH 7.5, 1 mL) containing 150 mM NaCl and
2.5 mM CaCl2. Control samples received no enzyme. Approximately 100 U of either porcine
pancreatic PLA2 or honey bee venom PLA2 (both from Sigma) was added and all samples were
stirred for 5 days at 25°C. At 5 days, the samples were acidified with glacial acetic acid and
extracted with CHCl3 (1 mL x 3 extractions). The pooled extracts were dried and suspended in
HPLC solvent (hexane:isopropanol:water, 6:8:0.75, v/v/v). The samples were evaluated using
MRM-MS and the ratio of lipid 430 to lipid 654 was determined for both control and enzyme
treated samples. The results in Figure 1 show that the (3R) diastereomer of synthetic lipid 654,
(3R)-L-serine-2, is hydrolyzed by PLA2 but the (3S)-L-serine-2 is not. This evidence suggests that
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the partial hydrolysis of P. gingivalis lipid 654 results from the presence of both (3R) and (3S)
diastereomers of lipid 654 in this organism where only the (3R) form is hydrolyzed. Of note, it
was recently reported that the lipid 430 recovered following porcine pancreatic PLA2 hydrolysis
of P. gingivalis lipid 654 is a potent inhibitor of osteoblast function both in vivo and in vitro.33

1.2.5 Conclusions
We have prepared (3R)-L-serine-2 and (3R)-L-serine 1, as well as (3S)-L-serine-2 and (3S)L-serine

1 by a convergent synthetic route that is significantly shorter than other published routes,

producing the targeted compounds in higher yield. In summary, the convergent synthesis described
herein confirms the proposed structures of lipid 654 produced from P. gingivalis. Our convergent
synthesis gave lipid 430, (R)-1, in 8 linear steps and 24% overall yield, using the protected
dipeptide 13 prepared separately. We similarly prepared (S)-1 in 8 linear steps and 27% overall
yield. Lipid 654, (R)-2, was prepared in 9 linear steps and 28% overall yield. We similarly
prepared (S)-2 in 8-linear steps and 34% overall yield. Using the same approaches, (rac)-1 was
prepared in 8 linear steps and 46% overall yield and (rac)-2 was prepared in 9 linear steps ad 40%
overall yield.
We have also successfully incorporated nine deuterium atoms into 24 and 25 from the
commercially available 11-bromoundecan-1-ol using commercially available d9-butan-1-ol as the
deuterium source. The convergent synthesis prepared 24 in 9 linear steps and 13% overall yield
from 11-bromoundecan-1-ol and 25 in 10 linear steps and 6% overall yield. Using an identical
route we have prepared 26 in 9 linear steps and 12% overall yield and 27 in 10 linear steps and 3%
overall yield. The d9-24 will be used as a standard for the lipid 430 isolated from Porphyromonas
gingivalis and d9-25 will be used as a standard for 654 isolated from P. gingivalis.
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Demonstration that there is a difference in enzymatic reactivity with the different
diastereomers allows us to use the (R) and (S) synthetic preparations of lipid 654 to evaluate
biological properties of enantioenriched or enantiopure lipids to engage the innate immune system,
including the engagement of Toll-like receptor 2. Furthermore, it is important to determine the
levels of (R) and (S) lipid 654 present in other members of the Bacteroidetes phylum as well as the
levels of these isoforms in diseased tissues where lipid 654 is known to accumulate. These studies
have begun, and the results will be the subject of a future communication.
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1.3 Experimental
General
All glassware was oven-dried, and all reactions were performed under a nitrogen atmosphere. All
chemicals were purchased from the Sigma-Aldrich Chemical Co., and used without further
purification unless otherwise noted.

Tetrahydrofuran (THF) was distilled from sodium

benzophenone ketyl, methylene chloride (dichloromethane, DCM) was distilled from calcium
hydride, and dimethylformamide (DMF) was distilled in vacuo from calcium hydride. Ethyl
acetate (EtOAc), methanol (MeOH), and diethyl ether were used as obtained from the vendor.
Bobbitt’s salt42 was provided as a gift from Dr. James Bobbitt (Department of Chemistry, The
University of Connecticut)), but it is commercially available from Sigma-Aldrich as 4-acetamido2,2,6,6-tetramethylpiperidine 1-oxyl. d9-Butan-1-ol was purchased from Sigma-Aldrich.
Thin-layer chromatography was done on Sorbent Technologies aluminum-backed TLC
plates with fluorescent indicator and 0.2 mm silica gel layer thickness, and p-anisaldehyde or
phosphomolybdic acid were used as developing agents. Column chromatography was done using
60 Å porosity, 32-63 µm silica gel. 1H and
(300.13 MHz 1H, 75.48 MHz

13

13

C NMR were collected on a Bruker Avance 300

C), Bruker DRX-400 (400.144 MHz 1H, 100.65 MHz

Bruker Avance 500 (500.13 MHz 1H, 125.65 MHz

13

13

C) or a

C). Chemical shifts are reported in ppm

downfield from tetramethylsilane (TMS) in the following format chemical shift, multiplicity
(s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet). Coupling constants are reported in Hz.
Mass spectrometry data was collected on a HP 5870B GC/MSD mass spectrometer with an HP-1
column, and high resolution MS and MS/MS spectra of synthetic 2 and 1 were obtained by direct
infusion of the target lipids into a QTOF mass spectrometer, QSTAR Elite from Sciex (Foster City,
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CA) or directly by using AccuTOF™ DART, JEOL (Peabody, MA). Multiple reaction monitoring
(MRM) transitions were selected based the MS/MS spectra of 2 and 1. Lipid samples were injected
into a triple quadrupole mass spectrometer, 4000 QTrap from Sciex (Foster City, CA). IR spectra
were taken on FT/IR-410/C031560585 JASCO and Nexus 670 FT-IR E.S.P, neat, unless otherwise
stated. All melting points to an upper limit of 270 °C were obtained using a Uni-melt capillary
melting point apparatus or Digimelt MPA160. Perfect. For products described as waxy solid or
semi-solids, melting points could not be obtained.

Methyl L-serinate

Thionyl chloride (2.75 mL, 37.8 mmol) was added, dropwise, to a suspension of L-serine
(4.015 g, 38.2 mmol) in 50 mL of dry methanol. The solution was heated at reflux with stirring for
5 h and then cooled to ambient temperature. The solvent was removed in vacuo and the crude
white solid was redissolved in a minimal amount of methanol. This solution was treated with an
equal volume of toluene and the flask was swirled periodically to induce crystallization. Filtration
yielded methyl L-serinate as a crystalline solid (3.9675 g, 33.3 mmol, 87.2%).51 MP, 161-162 °C.
1

H NMR (400 MHz, Methanol-d4) δ 4.14 (t, J=3.9 Hz, 1H), 4.01 (dd, J=11.8, 4.5 Hz, 1H), 3.93

(dd, J=11.8, 3.1 Hz, 1H), 3.85 (s, 3H).

13

C NMR (101 MHz, Methanol-d4) δ 169.4, 60.7, 56.1,

53.71.
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Methyl O-(tert-butyldiphenylsilyl)-L-serinate, (17)

A stirring solution of methyl L-serinate (2.003 g, 16.8 mmol) in 15 mL of DMF was treated
with imidazole (3.435 g, 50.4 mmol).52 (tert-Butyl)diphenylsilyl chloride (4.80 mL, 18.5 mmol)
was added, dropwise, and the reaction was stirred overnight at ambient temperature. At this time,
the solvent was removed in vacuo and the resulting oil was dissolved in 100 mL of diethyl ether.
This solution was washed with water (5 X 400 mL), 10 % LiCl (2 X 100), and brine (50 mL).
Drying with MgSO4, filtering, and concentration under reduced pressure yielded methyl O-(tertbutyldiphenylsilyl)-L-serinate, 17, as a yellow oil (5.331 g, 14.9 mmol, 88.7%). 1H NMR (400
MHz, CDCl3) δ 7.64 (td, J = 7.7, 1.6 Hz, 4H), 7.50-7.35 (m, 6H), 3.98 (dd, J = 9.9, 4.3 Hz, 1H),
3.89 (dd, J = 9.9, 3.8 Hz, 1H), 3.71 (s, 3H), 3.58 (t, J = 4.1 Hz, 1H), 1.04 (s, 9H). 13C NMR (101
MHz, CDCl3) δ 135.6, 133.1, 133.0, 129.9, 127.8, 127.7, 66.1, 56.5, 52.1, 26.8, 19.3. HRMS
(AccuTOF): [MH]+ Calc’d for C20H28NO3Si m/z 358.1838. Found: m/z 358.1819.

((Benzyloxy)carbonyl)glycine [N-Cbz-Glycine], (18)

Glycine (3.000 g, 40.0 mmol) and sodium bicarbonate (6.710 g, 79.9 mmol) were dissolved
in 100 mL of H2O at ambient temperature and this solution was cooled to 0 °C using an ice bath.
Benzyl chloroformate (8.56 mL, 59.9 mmol) in 25 mL of dioxane was added, dropwise. This
solution was slowly warmed to ambient temperature and stirred overnight. The reaction mixture
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was transferred to a separatory funnel and washed with EtOAc (2 X 50 mL). The aqueous layer
was acidified with 10 % HCl to a pH=1 (to pH paper) and extracted with EtOAc (3 X 50 mL). The
later organic layers were dried, filtered, and solvents evaporated at reduced pressure to yield
((benzyloxy)carbonyl)glycine, 18,53 as a white solid (6.982 g, 33.4 mmol, 83.5 %), MP, 112-114
°C. 1H NMR (400 MHz, Methanol-d4) δ 7.40–7.24 (m, 5H), 5.10 (s, 2H), 3.84 (s, 2H). 13C NMR
(101 MHz, Methanol-d4) δ 173.6, 159.1, 138.1, 129.4, 129.0, 128.8, 67.7, 43.1.

Methyl N-(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate, (14)

A solution of ((benzyloxy)carbonyl)glycine (1.748 g, 8.36 mmol) in 10 mL of DMF was
cooled to 0°C using an ice bath. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI, 1.603
g, 8.36 mmol), HOBt (1.280 g, 8.36 mmol) and then diisopropylethylamine (DIPEA, 1.46 mL,
8.36 mmol) were added in that order. The solution was stirred for 15 min before the addition of
methyl O-(tert-butyldiphenylsilyl)-L-serinate, 12 (2.988 g, 8.36 mmol). The reaction was warmed
to ambient temperature and stirred for 48 h. At that time, the DMF was removed in vacuo and the
resulting oil was dissolved in 100 mL of diethyl ether. The ether was washed with water (5 X 400
mL), saturated NaHCO3 (3 X 100) mL, and brine (50 mL). The organic layer was dried, filtered,
and solvents evaporated at reduced pressure. Purification by column chromatography (1 %
MeOH:DCM) yielded (((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate, 14,
as a clear oil (3.390 g, 6.18 mmol, 73.9%). 1H NMR (400 MHz, CDCl3) δ 7.59 (t, J = 7.6 Hz, 4H),
7.49–7.34 (m, 6H), 6.77 (d, J = 6.9 Hz, 1H), 5.36 (s, 1H), 5.12 (q, J= 12.3, 7.6 Hz, 2H) 4.68 (dt, J
= 8.3, 2.9 Hz, 1H), 4.13 (dd, J = 10.3, 2.8 Hz, 1H), 3.93–3.75 (m, 3H), 3.74 (s, 3H), 1.04 (s, 9H).
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C NMR (101 MHz, CDCl3) δ 170.5, 168.6, 156.4, 136.1, 135.5, 132.8, 132.6, 130.1, 128.6,
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128.2, 128.1, 127.9, 127.8, 67.3, 64.2, 54.1, 52.5, 44.4, 26.7, 19.3. HRMS (AccuTOF): [MH]+
Calc’d for C30H37N2O6Si m/z 549.2421. Found: m/z 549.2423.

13-Methyltetradecan-1-ol, (16)

Magnesium turnings (2.90 g, 0.119 mol) were added to a 500 mL round bottom flask with
a stirbar and flame-dried under a nitrogen atmosphere. After cooling, the Mg turnings were
suspended in dry THF (50 mL) and 1-bromo-2-methylpropane (8.00 mL, 0.0736 mol) was rapidly
added with vigorously stirring. Upon initiation, dry THF (50 mL) was added and the flask was
immersed in an ice bath to modulate the exothermic reaction. The reaction was stirred until the
flask cooled to ambient temperature and the temperature was lowered to -78 °C using dry ice
acetone bath. 11-Bromoundecan-1-ol (4.005 g, 0.0172 mol) dissolved in THF (20 mL) and LiCl
(1.53 g, 0.036 mol) and copper (II) chloride (2.54 g, 0.019 mol), dissolved in THF (30 mL), were
added. The mixture was slowly warmed to ambient temperature and stirred overnight. The
reaction was quenched with satd NH4Cl (100 mL) before being transferred to a separatory funnel
with diethyl ether (200 mL) and H2O (100 mL). The layers were separated and the organic layer
was washed with satd NaHCO3 (50 mL X 3) and brine (50 mL). The organic phase was dried with
MgSO4, gravity filtered, and solvents removed in vacuo. The crude product was purified by
column chromatography on silica gel (10% EtOAc:hexane) to yield 13-methyltetradecan-1-ol,
16,37,54 as a white solid (3.793 g, 0.017 mol, 96.7%), MP, 26-27 °C. 1H NMR (400 MHz, CDCl3)
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δ 3.64 (t, 2H), 1.63–1.44 (m, 3H), 1.27 (m, 18H), 1.17 (m, 3H), 0.86 (d, J = 6.6 Hz, 6H); 13C NMR
(101 MHz, CDCl3) δ 63.3, 39.2, 33.0, 30.1, 29.9, 29.8, 29.8, 29.6, 28.1, 27.6, 25.9, 22.8.

13-Methyltetradecanal, (15)

4-(Acetyamino)-2,2,6,6-tetramethyl-1-oxo-piperidinium tetrafluoroborate42 (Bobbit’s salt,
5.285 g, 0.0176 mol) was added to 13-ethyltetradecanol (7, 3.498 g, 0.0153 mol) dissolved in 250
mL of dry DCM. An equal mass of silica was slowly added to the stirring mixture. The bright
yellow solution stirred at ambient temperature until the color faded, giving a solution with a pale
yellow tint. The solution was filtered to remove the silica, and the filtrate was concentrated in
vacuo. The crude product was purified by column chromatography (5% EtOAc:hexanes) to yield
13-methyltetradecanal, 15,41 as a clear solid, (3.319 g, 0.0147 mol, 95.8%), MP, ~25 °C.

1

H

NMR(400 MHz, CDCl3) δ 9.76 (t, J = 1.9 Hz, 1H), 2.41 (td, J = 7.4, 1.9 Hz, 2H), 1.63 (quin, J =
7.2 Hz, 2H), 1.51 (sep, 1H), 1.36–1.22 (m, 16H), 1.15 (m, 2H), 0.86 (d, J = 6.6 Hz, 6H) 13C NMR
(101 MHz, CDCl3) δ 13C NMR (101 MHz, CDCl3) δ 203.0, 44.0, 39.1, 30.0, 29.8, 29.7, 29.6,
29.5, 29.4, 29.2, 28.0, 27.5, 22.7, 22.2.

13-Methyltetradecanoic acid, (13)

13-Methyltetradecanal (15, 1.251 g, 5.53 mmol) was dissolved in 50 mL of THF, and 5
mL of H2O and 0.5 mL of 1M HCl were added. The reaction mixture was stirred for 72 h at
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ambient temperature. The resulting solution was concentrated under reduced pressure, the residue
dissolved in 15 mL of H2O, and extracted with DCM (15 mL X 3). The resulting solution was
filtered through a small plug of silica gel and rinsed with DCM before being concentrated in vacuo
to yield 13-methyltetradecanoic acid32,37,55 (13) as a white solid (1.307 g, 5.39 mmol, 97.6%), MP,
48-49 °C. 1H NMR (400 MHz, CDCl3) δ 2.35 (t, J = 7.5 Hz, 2H), 1.63 (quin, J = 7.4 Hz, 2H),
1.51 (sep, J = 6.6 Hz, 1H), 1.39–1.18 (m, 16H), 1.15 (q, J = 6.7 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H).
C NMR (101 MHz, CDCl3) δ 13C NMR (101 MHz, CDCl3) δ 179.6, 39.1, 34.0, 30.0, 29.8, 29.7,
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29.7, 29.5, 29.3, 29.1, 28.0, 27.5, 24.8, 22.7.

Ethyl 15-methyl-3-oxohexadecanoate, (11)

Tin (II) chloride dehydrate (0.417 g, 1.85 mmol) was suspended in 15 mL of dry DCM.
Ethyl diazoacetate (2.60 g, 19.4 mmol) was added, dropwise via syringe, and the reaction was
stirred for 15 min. 13-Methylpentadecanal (15, 4.186 g, 18.5 mmol) was dissolved in 10 mL of
DCM and added to the reaction, dropwise, via cannula. The mixture was stirred at ambient
temperature for about 6 h, until nitrogen evolution ceased. The reaction mixture was diluted with
100 mL of DCM and washed with a satd brine solution (2 X 50 mL). The aqueous layers were
combined and extracted with DCM (2 X 25 mL). All organic layers were combined, dried with
MgSO4, filtered, and solvents evaporated at reduced pressure. The resulting crude product was
purified via column chromatography (5% EtOAc:hexanes) to yield ethyl 15-methyl-3oxohexadecanoate,37,56 11, as a clear solid (4.871 g, 0.0156 mol, 84.3%), MP, ~25 °C. 1H NMR
(400 MHz, CDCl3) δ 4.20 (q, J = 7.1 Hz, 2H), 3.42 (s, 2H), 2.53 (t, J = 7.3 Hz, 2H), 1.60 (quin, J
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= 7.2 Hz, 2H), 1.50 (sep, J = 6.5 Hz, 1H), 1.30-1.20 (m, 20H), 1.15 (q, J = 7.3, 6.8 Hz, 2H), 0.86
(d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 203.0, 167.3, 61.4, 49.4, 43.1, 39.1, 30.0, 29.8,
29.7, 29.7, 29.5, 29.4, 29.1, 28.0, 27.5, 23.5, 22.7, 14.2.

Ethyl 3-hydroxy-15-methylhexadecanoate, (19)

A solution of ethyl 15-methyl-3-oxohexadecanoate (11, 3.114 g, 0.001 mol) in 2.5 mL of
ethanol and 22.5 mL of THF was cooled to 0 °C on an ice bath. Sodium borohydride (0.301 g,
0.008 mol) was added and the resulting slurry was stirred vigorously for 1 h. The reaction was
quenched by the slow addition of 50 mL of a 10 % aq citric acid solution.

Subsequent

neutralization with satd K2CO3 solution was followed by extraction with EtOAc (3 X 50 mL).
The organic layers were washed with 25 mL of satd brine solution, dried with MgSO4, filtered,
and the solvents were removed at reduced pressure. The crude product was purified by column
chromatography (10% EtOAc:hexanes) to yield ethyl 3-hydroxy-15-methylhexadecanoate,37 19 as
a clear oil (2.674 g, 0.0085 mol, 85.3 %). 1H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.1 Hz, 2H),
4.06–3.93 (m, 1H), 2.91 (d, J = 3.9 Hz, 1H), 2.50 (dd, J = 16.4, 3.1 Hz, 1H), 2.39 (dd, J = 16.4,
9.0 Hz, 1H), 1.60–1.20 (m, 23H), 1.15 (q, J = 6.6 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101
MHz, CDCl3) δ 173.2, 68.1, 60.7, 41.4, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.6, 28.0, 27.5, 25.5,
22.7, 14.2.
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Ethyl (3R)-hydroxy-15-methylhexadecanoate, ((3R)-19)

In a nitrogen atmosphere glove box, (R)-BINAP (45 mg, 0.072 mmol) and bis(2methylallyl)(1,5-cyclooctadiene)ruthenium(II) (20 mg, 0.063 mmol) were dissolved in 9 mL of
freshly distilled acetone.

Methanolic HBr (0.22 mL, 0.73 M, 0.16 mmol) was added, and the

solution was stirred for 1 h. The reaction was concentrated to dryness in vacuo before being
redissolved in 15 mL of ethanol and β-keto ester 11 (0.962 g, 3.08 mmol) was added. The system
was flushed with hydrogen and heated at reflux for 48 h. The resulting solution was filtered and
the solvents removed at reduced pressure. Subsequent purification via column chromatography
(10% EtOAc:hexanes) yielded ethyl (3R)-hydroxy-15-methylhexadecanoate, (3R)-1937 as a clear
solid (0.901 g, 2.86 mol, 93.0 %), MP, ~25 °C. 1H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.2 Hz,
2H), 4.05–3.94 (m, 1H), 2.91 (d, J = 4.0 Hz, 1H), 2.50 (dd, J = 16.4, 3.1 Hz, 1H), 2.39 (dd, J =
16.4, 9.0 Hz, 1H), 1.60–1.20 (m, 23H), 1.15 (q, J = 6.6 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H).

13

C

NMR (101 MHz, CDCl3) δ 173.2, 68.1, 60.7, 41.4, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.6, 28.0,
27.5, 25.5, 22.7, 14.2. A 1H NMR analysis that showed a 97R:03S mixture for (3R)-19.

Ethyl (3S)-hydroxy-15-methylhexadecanoate, ((3S)-19)

In a nitrogen atmosphere glove box, (S)-BINAP (45 mg, 0.072 mmol) and bis(2methylallyl)(1,5-cyclooctadiene)ruthenium(II) (20 mg, 0.063 mmol) were dissolved in 9 mL of
freshly distilled acetone. Methanolic HBr (0.22 mL, 0.73 M, 0.16 mmol) was added, and the
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solution stirred for 1 h. The reaction was concentrated to dryness in vacuo before being redissolved
in 15 mL of ethanol and β-keto ester 11 (0.954 g, 3.05 mmol) was added. The system was flushed
with hydrogen gas and heated at reflux for 48 h. The resulting solution was filtered and the
solvents removed at reduced pressure. Subsequent purification via column chromatography (10%
EtOAc:hexanes) yielded ethyl (3S)-hydroxy-15-methylhexadecanoate, (3S)-1937 as a clear solid
(0.917 g, 2.92 mol, 95.5 %), MP, ~25 °C. [α]D23 +11.8° (c 1.0, CHCl3), 1H NMR (400 MHz,
CDCl3) δ 4.17 (q, J = 7.1 Hz, 2H), 4.06–3.93 (m, 1H), 2.91 (d, J = 4.0 Hz, 1H), 2.50 (dd, J = 16.4,
3.1 Hz, 1H), 2.39 (dd, J = 16.4, 9.0 Hz, 1H), 1.55–1.39 (m, 3H), 1.38–1.21 (m, 20H), 1.15 (q, J =
7.1, 6.6 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.2, 68.1, 60.7, 41.4,
39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.6, 28.0, 27.5, 25.5, 22.7, 14.2. A 1H NMR analysis that
showed a 02R:98S mixture for (3S)-19.

Enzymatic Resolution
Lipase PS (.275 g) was added to a stirred solution of (±)-19 (5.50 g, 1.92 mmol) and 2,6di-tert-butyl-4-methylphenol (5 mg) in vinyl acetate (8.8 mL), and stirred at 52-58 °C for 168 h.
The resulting mixture was cooled to ambient temperature and filtered through Celite and
concentrated under reduced pressure. Column chromatography (MeOH: DCM), yielded (3R)-5
(128 mg) as a white solid; [α]

23
D

+6.4° (c 1.02, CHCl3). After saponification of the acetate

product, (3S)-5 (177 mg) was purified to give a white solid; [α]

23
D

–8.7° (c 1.02, CHCl3). 1H

NMR spectra were identical with those of (±)-5.16c Conversion to the corresponding Mosher’s
ester as described above was followed by 1H NMR analysis that showed a 84R:15S mixture for
(3R)-19 and a 11R:89S mixture for (3S)-19.
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Ethyl (R)-15-methyl-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl) oxy)Hexadecanoate

Under a nitrogen atmosphere, (S)-(–)-α-Methoxy-α-(trifluoromethyl)phenylacetic acid
(Mosher’s acid,45 23 mg, 0.098 mmol) was dissolved in 2 mL of dry DCM and cooled to 0 °C in
an ice bath. Subsequent addition of DCC (24 mg, 0.12 mol) was followed by stirring for 15 min,
at which time ethyl (3R)-hydroxy-15-methylhexadecanoate, (3R)-19 (29 mg, 0.092 mmol) was
added, along with a catalytic amount of DMAP. The reaction was equilibrated to ambient
temperature slowly and stirred overnight. Evaporation of solvents in vacuo was followed by
addition of 15 mL of EtOAc and washing with H2O 3 X 10 mL and 10 mL of satd brine. The
resulting organic layer was dried over MgSO4, filtered, and the solvents removed at reduced
pressure. Subsequent purification via column chromatography (1-10% EtOAc:hexanes) yielded
ethyl (R)-15-methyl-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)hexadecanoate as
a clear oil (38 mg, 0.072 mmol, 78 %). 1H NMR (400 MHz, CDCl3) δ 7.55-7.50 (m, 2H), 7.427.37 (m, 3H), 5.52-5.45 (p, J = 6.4 Hz, 1H), 4.06 (q, J = 7.1 Hz, 2H), 3.53 (s, 3H), 2.64 (dd, J =
16.0, 7.9 Hz, 1H), 2.55 (dd, J= 16.0, 5.0 Hz, 1H) 1.80-1.60 (m, 2H), 1.55-1.47 (sep, J = 6.6 Hz,
1H), 1.36-1.12 (m, 23H), 0.86 (d, J = 6.6 Hz, 6H).
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Ethyl (S)-15-methyl-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)Hexadecanoate

Under a nitrogen atmosphere, (S)-(–)-α-Methoxy-α-(trifluoromethyl)phenylacetic acid
(Mosher’s acid,45 23 mg, 0.098 mmol) was dissolved in 2 mL of dry DCM and cooled to 0 °C in
an ice bath. Subsequent addition of DCC (23 mg, 0.11 mmol) was followed by stirring for 15 min,
at which time ethyl (3S)-hydroxy-15-methylhexadecanoate, (3S)-19 ((28 mg, 0.089 mmol) was
added, along with a catalytic amount of DMAP. The reaction was equilibrated to ambient
temperature slowly and stirred overnight. Evaporation of solvents in vacuo was followed by
addition of 15 mL of EtOAc and washing with H2O 3 X 10 mL and 10 mL of satd brine. The
resulting organic layer was dried over MgSO4, filtered, and the solvents removed at reduced
pressure. Subsequent purification via column chromatography (1-10% EtOAc:hexanes) yielded
ethyl (R)-15-methyl-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)hexadecanoate as
a clear oil (45 mg, 0.084 mmol, 94 %). 1H NMR (400 MHz, CDCl3) δ 7.50-7.55 (m, 2H), 7.377.42 (m, 3H), 5.48 (quin, J = 6.3 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.55 (s, 3H), 2.69 (dd, J = 16.0,
8.0 Hz, 1H), 2.59 (dd, J= 16.0, 4.8 Hz, 1H), 1.70-1.57 (m, 2H), 1.52 (sep, J = 6.6 Hz, 1H), 1.361.12 (m, 23H), 0.86 (d, J = 6.6 Hz, 6H).
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3-Hydroxy-15-methylhexadecanoic acid, ((rac)-20)

Hydroxy ester 19 (2.674 g, 0.0085 mol) was dissolved in 8 mL of MeOH and 16 mL of
THF and 1 M aqueous LiOH (9.40 mL, 0.0094 mol) were added. The mixture was stirred
overnight at ambient temperature. The reaction was then acidified with 1 M HCl and extracted
with EtOAc (3 X 50 mL). The organic layers were washed with 25 mL of brine, dried with MgSO4,
filtered, and the solvents were removed at reduced pressure. The crude solid was recrystallized
from hexanes to yield 3-hydroxy-15-methylhexadecanoic acid,37 (3R+3S)-20, as a white solid
(2.257 g, 0.0079 mol, 92.7 %), MP, 54-56 °C. 1H NMR (400 MHz, CDCl3) δ 4.09–3.98 (m, 1H),
2.58 (dd, J = 16.6, 3.2 Hz, 1H), 2.48 (dd, J = 16.6, 8.9 Hz, 1H), 1.59–1.43 (m, 3H), 1.35-1.20 (m,
18H), 1.15 (q, J = 6.7 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 177.4,
68.1, 41.2, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.6, 29.5, 28.0, 27.5, 25.5, 22.7.

3(R)-Hydroxy-15-methylhexadecanoic acid, ((3R)-20)

Hydroxy ester (3R)-19 (0.818 g, 0.0026 mol) was dissolved in 8 mL of methanol and 16
mL of THF and 1 M aqueous LiOH (2.9 mL, 0.0029 mol) were added. The mixture was stirred
overnight at ambient temperature. The reaction was then acidified with 1 M HCl and extracted
with EtOAc (3 X 50 mL). The organic layers were washed with 25 mL of brine, dried with MgSO4,
filtered, and the solvents were removed at reduced pressure. The crude solid was recrystallized
from hexanes to yield (3R)-3-hydroxy-15-methylhexadecanoic acid,37 (3R)-20, as a white solid
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(0.708 g, 0.0024 mol, 92 %), [α]D23 –10.5° (c 1.0, CHCl3), MP, 54-55 °C. 1H NMR (400 MHz,
CDCl3) δ 4.09–3.98 (m, 1H), 2.58 (dd, J = 16.6, 3.2 Hz, 1H), 2.48 (dd, J = 16.6, 8.9 Hz, 1H), 1.59–
1.43 (m, 4H), 1.35-1.20 (m, 18H), 1.15 (q, J = 6.7 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR
(101 MHz, CDCl3) δ 177.8, 68.1, 41.1, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.5, 28.0, 27.5, 25.5,
22.7.

3(S)-Hydroxy-15-methylhexadecanoic acid, ((3S)-20)

Hydroxy ester (3S)-19 (0.815 g, 0.0026 mol) was dissolved in 8 mL of methanol and 16
mL of THF and 1 M aqueous LiOH (2.9 mL, 0.0029 mol) were added. The mixture was stirred
overnight at ambient temperature. The reaction was then acidified with 1 M HCl and extracted
with EtOAc (3 X 50 mL). The organic layers were washed with 25 mL of brine, dried with MgSO4,
filtered, and the solvents were removed at reduced pressure. The crude solid was recrystallized
from hexanes to yield (3S)-3-hydroxy-15-methylhexadecanoic acid,37 (3S)-20, as a white solid
23

(0.679 g, 0.0024 mol, 92 %), [ ]D +14.5° (c 1.0, CHCl3), MP, 54-55 °C. 1H NMR (400 MHz,
CDCl3) δ 4.09–3.98 (m, 1H), 2.58 (dd, J = 16.6, 3.2 Hz, 1H), 2.48 (dd, J = 16.6, 8.9 Hz, 1H), 1.59–
1.43 (m, 4H), 1.35-1.20 (m, 18H), 1.15 (q, J = 6.7 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR
(101 MHz, CDCl3) δ 177.3, 68.1, 41.0, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.5, 28.0, 27.5, 25.5,
22.7.
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Methyl

O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-15-methylhexadecanoyl)glycyl)-L-

serinate, ((rac)-12)

N-Hydroxysuccinimide (116 mg, 1.00 mmol) and dicyclohexylcarbodiimide (DCC, 216
mg, 1.05 mmol) were added to a stirring solution of 3-hydroxy-15-methylhexadecanoic acid (20,
250 mg, 0.873 mmol) in 10 mL of dry THF. The solution was stirred for 5 h at ambient
temperature, filtered, and the filtrate was concentrated in vacuo. The resulting white solid was
dissolved in 5 mL of dioxane and this solution was added via cannula to a solution of methyl N(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate (14, 598 mg, 1.09 mmol)
and Pd/C (176 mg) in 10 mL of dioxane. The reaction vessel was flushed with H2 and the mixture
was stirred overnight, filtered through Celite, and concentrated under reduced pressure. The crude
product was purified via column chromatography (2% MeOH:DCM) to yield methyl O-(tertbutyldiphenylsilyl)-N-((3-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3R+3S)-L-serine12, as a clear oil (0.478 g, 0.700 mmol, 80.2%). 1H NMR (400 MHz, CDCl3) δ 7.62-7.55 (m, 4H),
7.49–7.34 (m, 6H), two signals [6.86 and 6.99 (d, J= 7.0 and 8.1 Hz, 1H)], two signals [6.34 and
6.56 (d, J= 5.4 and 5.6 Hz, 1H), 4.67 (dt, J = 8.2, 3.0 Hz, 1H), 4.17–4.06 (m, 2H), 4.04–3.82 (m,
3H), 3.82–3.71 (m, 4H), 2.40 (dt, J = 14.7, 2.2 Hz, 1H), 2.26 (dd, J = 14.5, 9.4 Hz, 1H), 1.57-1.35
(m, 4H), 1.35-1.18 (m, 18H), 1.16 (dd, J = 13.6, 7.8 Hz, 2H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz,
6H). 13C NMR (101 MHz, CDCl3) δ 172.9, 172.8, 170.8, 168.9, 168.7, 135.5, 135.5, 132.9, 132.9,
132.7, 132.6, 130.0, 127.9, 127.9, 68.9, 68.9, 64.2, 54.3, 52.6, 43.1, 43.0, 43.0, 42.8, 39.1, 37.1,
30.0, 29.8, 29.7, 29.6, 29.6, 28.0, 27.5, 26.8, 25.5, 22.7, 19.3. HRMS (AccuTOF): [MH]+ Calc’d
for C39H63N2O6Si m/z 683.4455. Found: m/z 683.4470.
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Methyl

O-(tert-butyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-

serinate, ((3R)-12)

N-Hydroxysuccinimide (96 mg, 0.830 mmol) and dicyclohexylcarbodiimide (DCC, 188
mg, 0.913 mmol) were added to a stirring solution of 3-hydroxy-15-methylhexadecanoic acid
(3R)-20, 159 mg, 0.554 mmol) in 10 mL of dry THF. The solution was stirred for 5 h at ambient
temperature, filtered, and the filtrate was concentrated in vacuo. The resulting white solid was
dissolved in 5 mL of dioxane and this solution was added via cannula to a solution of methyl N(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate (14, 349 mg, 0.637 mmol)
and Pd/C (122 mg) in 10 mL of dioxane. The reaction vessel was flushed with H2 and the mixture
was stirred overnight, filtered through Celite, and concentrated under reduced pressure. The crude
product was purified via column chromatography (2% MeOH:DCM) to yield O-(tertbutyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3R)-L-serine-12
as a clear oil (0.279 g, 0.405 mmol, 73.6%) 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.54 (m, 4H),
7.49 – 7.35 (m, 6H), 6.89 (d, J = 8.1 Hz, 1H), 6.39 (t, J = 5.6 Hz, 1H), 4.67 (dt, J = 8.2, 2.9 Hz,
1H), 4.18 – 4.06 (m, 2H), 3.97 (s, 1H), 3.94 – 3.77 (m, 2H), 3.75 (s, 3H), 3.36 (d, J = 3.6 Hz, 1H),
2.41 (dd, J = 14.6, 2.6 Hz, 1H), 2.27 (dd, J = 14.6, 9.4 Hz, 1H), 1.56 – 1.34 (m, 4H), 1.34 – 1.20
(m, 18H), 1.19 – 1.13 (m, 2H), 1.04 (s, 9H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3)
δ 172.8, 170.7, 168.6, 135.6, 135.5, 132.9, 132.6, 130.1, 128.0, 127.9, 77.4, 77.1, 76.8, 68.9, 64.3,
54.3, 52.6, 43.1, 42.9, 39.1, 37.2, 30.0, 29.8, 29.7, 29.6, 29.6, 28.0, 27.5, 26.8, 25.5, 22.7, 19.3.
HRMS (AccuTOF): [MH]+ Calc’d for C39H63N2O6Si m/z 683.4455. Found: m/z 683.4434.
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Methyl

O-(tert-butyldiphenylsilyl)-N-((3S-hydroxy-15-methylhexadecanoyl)glycyl)-L-

serinate, ((S)-12)

N-Hydroxysuccinimide (87 mg, 0.752 mmol) and dicyclohexylcarbodiimide (DCC, 171
mg, 0.827 mmol) were added to a stirring solution of 3-hydroxy-15-methylhexadecanoic acid
((3S)-20, 144 mg, 0.501 mmol) in 10 mL of dry THF. The solution was stirred for 5 h at ambient
temperature, filtered, and the filtrate was concentrated in vacuo. The resulting white solid was
dissolved in 5 mL of dioxane and this solution was added via cannula to a solution of methyl N(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate (14, 316 mg, 0.576 mmol)
and Pd/C (111 mg) in 10 mL of dioxane. The reaction vessel was flushed with H2 and the mixture
was stirred overnight, filtered through Celite, and concentrated under reduced pressure. The crude
product was purified via column chromatography (2% MeOH:DCM) to yield O-(tertbutyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3S)-L-serine-12
as a clear oil (0.261 g, 0.382 mmol, 76.0%) 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.54 (m, 4H),
7.49 – 7.34 (m, 6H), 6.86 (d, J = 7.0 Hz, 1H), 6.34 (d, J = 5.4 Hz, 1H), 4.67 (dt, J = 8.2, 3.0 Hz,
1H), 4.13 (dd, J = 10.4, 2.9 Hz, 1H), 4.03 – 3.81 (m, 4H), 3.74 (s, 3H), 3.53 – 3.44 (m, 1H), 2.40
(dd, J = 14.6, 2.6 Hz, 1H), 2.26 (dd, J = 14.7, 9.5 Hz, 1H), 1.57 – 1.36 (m, 4H), 1.35 – 1.20 (m,
18H), 1.20 – 1.11 (m, 2H), 1.04 (s, 9H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ
172.8, 170.7, 168.5, 135.6, 133.0, 132.7, 130.1, 127.9, 127.9, 77.4, 77.1, 76.7, 68.9, 64.3, 54.3,
52.6, 43.0, 42.8, 39.1, 37.2, 30.0, 29.8, 29.7, 29.7, 29.6, 28.0, 27.5, 26.8, 25.5, 22.7, 19.3. HRMS
(AccuTOF): [MH]+ Calc’d for C39H63N2O6Si m/z 683.4455. Found: m/z 683.4435.
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Methyl (3-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate, ((rac)-21)

Methyl

O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-15-methylhexadecanoyl)glycyl)-L-

serinate ((3R+3S)-L-serine-12, 162 mg, 0.237 mmol) was dissolved in 5 mL of dry THF under
nitrogen. The solution was cooled to 0°C and was treated with 1 M tetrabutylammonium fluoride
(TBAF, 0.26 mL, 0.261 mmol). The reaction was slowly warmed to ambient temperature and
stirred for 6 h. The solvent was removed under reduced pressure, and the resulting oil was purified
by column chromatography (2.5 % MeOH:DCM) to yield methyl (3-hydroxy-15methylhexadecanoyl)glycyl-L-serinate, (3R+3S)-21, as a white solid, (101 mg, 0.227 mmol, 95.8
%), MP, 105-107 °C. 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 7.6 Hz, 1H), 7.20 – 7.11 (m,
1H), 4.67 – 4.58 (m, 1H), 4.12 (dd, J = 16.9, 6.2 Hz, 1H), 4.03 – 3.83 (m, 5H), 3.76 (s, 3H), 2.44
(dd, J = 14.0, 2.4 Hz, 1H), 2.30 (dd, J = 14.1, 9.7 Hz, 1H), 1.60 – 1.05 (m, 23H), 0.86 (d, J = 6.6
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.4, 173.3, 171.2, 171.0, 169.6, 77.4, 77.1, 76.7, 69.6,
62.6, 54.9, 52.8, 43.7, 43.2, 39.1, 37.5, 30.0, 29.8, 29.8, 29.7, 29.6, 28.0, 27.5, 25.7, 22.7. HRMS
(AccuTOF): [MH]+ Calc’d for C23H45N2O6 m/z 445.3278. Found: m/z 445.3307.

Methyl (3(R)-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate, ((R)-21)

Methyl

O-(tert-butyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-

serinate ((3R)-L-serine-12, 276 mg, 0.403 mmol) was dissolved in 5 mL of dry THF under nitrogen.
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The solution was cooled to 0 °C and was treated with 1 M tetrabutylammonium fluoride (TBAF,
0.44 mL, 0.444 mmol). The reaction was slowly warmed to ambient temperature and stirred for 6
h. The solvent was removed under reduced pressure, and the resulting oil was purified by column
chromatography

(2.5

%

MeOH:DCM)

to

yield

methyl

(3R-hydroxy-15-

methylhexadecanoyl)glycyl-L-serinate, (3R)-L-serine-21, as a white solid, (129 mg, 0.289 mmol,
71.6 %), MP, 100-104 °C. 1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 7.8 Hz, 1H), 7.00 (t, J = 5.9
Hz, 1H), 4.73 – 4.65 (m, 1H), 4.19 (dd, J = 16.9, 6.3, 2.1 Hz, 1H), 4.12-4.04 (m, 1H), 4.04 – 3.86
(m, 3H), 3.82 (s, 3H), 2.50 (dt, J = 14.1, 2.6 Hz, 1H), 2.40 – 2.30 (m, 1H), 1.63 – 1.44 (m, 4H),
1.44 – 1.23 (m, 18H), 1.19 (q, J = 6.8 Hz, 2H), 0.91 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz,
CDCl3) δ 173.31, 171.10, 169.40, 77.27, 77.02, 76.76, 69.56, 62.71, 54.85, 52.80, 43.67, 43.30,
39.08, 37.43, 29.97, 29.75, 29.70, 29.63, 29.54, 27.98, 27.44, 25.62, 25.56, 22.67. HRMS
(AccuTOF): [MH]+ Calc’d for C23H45N2O6 m/z 445.3278. Found: m/z 445.3285.

Methyl (3(S)-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate, ((S)-21)

Methyl

O-(tert-butyldiphenylsilyl)-N-((3S-hydroxy-15-methylhexadecanoyl)glycyl)-L-

serinate ((3S)-L-serine-12, 216 mg, 0.316 mmol) was dissolved in 5 mL of dry THF under nitrogen.
The solution was cooled to 0°C and was treated with 1 M tetrabutylammonium fluoride (TBAF,
0.35 mL, 0.347 mmol). The reaction was slowly warmed to ambient temperature and stirred for 6
h. The solvent was removed under reduced pressure, and the resulting oil was purified by column
chromatography

(2.5

%

MeOH:DCM)
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to

yield

methyl

(3S-hydroxy-15-

methylhexadecanoyl)glycyl-L-serinate, (3S)-L-serine-21, as a white solid, (96 mg, 0.216 mmol,
68.4 %), MP, 109-111 °C. 1H NMR (500 MHz, CDCl3) δ 7.36 (d, J= 7.4 Hz, 1H), 6.88-6.78 (m,
1H), 4.65 (dt, J = 7.3, 3.4 Hz, 1H), 4.21 – 4.10 (m, 1H), 4.04 (s, 1H), 3.98 – 3.92 (m, 2H), 3.92 –
3.80 (m, 2H), 3.78 (s, 3H), 2.45 (dt, J = 13.9, 2.5 Hz, 1H), 2.35 – 2.26 (m, 1H), 1.56 – 1.45 (m,
3H), 1.29 – 1.23 (m, 18H), 1.15 (q, J = 6.8 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz,
CDCl3) δ 173.16, 170.90, 169.43, 77.28, 77.02, 76.77, 69.27, 62.83, 62.80, 54.86, 54.81, 52.84,
43.51, 43.26, 39.09, 37.25, 29.97, 29.75, 29.70, 29.63, 29.53, 28.00, 27.45, 25.60, 22.68. HRMS
(AccuTOF): [MH]+ Calc’d for C23H45N2O6 m/z 445.3278. Found: m/z 445.3242.

(3-Hydroxy-15-methylhexadecanoyl)glycyl-L-serine, ((rac)- 1)

A solution of 0.96 M LiOH (0.49 mL, 0.466 mmol) was added to a solution of methyl (3hydroxy-15-methylhexadecanoyl)glycyl-L-serinate ((3R+3S)-L-serine-21, 189 mg, 0.424 mmol) in
2 mL of methanol at 0 °C, and 4 mL of tetrahydrofuran was subsequently added. The resulting
solution was warmed to ambient temperature and stirred for 2 h. The solution was then neutralized
with 10% HCl and diluted with 25 mL of H2O. The solution was then extracted with EtOAc (3 X
25 mL) and the organic layers were concentrated in vacuo. The resulting crude material was
recrystallized from hot EtOAc to yield (3-hydroxy-15-methylhexadecanoyl)glycyl-L-serine,
(3R+3S)-L-serine-1, as a crystalline solid (177 mL, 0.412 mmol, 97.1 %), MP, 117-120 °C. 1H
NMR 1H NMR (400 MHz, Methanol-d4) δ 4.49 and 4.51 (two s, 1H), 4.11 (d, J= 17.3 Hz, 1H),
4.04 – 3.86 (m, 2H), 3.85 – 3.74 (m, 2H), 3.66 (d, J= 17.0 Hz, 1H), 3.37 – 3.29 (m, 1H), 2.41 –
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2.33 (m, 1H), 2.27 – 2.19 (m, 1H), 1.53 – 1.34 (m, 4H), 1.34 – 1.14 (m, 18H), 1.09 (q, J = 7.1, 6.7
Hz, 2H), 0.80 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CD3OD+CDCl3) δ 173.79, 173.58, 172.23,
172.09, 169.65, 169.56, 77.38, 77.06, 76.74, 69.24, 68.90, 62.14, 62.04, 54.69, 54.56, 49.83, 49.62,
49.40, 49.19, 48.97, 48.76, 48.55, 43.48, 43.29, 42.87, 42.77, 38.99, 37.44, 37.17, 29.87, 29.65,
29.60, 29.54, 29.47, 27.89, 27.34, 25.48, 25.43, 22.54. HRMS (AccuTOF): [MH]+ Calc’d for
C22H43N2O6 m/z 431.3121. Found: m/z 431.3131.

(3(R)-Hydroxy-15-methylhexadecanoyl)glycyl-L-serine, ((R)-1)

A solution of 0.51 M LiOH (0..33 mL, 0.168 mmol) was added to a solution of methyl
(3R)-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate ((3R)-L-serine-21, 68 mg, 0.153 mmol)
in 2 mL of methanol at 0 °C, and 4 mL of tetrahydrofuran was subsequently added. The resulting
solution was warmed to ambient temperature and stirred for 2 h. The solution was then neutralized
with 10% HCl and diluted with 25 mL of H2O. The solution was then extracted with EtOAc (3 X
25 mL) and the organic layers were concentrated in vacuo. The resulting crude material was
recrystallized from hot EtOAc to yield (3(R)-hydroxy-15-methylhexadecanoyl)glycyl-L-serine,
(3R)-L-serine-1, as a crystalline solid (44 mg, 0.102 mmol, 66.7 %), MP, 122-126 °C. 1H NMR
(500 MHz, CDCl3) δ 4.53 (s, 1H), 4.15 (d, J = 16.8 Hz, 1H), 3.95 (s, 1H), 3.68 (d, J = 16.9 Hz,
1H), 3.31 (d, 25.0 Hz, 1H), 2.38 (d, J = 13.7 Hz, 1H), 2.24 (t, J = 12.1 Hz, 1H), 1.60 – 1.42 (m,
3H), 1.40 – 1.20 (m, 18H), 1.13 – 1.09 (m, 2H), 0.82 (d, 6H). 13C NMR (126 MHz, CDCl3) δ
173.74, 172.42, 169.59, 77.31, 77.06, 77.06, 76.80, 69.32, 62.23, 55.93, 43.54, 42.96, 39.04, 37.47,
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29.92, 29.69, 29.65, 29.58, 29.51, 27.94, 27.39, 25.48, 22.65, 22.60. HRMS (AccuTOF): [MH]+
Calc’d for C22H43N2O6 m/z 431.3121. Found: m/z 431.3131.

(3(S)-Hydroxy-15-methylhexadecanoyl)glycyl-L-serine, ((S)-1)

A solution of 0.51 M LiOH (0.40 mL, 0.203 mmol) was added to a solution of methyl
(3(S)-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate (3S)-L-serine-21, 82 mg, 0.184 mmol) in
2 mL of methanol at 0 °C, and 4 mL of tetrahydrofuran was subsequently added. The resulting
solution was warmed to ambient temperature and stirred for 2 h. The solution was then neutralized
with 10% HCl and diluted with 25 mL of H2O. The solution was then extracted with EtOAc (3 X
25 mL) and the organic layers were concentrated in vacuo. The resulting crude material was
recrystallized from hot EtOAc to yield (3(S)-hydroxy-15-methylhexadecanoyl)glycyl-L-serine,
(3S)-L-serine-1, as a crystalline solid (59 mg, 0.137 mmol, 74.6 %), MP, 109-111 °C. 1H NMR
(400 MHz, CDCl3) δ 4.53 (s, 1H), 4.13 (d, J = 16.9 Hz, 1H), 3.94 (d, J = 11.6 Hz, 2H), 3.82 (d, J
= 11.6 Hz, 1H), 3.76 – 3.64 (m, 2H), 2.38 (d, J = 13.8 Hz, 1H), 2.24 (t, J = 12.0 Hz, 1H), 1.21 (s,
17H), 1.11 (s, 2H), 0.82 (d, J = 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.77, 172.35, 169.54,
77.37, 77.06, 76.74, 69.31, 62.20, 54.59, 43.53, 42.91, 39.02, 37.47, 29.90, 29.68, 29.63, 29.56,
29.49, 27.92, 27.38, 25.46, 22.59. HRMS (AccuTOF): [MH]+ Calc’d for C22H43N2O6 m/z
431.3121. Found: m/z 431.3131.
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6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3silahexacosan-13-yl 13-methyltetradecanoate, ((rac)-22)

13-Methyltetradecanoic acid (35 mg, 0.156 mmol) was dissolved in 5 mL of dry DCM and
stirred at 0 °C. To the solution was then treated with DCC (32 mg, 0.156 mmol), HOBt (21 mg,
0.156 mmol), and a catalytic amount of DMAP. After stirring for 15 min, methyl O-(tertbutyldiphenylsilyl)-N-((3-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, ((3R+3S)-12, 98
mg, 0.142 mmol) dissolved in 5 mL of dry DCM was added to the reaction via cannula. The
resulting solution was warmed to ambient temperature and stirred overnight. The solvent was
removed under reduced pressure and the resulting oil was redissolved in 20 mL of diethyl ether.
The resulting precipitate was filtered, and the filtrate washed with satd NaHCO3 (3 X 10 mL). The
organic layer was dried, filtered, and solvents evaporated under reduced pressure. Purification via
column chromatography (1% MeOH:DCM) yielded 6-(methoxycarbonyl)-2,2,25-trimethyl-8,11dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-silahexacosan-13-yl 13-methyltetradecanoate, (3R+3S)-Lserine-22, as a clear oil (124 mg, 0.137 mmol, 96.3%). 1H NMR (400 MHz, CDCl3) δ 7.58 (tt, J =
6.8, 1.6 Hz, 4H), 7.49–7.34 (m, 6H), 6.54 (dd, J = 8.1, 5.2 Hz, 1H), 6.36 (t, J= 4.6 Hz, 1H), 5.16
(quin, J = 6.3 Hz, 1H), 4.69-4.62 (m, 1H), 4.12 (dd, J = 10.3, 2.9 Hz, 1H), 4.02–3.81 (m, 3H), 3.74
(s, 3H), 2.55–2.42 (m, 2H), 2.29 (t, J = 7.5 Hz, 2H), 1.70-1.59 (m, 4H), 1.50 (sep, J = 6.6 Hz, 2H),
1.37-1.20 (m, 36H), 1.15 (q, J = 7.1, 6.7 Hz, 4H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR
(101 MHz, CDCl3) δ 173.41, 170.44, 170.40, 169.95, 168.24, 135.55, 135.51, 132.83, 132.80,
132.64, 130.10, 130.05, 127.96, 127.87, 77.38, 77.06, 76.74, 71.10, 64.15, 54.25, 52.56, 42.88,
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41.42, 39.11, 34.55, 34.17, 30.00, 29.77, 29.73, 29.61, 29.56, 29.41, 29.35, 29.20, 28.02, 27.47,
26.77, 25.31, 25.05, 22.71, 19.30.

HRMS (AccuTOF): [MH]+ Calc’d for C54H91N2O7Si m/z

907.6596. Found: m/z 907.6557.

(6S,13R)-6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza3-silahexacosan-13-yl 13-methyltetradecanoate, ((R)-22)

13-Methyltetradecanoic acid (77 mg, 0.316 mmol) was dissolved in 5 mL of dry DCM and
stirred at 0 °C. To the solution was then treated with DCC (78 mg, 0.380 mmol), HOBt (58 mg,
0.379 mmol), and a catalytic amount of DMAP. After stirring for 15 min, methyl O-(tertbutyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3R)-L-serine-12
(178 mg, 0.261 mmol) dissolved in 5 mL of dry DCM was added to the reaction via cannula. The
resulting solution was warmed to ambient temperature and stirred overnight. The solvent was
removed under reduced pressure and the resulting oil was redissolved in 20 mL of diethyl ether.
The resulting precipitate was filtered, and the filtrate washed with satd NaHCO3 (3 X 10 mL). The
organic layer was dried, filtered, and solvents evaporated under reduced pressure. Purification via
column chromatography (1% MeOH:DCM) yielded (6S,13R)-6-(methoxycarbonyl)-2,2,25trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-silahexacosan-13-yl

13-

methyltetradecanoate, (3R)-L-serine-22 as a clear oil (231 mg, 0.255 mmol, 97.7%). 1H NMR (400
MHz, CDCl3) δ 7.58 (t, J = 6.6 Hz, 4H), 7.49 – 7.34 (m, 6H), 6.53 (d, J = 8.1 Hz, 1H), 6.36 (t, J=
4.6 Hz, 1H), 5.16 (d, J = 24.6 Hz, 1H), 4.69-4.62 (m, 1H), 4.12 (dd, J = 10.3, 2.9 Hz, 1H), 4.00 –
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3.82 (m, 3H), 3.74 (s, 3H), 2.55 – 2.43 (m, 2H), 2.29 (t, J = 7.5 Hz, 2H), 1.70 – 1.55 (m, 4H), 1.50
(sep, J = 6.6 Hz, 2H), 1.25 (s, 36H), 1.15 (q, J = 7.1, 6.7 Hz, 4H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz,
12H).

13

C NMR (101 MHz, CDCl3) δ 173.43, 170.42, 169.96, 168.23, 135.56, 135.52, 132.83,

132.65, 130.10, 130.05, 127.96, 127.87, 77.38, 77.06, 76.74, 71.10, 64.15, 54.28, 52.57, 42.87,
41.43, 39.12, 34.55, 34.17, 30.00, 29.78, 29.73, 29.62, 29.57, 29.42, 29.35, 29.21, 28.02, 27.48,
26.78, 25.32, 25.05, 22.71, 19.31, 1.07. HRMS (AccuTOF): [MH]+ Calc’d for C54H91N2O7Si m/z
907.6596. Found: m/z 907.6586.

(6S,13S)-6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3silahexacosan-13-yl 13-methyltetradecanoate, ((S)-22)

13-Methyltetradecanoic acid (84 mg, 0.346 mmol) was dissolved in 5 mL of dry DCM and
stirred at 0 °C. The solution was then treated with DCC (85 mg, 0.415 mmol), HOBt (64 mg, 0.418
mmol), and a catalytic amount of DMAP.

After stirring for 15 min, methyl O-(tert-

butyldiphenylsilyl)-N-((3S-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3S)-L-serine-12
(189 mg, 0.277 mmol) dissolved in 5 mL of dry DCM was added to the reaction via cannula. The
resulting solution was warmed to ambient temperature and stirred overnight. The solvent was
removed under reduced pressure and the resulting oil was redissolved in 20 mL of diethyl ether.
The resulting precipitate was filtered, and the filtrate washed with satd NaHCO3 (3 X 10 mL). The
organic layer was dried, filtered, and solvents evaporated under reduced pressure. Purification via
column chromatography (1% MeOH:DCM) yielded (6S,13S)-6-(methoxycarbonyl)-2,2,2556

trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-silahexacosan-13-yl

13-

methyltetradecanoate, (3S)-L-serine-22 as a clear oil (245 mg, 0.269 mmol, 97.4%). 1H NMR (400
MHz, CDCl3) δ 7.63 – 7.54 (m, 4H), 7.48 – 7.34 (m, 6H), 6.53 (d, J = 8.1 Hz, 1H), 6.36 (t, J= 4.6
Hz, 1H), 5.16 (d, J = 24.6 Hz, 1H), 4.69-4.62 (m, 1H), 4.12 (dd, J = 10.3, 2.9 Hz, 1H), 4.04 – 3.79
(m, 2H), 3.73 (s, 3H), 2.57 – 2.41 (m, 2H), 2.28 (t, J = 7.5 Hz, 2H), 1.70-1.40 (m, 6H), 1.35-1.10
(m, 40H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 173.40, 170.46,
169.98, 168.31, 135.53, 135.49, 132.78, 132.62, 130.08, 130.02, 127.93, 127.85, 77.38, 77.06,
76.74, 71.08, 64.13, 54.24, 52.52, 42.89, 41.37, 39.09, 34.53, 34.15, 29.98, 29.76, 29.71, 29.60,
29.55, 29.39, 29.33, 29.19, 28.00, 27.45, 26.75, 26.69, 25.29, 25.03, 22.69, 22.63, 19.27, 1.05.
HRMS (AccuTOF): [MH]+ Calc’d for C54H91N2O7Si m/z 907.6596. Found: m/z 907.6583.

1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-methyl-1oxohexadecan-3-yl 13-methyltetradecanoate, ((rac)-23)

6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3silahexacosan-13-yl 13-methyltetradecanoate ((3R+3S)-L-serine-22, 197 mg, 0.217 mmol) was
dissolved in 5 mL of dry THF under nitrogen. The solution was cooled to 0 °C and was treated
with 1 M TBAF (0.24 mL, 0.24 mmol). The reaction was slowly warmed to ambient temperature
and stirred for 6 h. The solvent was removed under reduced pressure, and the resulting oil was
purified by column chromatography (2% MeOH:DCM) to yield 1-((2-(((S)-3-hydroxy-1-methoxy1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl
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13-

methyltetradecanoate, (3R+3S)-L-serine-23, as a clear oil (132 mg, 0.202 mmol, 93.1 %). 1H NMR
(400 MHz, CDCl3) δ two signals [7.05 and 7.12 (d, J= 7.6 and 7.8 Hz, 1H), 6.74 – 6.64 (m, 1H),
5.26 – 5.11 (m, 1H), 4.65 (h, J = 7.7, 3.8 Hz, 1H), 4.08 – 3.87 (m, 4H), 3.78 (d, J = 1.9 Hz, 3H),
2.52 – 2.45 (m, 2H), 2.30 (td, J = 7.6, 1.7 Hz, 2H), 1.68 – 1.43 (m, 6H), 1.40 – 1.20 (m, 36H), 1.15
(t, J = 6.6 Hz, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 174.45, 174.28,
170.92, 170.80, 170.70, 169.05, 169.01, 77.38, 77.06, 76.74, 71.46, 62.82, 55.05, 52.72, 43.32,
41.91, 41.81, 39.12, 39.08, 34.60, 34.56, 34.50, 30.01, 29.78, 29.74, 29.70, 29.62, 29.57, 29.40,
29.33, 29.22, 29.19, 28.02, 27.48, 25.31, 25.06, 25.01, 22.71. HRMS (AccuTOF): [MH]+ Calc’d
for C38H73N2O7 m/z 669.5418. Found: m/z 669.5425.

(R)-1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate, ((R)-23)

(6S,13R)-6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10diaza-3-silahexacosan-13-yl 13-methyltetradecanoate, ((3R)-L-serine-22, 231 mg, 0.255 mmol)
was dissolved in 5 mL of dry THF under nitrogen. The solution was cooled to 0 °C and was treated
with 1 M TBAF (0.25 mL, 0.25 mmol). The reaction was slowly warmed to ambient temperature
and stirred for 6 h. The solvent was removed under reduced pressure, and the resulting oil was
purified by column chromatography (2% MeOH:DCM) to yield ((R)-1-((2-(((S)-3-hydroxy-1methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl
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13-

methyltetradecanoate, (3R)-L-serine-23, as a clear oil (153 mg, 0.229 mmol, 89.9 %) 1H NMR (400
MHz, CDCl3) δ 7.12 (d, J= 7.7 Hz, 1H), 6.45 (t, J = 5.5 Hz, 1H), 5.25-5.10 (m, 1H), 4.67 (dq, J =
7.1, 3.5 Hz, 1H), 4.13-3.87 (m, 4H), 3.79 (s, 3H), 2.49 (d, J = 6.1 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H),
1.69 – 1.44 (m, 6H), 1.38-1.20 (m, 36H), 1.15 (q, J = 6.7 Hz, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C
NMR (101 MHz, CDCl3) δ 174.56, 170.70, 170.65, 168.95, 77.38, 77.06, 76.74, 71.54, 62.99,
55.01, 52.77, 43.43, 42.06, 39.12, 34.62, 30.01, 29.78, 29.74, 29.62, 29.56, 29.38, 29.33, 29.19,
28.03, 27.48, 25.32, 25.06, 25.01, 22.72. HRMS (AccuTOF): [MH]+ Calc’d for C38H73N2O7 m/z
669.5418. Found: m/z 669.5389.

(S)-1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate, , ((S)-23)

(6S,13S)-6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10diaza-3-silahexacosan-13-yl 13-methyltetradecanoate, ((3S)-L-serine-22, 245 mg, 0.269 mmol)
was dissolved in 5 mL of dry THF under nitrogen. The solution was cooled to 0 °C and was treated
with 1 M TBAF (0.27 mL, 0.27 mmol). The reaction was slowly warmed to ambient temperature
and stirred for 6 h. The solvent was removed under reduced pressure, and the resulting oil was
purified by column chromatography (2% MeOH:DCM) to yield ((S)-1-((2-(((S)-3-hydroxy-1methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl

13-

methyltetradecanoate, (3S)-L-serine-23, as a clear oil (164 mg, 0.245 mmol, 90.8 %) 1H NMR (400
MHz, CDCl3) δ 7.05 (d, J= 7.6 Hz, 1H), 6.49 (t, J = 5.3 Hz, 1H), 5.26-5.10 (m, 1H), 4.70 – 4.61
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(m, 1H), 4.13 – 3.88 (m, 4H), 3.79 (s, 3H), 2.49 (d, J = 5.9 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.72
– 1.44 (m, 6H), 1.43 – 1.19 (m, 36H), 1.15 (q, J = 6.7 Hz, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR
(101 MHz, CDCl3) δ 174.38, 170.79, 170.61, 168.94, 77.38, 77.06, 76.74, 71.54, 62.92, 55.02,
52.76, 43.43, 41.94, 39.12, 34.63, 34.55, 30.01, 29.79, 29.74, 29.62, 29.57, 29.38, 29.34, 29.22,
28.03, 27.48, 25.32, 25.06, 22.72. HRMS (AccuTOF): [MH]+ Calc’d for C38H73N2O7 m/z
669.5418. Found: m/z 669.5395.

(15-Methyl-3-((13-methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, ((rac)-2)

A

stirring

solution

of

1-((2-(3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-

oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate ((3R+3S)-L-serine-23,
119 mg, 0.178 mmol), in 10 mL of dry DCM, was cooled to 0 °C. Potassium trimethylsilonoate
(25 mg, 0.196 mmol) was added, and the reaction was stirred on the ice bath for 1.5 h before being
warmed to ambient temperature and stirred for an additional 1.5 hrs. The solvents were evaporated
under reduced pressure, and the resulting oil was dissolved in 10 mL of H2O and acidified with
10%

HCl.

The

resulting

precipitate

was

filtered

to

yield

15-methyl-3-((13-

methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, (3R+3S)-L-serine-2, as a white sticky
solid (105 mg, 0.161 mmol, 90.2%). 1H NMR (500 MHz, CDCl3) δ 5.17 (bs, 1H), 4.27 (bs, 1H),
4.12-3.50 (s, 5H), 1.67 – 1.41 (m, 6H), 1.40-1.20 (m, 36H), 1.12 (t, J = 6.6 Hz, 4H), 0.83 (d, J =
6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 174.04, 171.67, 169.92, 77.32, 77.06, 76.81, 71.21,
62.26, 55.95, 42.78, 41.09, 39.07, 34.58, 34.33, 31.91, 29.98, 29.76, 29.70, 29.67, 29.60, 29.52,
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29.38, 29.22, 27.96, 27.44, 25.28, 25.07, 22.63. HRMS (+TOF MS): [MNa]+ Calc’d for
C37H70N2NaO7 m/z 677.5075. Found: m/z 677.5081.

((R)-15-methyl-3-((13-methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, ((R)-2)

A stirring solution of 1(R)-1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate, ((3R)-L-serine-23, 25
mg, 0.037 mmol) in 10 mL of dry DCM was cooled to 0 °C. Potassium trimethylsilonoate (5.3
mg, 0.051 mmol) was added, and the reaction was stirred on the ice bath for 1.5 h before being
warmed to ambient temperature and stirred for an additional 1.5 hrs. The solvents were evaporated
under reduced pressure, and the resulting oil was dissolved in 10 mL of H2O and acidified with
10% HCl.

The resulting precipitate was filtered to yield ((R)-15-methyl-3-((13-

methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, (3R)-L-serine-2, as a white sticky solid
(18 mg, 0.028 mmol, 74%).

23
D

= +12.85° (c 1.02, CHCl3). 1H NMR (400 MHz, CDCl3) δ

5.15 (bs, 1H), 4.31 (bs, 1H), 4.11 – 3.44 (m, 4H), 2.47 (s, 2H), 2.24 (t, J = 7.5 Hz, 2H), 1.68 – 1.35
(m, 6H), 1.35 – 0.99 (m, 36H), 0.81 (d, J = 6.6 Hz, 12H). 13C NMR (101 MHz, CD3OD+ CDCl3)
δ 174.08, 173.94, 171.48, 169.54, 77.38, 77.06, 76.74, 71.08, 62.05, 49.39, 49.17, 48.96, 48.74,
48.53, 48.32, 48.10, 42.63, 40.87, 38.89, 34.37, 34.09, 29.78, 29.56, 29.52, 29.48, 29.43, 29.37,
29.26, 29.16, 29.00, 27.78, 27.25, 25.06, 24.87, 22.39. HRMS (+TOF MS): [MNa]+ Calc’d for
C37H70N2NaO7 m/z 677.5075. Found: m/z 677.5081.
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((S)-15-methyl-3-((13-methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, ((S)-2)

A stirring solution of 1(S)-1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate, ((3S)-L-serine-23, 25
mg, 0.037 mmol) in 10 mL of dry DCM was cooled to 0 °C. Potassium trimethylsilonoate (5.3
mg, 0.051 mmol) was added, and the reaction was stirred on the ice bath for 1.5 h before being
warmed to ambient temperature and stirred for an additional 1.5 hrs. The solvents were evaporated
under reduced pressure, and the resulting oil was dissolved in 10 mL of H2O and acidified with
10% HCl.

The resulting precipitate was filtered to yield ((S)-15-methyl-3-((13-

methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, (3S)-L-serine-2, as a white sticky solid
(16 mg, 0.024 mmol, 65%).

23
D

= +6.3° (c 1.02, CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.16

(t, J= 5.6 Hz, 1H), 4.29 (s, 1H), 4.10 – 3.60 (m, 4H), 2.56 – 2.35 (m, 2H), 2.23 (t, J = 7.5 Hz, 2H),
1.65 – 1.40 (m, 6H), 1.40 – 0.99 (m, 40H), 0.81 (d, J = 6.6 Hz, 12H). 13C NMR (101 MHz, CDCl3)
δ 174.03, 173.75, 171.50, 169.73, 77.38, 77.06, 76.74, 71.20, 62.24, 55.60, 50.01, 49.80, 49.58,
49.37, 49.16, 48.94, 48.73, 42.74, 41.11, 39.04, 34.53, 34.33, 29.95, 29.73, 29.70, 29.66, 29.62,
29.55, 29.46, 29.40, 29.33, 29.18, 27.93, 27.41, 25.24, 25.02, 22.60. HRMS (+TOF MS): [MNa]+
Calc’d for C37H70N2NaO7 m/z 677.5075. Found: m/z 677.5081.
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((11-Bromoundecyl)oxy)(tert-butyl)dimethylsilane, (28)

A flame-dried 100 mL round bottom flask was charged with 11-bromoundecan-1-ol (2.00
g, 7.96 mmol). The starting material was dissolved in CH2Cl2 (50 mL) and cooled on an ice bath.
tert-Butyldimethylsilyl chloride (1.40 g, 9.15 mmol) was added and stirred for 15 min before the
addition of imidazole (0.705 g, 10.4 mmol). The reaction was stirred overnight at room
temperature. Upon completion the suspension was gravity filtered and concentrated under reduced
pressure. The crude product was purified by column chromatography on silica gel (5%
EtOAc:hexane) to yield ((11-bromoundecyl)oxy)(tert-butyl)dimethylsilane,57 28, as a clear liquid
(2.85 g, 7.78 mmol, 97.7%). 1H NMR (400 MHz, CDCl3) δ 3.60 (t, J = 6.6 Hz, 2H), 3.41 (t, J =
6.9 Hz, 2H), 1.85 (p, J = 7.0 Hz, 2H), 1.51 (t, J = 6.8 Hz, 2H), 1.42 (t, J = 7.4 Hz, 2H), 1.28 (s,
12H), 0.90 (s, 9H), 0.05 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 63.38, 34.09, 32.94, 32.91, 29.63,
29.53, 29.47, 28.82, 28.24, 26.05, 25.85, 18.44, -5.19. ppm HRMS (AccuTOF): [MH]+ Calc’d for
C17H37BrOSi m/z 365.1875. Found: m/z 365.1869.

1-Bromobutane

A solution of 48% HBr (2.50 g) was added to a flame dried 25 mL round bottomed flask.
Dropwise addition of H2SO4 (0.40 mL) was followed by stirring until the flask was cool to the
touch. Dropwise addition of butan-1-ol (1.00 g, 13.5 mmol) was followed by treatment with
H2SO4 (0.35 mL). A reflux condenser was attached and the solution was heated for 3 h. A vacuum
distillation apparatus was set up through the top of the original reflux condenser. The product was
gently vacuum-distilled into an ice-chilled flask while the vertical condenser was slowly warmed.
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The distillate was dried over CaCO3 to yield 1-bromobutane58 as a clear liquid (1.13 g, 8.25 mmol,
61%). 1H NMR (400 MHz, CDCl3) δ 3.42 (t, J = 6.8 Hz, 2H), 1.84 (p, J = 6.9 Hz, 2H), 1.48 (hept,
J = 7.5 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H).

C NMR (101 MHz, CDCl3) δ 34.83, 33.72, 21.37,

13

13.23.

d9-1-Bromobutane

A solution of 48% HBr (2.50 g) was added to a flame-dried 25 mL round bottomed flask.
Dropwise addition of H2SO4 (0.40 mL) was followed by stirring until the flask was cool to the
touch. Dropwise addition of commercially available d9-butan-1-ol (1.00 g, 12.0 mmol), was
followed by addition of H2SO4 (0.35 mL). A reflux condenser was attached and the solution was
heated at reflux for 3 h. A vacuum distillation apparatus was set up through the top of the original
reflux condenser. The product was gently vacuum distilled into an ice-chilled flask while the
vertical condenser was slowly warmed. The distillate was dried over CaCO3 to yield d9-1bromobutane59 as a clear liquid (0.99 g, 6.78 mmol, 56.4%).

tert-Butyldimethyl(pentadecyloxy)silane, (29)

Magnesium turnings (33 mg, 1.37 mmol) were added to a 25 mL round bottomed flask that
was fitted with a stirbar and the apparatus was flame-dried under a nitrogen atmosphere. After
cooling, the Mg turnings were suspended in dry THF (5 mL) and 1-bromobutane (0.13 mL, 1.20
mmol) was rapidly added with vigorously stirring. The reaction was stirred until the flask cooled
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to ambient temperature and the flask was subsequently chilled to 0 °C. The Grignard reagent was
added to a mixture of ((11-bromoundecyl)oxy)(tert-butyl)dimethylsilane (28, 0.250 g,0.684
mmol), LiCl (0.88 mg, 0.021 mmol), copper (II) chloride (2.8 mg, 0.021 mmol), and N-methyl-2pyrrolidone (NMP, 0.30 mL, 3.11 mmol) dissolved in THF (5 mL) and held at 0 °C. The mixture
was slowly warmed to ambient temperature and stirred for 1 h. The reaction was quenched on ice
with 1M HCl (10 mL) before being transferred to a separatory funnel with EtOAc (15 mL) and
H2O (10 mL). The layers were separated and the aqueous layer was extracted once with EtOAc
(15 mL). The organic layers were combined and then washed with 1M HCl (10 mL), H 2O (2 X
10 mL), and brine (10 mL). The organic phase was dried with MgSO4, gravity filtered, and
solvents removed in vacuo. The crude product was purified by column chromatography on silica
gel (hexane) to yield tert-butyldimethyl(pentadecyloxy)silane, 29, as a clear liquid (0.218 g,0.636
mmol, 93.0%). 1H NMR (400 MHz, CDCl3) δ 3.60 (t, J = 6.6 Hz, 2H), 1.52 (d, J = 6.8 Hz, 2H),
1.26 (s, 24H), 0.96–0.79 (m, 12H), 0.05 (s, 6H).

C NMR (101 MHz, CDCl3) δ 63.41, 32.97,

13

31.99, 29.75, 29.72, 29.51, 29.42, 26.05, 25.87, 22.75, 14.18, -5.19. HRMS (AccuTOF): [MH]+
Calc’d for C21H46OSi m/z 343.3396. Found: m/z 343.3373.

tert-Butyldimethyl((pentadecyl-12,12,13,13,14,14,15,15,15-d9)oxy)silane, (37)

Magnesium turnings (133 mg, 5.48 mmol) were added to a 50 mL round bottom flask fitted
with a stirbar and the apparatus was flame-dried under a nitrogen atmosphere. After cooling, the
Mg turnings were suspended in dry THF (10 mL) and d9-1-bromobutane (0.52 mL, 4.80 mmol)
was rapidly added with vigorously stirring. The reaction was stirred until the flask cooled to
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ambient temperature and the temperature was lowered to 0 °C. The Grignard reagent was added
to a mixture of ((11-bromoundecyl)oxy)(tert-butyl)dimethylsilane (28, 1.00 g, 2.74 mmol), LiCl
(5.8 mg, 0.14 mmol), copper (II) chloride (9.2 mg, 0.069 mmol), and NMP (1.98 mL, 20.6 mmol)
dissolved in THF (10 mL) and the reaction mixture was maintained at 0 °C. The mixture was
slowly warmed to ambient temperature and stirred for 1 h. The reaction was quenched on ice with
1M HCl (25 mL) before being transferred to a separatory funnel with EtOAc (50 mL) and H2O
(50 mL). The layers were separated and the aqueous layer was extracted once with EtOAc (50
mL). The organic layers were combined and washed with 1M HCl (25 mL), H2O (2 X 25 mL),
and brine (25 mL). The organic phase was dried with MgSO4, gravity filtered, and solvents
removed in vacuo. The crude product was purified by column chromatography on silica gel
(hexane) to yield tert-butyldimethyl((pentadecyl-12,12,13,13,14,14,15,15,15-d9)oxy)silane, 37, as
a clear liquid (0.949 g, 2.69 mmol, 98.3%). 1H NMR (400 MHz, CDCl3) δ 3.60 (t, J = 6.6 Hz, 2H),
1.51 (t, J = 6.8 Hz, 2H), 1.25 (s, 18H), 0.89 (s, 9H), 0.05 (s, 6H). 13C NMR (101 MHz, CDCl3) δ
63.42, 32.96, 29.76, 29.72, 29.68, 29.52, 29.47, 26.05, 25.87, 18.44, -5.19. HRMS (AccuTOF):
[MH]+ Calc’d for C21H37D9OSi m/z 352.3961. Found: m/z 352.3949.

Pentadecan-1-ol, (30)

tert-Butyldimethyl(pentadecyloxy)silane (29, 678 mg, 1.98 mmol) was dissolved in 25 mL
of dry THF under nitrogen. The solution was cooled to 0 °C and was treated with 1 M TBAF (4.95
mL, 4.95 mmol). The reaction was slowly warmed to ambient temperature and stirred for 6 h.
The solvent was removed under reduced pressure, and the resulting oil was purified by column
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chromatography (15% EtOAc:Hexanes) to yield ethyl 3-hydroxyheptadecanoate,60 30, as a white
solid (395 mg, 1.73 mmol, 87.4 %), MP 44-46 °C. 1H NMR (400 MHz, CDCl3) δ 3.64 (t, J = 6.6
Hz, 2H), 1.57 (t, J = 7.2, 6.7 Hz, 2H), 1.35–1.23 (m, 25H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (101
MHz, CDCl3) δ 63.17, 32.88, 31.98, 29.74, 29.72, 29.66, 29.49, 29.41, 25.80, 22.75, 14.17. HRMS
(AccuTOF): [M2H]+ Calc’d for C15H32O m/z 457.4985. Found: m/z 457.4998.

Pentadecan-12,12,13,13,14,14,15,15,15-d9-1-ol, (38)

tert-Butyldimethyl((pentadecyl-12,12,13,13,14,14,15,15,15-d9)oxy)silane (37, 961 mg,
2.73 mmol) was dissolved in 25 mL of dry THF under nitrogen. The solution was cooled to 0 °C
and was treated with 1 M TBAF (6.83 mL, 6.83 mmol). The reaction was slowly warmed to
ambient temperature and stirred for 6 h. The solvent was removed under reduced pressure, and
the resulting oil was purified by column chromatography (15% EtOAc:Hexanes) to yield
pentadecan-12,12,13,13,14,14,15,15,15-d9-1-ol, 38, as a white solid (643 mg, 2.71 mmol, 99.1 %),
MP 42-45 °C. 1H NMR (400 MHz, CDCl3) δ 3.64 (t, J = 6.6 Hz, 2H), 1.57 (p, J = 6.9 Hz, 2H),
1.39–1.22 (m, 19H).

13

C NMR (101 MHz, CDCl3) δ 63.18, 32.89, 29.72, 29.67, 29.49, 25.80.

HRMS (AccuTOF): [M-OH]+ Calc’d for C15H23D9O m/z 220.2991. Found: m/z 220.2975.
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Pentadecanal, (31)

4-(Acetyamino)-2,2,6,6-tetramethyl-1-oxo-piperidinium

tetrafluoroboratesmith-bobbit

(Bobbit’s salt, 3.552 g, 11.84 mmol) was added to pentadecan-1-ol (30, 2.351 g, 10.29 mmol)
dissolved in 200 mL of dry DCM. An equal mass of silica was slowly added to the stirring mixture.
The bright yellow solution stirred at ambient temperature until the color faded, giving a solution
with a pale yellow tint. The solution was filtered to remove the silica, and the filtrate was
concentrated in vacuo.

The crude product was purified by column chromatography (5%

EtOAc:hexanes) to yield pentadecanal,61 31, as a clear solid, (2.116 g, 9.346 mmol, 90.8%), MP
~25 °C. 1H NMR (400 MHz, CDCl3) δ 9.76 (t, J = 1.9 Hz, 1H), 2.41 (td, J = 7.3, 1.9 Hz, 2H), 1.63
(p, J = 7.3 Hz, 2H), 1.35–1.22 (m, 22H), 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ
203.01, 43.98, 31.98, 29.70, 29.63, 29.48, 29.41, 29.23, 22.74, 22.16, 14.17. HRMS (AccuTOF):
[M-H]+ Calc’d for C15H30O m/z 225.2218. Found: m/z 225.2216.

Pentadecanal-12,12,13,13,14,14,15,15,15-d9, (39)

4-(Acetyamino)-2,2,6,6-tetramethyl-1-oxo-piperidinium

tetrafluoroboratesmith-bobbit

(Bobbit’s salt, 829 mg, 2.76 mmol) was added to pentadecan-12,12,13,13,14,14,15,15,15-d9-1-ol
(38, 625 mg, 2.63 mmol) dissolved in 100 mL of dry DCM. An equal mass of silica was slowly
added to the stirring mixture. The bright yellow solution stirred at ambient temperature until the
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color faded, giving a solution with a pale yellow tint. The solution was filtered to remove the
silica, and the filtrate was concentrated in vacuo. The crude product was purified by column
chromatography (5% EtOAc:hexanes) to yield pentadecanal-12,12,13,13,14,14,15,15,15-d9, 39,
as a clear solid, (468 mg, 1.99 mmol, 75.6%), MP, ~25 °C. 1H NMR (400 MHz, CDCl3) δ 9.76 (t,
J = 2.0 Hz, 1H), 2.41 (td, J = 7.4, 1.9 Hz, 2H), 1.64 (p, J = 7.2 Hz, 2H), 1.32–1.20 (m, 16H). 13C
NMR (101 MHz, CDCl3) δ 203.01, 43.98, 29.73, 29.69, 29.64, 29.48, 29.46, 29.41, 29.23, 22.16.
HRMS (AccuTOF): [MH]+ Calc’d for C15H21D9O m/z 234.2783. Found: m/z 234.2808.

Ethyl 3-oxoheptadecanoate, (32)

Tin (II) chloride dihydrate (52 mg, 0.231 mmol) was suspended in 20 mL of dry DCM.
Ethyl diazoacetate (319 mg, 2.43 mmol) was added, dropwise via syringe, and the reaction was
stirred for 15 min. Pentadecanal (31, 524 mg, 2.31 mmol) was dissolved in 10 mL of DCM and
added to the reaction, dropwise, via cannula. The mixture was stirred at ambient temperature for
about 6 h, until nitrogen evolution ceased. The reaction mixture was diluted with 100 mL of DCM
and washed with a saturated brine solution (2 X 50 mL). The aqueous layers were combined and
extracted with DCM (2 X 25 mL). All organic layers were combined, dried with MgSO4, filtered,
and solvents evaporated at reduced pressure. The resulting crude product was purified via column
chromatography (5% EtOAc:hexanes) to yield ethyl 3-oxoheptadecanoate,62 32, as a clear solid
(642 mg, 2.07 mmol, 89.6%), MP 37-39 °C. 1H NMR (400 MHz, CDCl3) δ 4.20 (q, J = 7.1 Hz,
2H), 3.42 (s, 2H), 2.53 (t, J = 7.4 Hz, 2H), 1.59 (p, J = 7.1 Hz, 2H), 1.34–1.22 (m, 25H), 0.88 (t, J
= 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 203.03, 167.32, 61.38, 49.38, 43.12, 31.98, 29.71,
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29.65, 29.50, 29.41, 29.09, 23.54, 22.75, 14.17. HRMS (AccuTOF): [MH]+ Calc’d for C19H36O3
m/z 313.2743. Found: m/z 313.2724.

Ethyl 3-oxoheptadecanoate-14,14,15,15,16,16,17,17,17-d9, (40)

Tin (II) chloride dihydrate (46 mg, 0.206 mmol) was suspended in 15 mL of dry DCM.
Ethyl diazoacetate (0.275 mL, 2.27 mmol) was added, dropwise via syringe, and the reaction was
stirred for 15 min. The pentadecanal-12,12,13,13,14,14,15,15,15-d9 (39, 486 mg, 2.06 mmol) was
dissolved in 10 mL of DCM and added to the reaction, dropwise, via cannula. The mixture was
stirred at ambient temperature for about 6 h, until nitrogen evolution ceased. The reaction mixture
was diluted with 100 mL of DCM and washed with a saturated brine solution (2 X 50 mL). The
aqueous layers were combined and extracted with DCM (2 X 25 mL). All organic layers were
combined, dried with MgSO4, filtered, and solvents evaporated at reduced pressure. The resulting
crude product was purified via column chromatography (5% EtOAc:hexanes) to yield ethyl 3oxoheptadecanoate-14,14,15,15,16,16,17,17,17-d9, 40, as a clear solid (534 mg, 1.66 mmol,
80.6%), MP 36-38 °C. 1H NMR (400 MHz, CDCl3) δ 4.19 (q, J = 7.1 Hz, 2H), 3.42 (s, 2H), 2.52
(t, J = 7.4 Hz, 2H), 1.59 (t, J = 7.2 Hz, 2H), 1.29–1.24 (m, 19H). 13C NMR (101 MHz, CDCl3) δ
203.05, 167.32, 61.38, 49.38, 43.12, 29.73, 29.70, 29.65, 29.50, 29.46, 29.41, 29.09, 23.54, 14.16.
HRMS (AccuTOF): [MH]+ Calc’d for C19H27D9O3 m/z 322.3308. Found: m/z 322.3324.

70

Ethyl 3-hydroxy-heptadecanoate, (33)

A solution of ethyl 3-oxoheptadecanoate (32, 620 mg, 1.98 mmol) in 2 mL of ethanol and
18 mL of THF was cooled to 0 °C on an ice bath. Sodium borohydride (60 mg, 1.59 mmol) was
added and the resulting slurry was stirred vigorously for 1 h. The reaction was quenched by the
slow addition of 10 mL of a 10 % aq. citric acid solution. Subsequent neutralization with satd.
K2CO3 solution was followed by extraction with EtOAc (3 X 20 mL). The organic layers were
washed with 10 mL of satd. brine solution, dried with MgSO4, filtered, and the solvents were
removed at reduced pressure. The crude product was purified by column chromatography (10%
EtOAc:Hexanes) to yield ethyl 3-hydroxy-heptadecanoate, 33, as a white solid (455 mg, 1.45
mmol, 77.6 % brsm) MP 41-43 °C. 1H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.1 Hz, 2H), 3.99
(tt, J = 7.9, 3.9 Hz, 1H), 2.90 (d, J = 4.0 Hz, 1H), 2.50 (dd, J = 16.4, 3.1 Hz, 1H), 2.39 (dd, J =
16.4, 9.0 Hz, 1H), 1.43 (dd, J = 8.5, 4.3 Hz, 2H), 1.38–1.19 (m, 27H), 0.88 (t, J = 6.6 Hz, 3H). 13C
NMR (101 MHz, CDCl3) δ 173.19, 68.11, 60.71, 41.35, 36.59, 31.99, 29.74, 29.71, 29.64, 29.59,
29.42, 25.54, 22.75, 14.25, 14.18. HRMS (AccuTOF): [MH]+ Calc’d for C19H38O3 m/z 315.2899.
Found: m/z 315.2899.
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Ethyl 3-hydroxyheptadecanoate-14,14,15,15,16,16,17,17,17-d9, (41)

A solution of ethyl 3-oxoheptadecanoate-14,14,15,15,16,16,17,17,17-d9 (40, 515 mg, 1.60
mmol) in 2 mL of ethanol and 18 mL of THF was cooled to 0 °C on an ice bath. Sodium
borohydride (48 mg, 1.28 mmol) was added and the resulting slurry was stirred vigorously for 1
h. The reaction was quenched by the slow addition of 10 mL of a 10 % aq. citric acid solution.
Subsequent neutralization with satd. K2CO3 solution was followed by extraction with EtOAc (3 X
20 mL). The organic layers were washed with 10 mL of satd. brine solution, dried with MgSO 4,
filtered, and the solvents were removed at reduced pressure. The crude product was purified by
column chromatography (10% EtOAc:Hexanes) to yield ethyl 3-hydroxyheptadecanoate14,14,15,15,16,16,17,17,17-d9, 41, as a white solid (392 mg, 1.21 mmol, 79.7 % brsm) MP 38-40
°C. 1H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.2 Hz, 2H), 4.00 (ddt, J = 12.0, 7.3, 4.0 Hz, 1H),
2.90 (d, J = 4.0 Hz, 1H), 2.50 (dd, J = 16.4, 3.2 Hz, 1H), 2.39 (dd, J = 16.4, 9.0 Hz, 1H), 1.47–1.39
(m, 2H), 1.39–1.12 (m, 21H). 13C NMR (101 MHz, CDCl3) δ 173.19, 68.11, 60.72, 41.35, 36.59,
29.75, 29.71, 29.64, 29.59, 29.47, 25.54, 14.25. HRMS (AccuTOF): [MH]+ Calc’d for
C19H29D9O3 m/z 324.3464. Found: m/z 324.2442.
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3-Hydroxy heptadecanoic acid, (34)

Hydroxy ester 33 (440 mg, 1.40 mmol) was dissolved in 2 mL of MeOH and 4 mL of THF
and 1 M aqueous LiOH (1.68 mL, 1.61 mmol) were added. The mixture was stirred overnight at
ambient temperature. The reaction was then acidified with 1 M HCl and extracted with EtOAc (3
X 15 mL). The organic layers were washed with 10 mL of brine, dried with MgSO4, filtered, and
the solvents were removed at reduced pressure. The crude solid was recrystallized from hexanes
to yield 3-hydroxy-heptadecanoic acid, 34, as a white solid (335 mg, 1.17 mmol, 83.6%), MP 8688 °C. 1H NMR (400 MHz, CDCl3) δ 4.04 (tt, J = 8.1, 3.8 Hz, 1H), 2.59 (dd, J = 16.6, 3.2 Hz, 1H),
2.48 (dd, J = 16.6, 8.9 Hz, 1H), 1.55–1.43 (m, 3H), 1.40–1.15 (m, 24H), 0.88 (t, J = 6.7 Hz, 3H).
C NMR (101 MHz, CDCl3) δ 175.72, 68.07, 40.73, 36.62, 31.98, 29.75, 29.71, 29.63, 29.60,

13

29.52, 29.42, 25.48, 22.75, 14.18. HRMS (AccuTOF): [MH]+ Calc’d for C17H34O3 m/z 287.2586.
Found: m/z 287.2605.

3-Hydroxyheptadecanoic-14,14,15,15,16,16,17,17,17-d9 acid, (42)

Ethyl 3-hydroxyheptadecanoate-14,14,15,15,16,16,17,17,17-d9, 41 (390 mg, 1.21 mmol)
was dissolved in 2 mL of MeOH and 4 mL of THF and 1 M aqueous LiOH (1.45 mL, 1.39 mmol)
were added. The mixture was stirred overnight at ambient temperature. The reaction was then
acidified with 1 M HCl and extracted with EtOAc (3 X 15 mL). The organic layers were washed
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with 10 mL of brine, dried with MgSO4, filtered, and the solvents were removed at reduced
pressure. The crude solid was recrystallized from hexanes to yield 3-hydroxyheptadecanoic14,14,15,15,16,16,17,17,17-d9 acid, 42, as a white solid (318 mg, 1.08 mmol, 89.3%), MP 79-81
°C. 1H NMR (400 MHz, CDCl3) δ 4.03 (s, 1H), 2.58 (dd, J = 16.6, 3.2 Hz, 1H), 2.48 (dd, J = 16.6,
8.9 Hz, 1H), 1.58–1.40 (m, 3H), 1.25 (s, 18H).

13

C NMR (101 MHz, CDCl3) δ 175.79, 68.06,

40.76, 36.63, 29.71, 29.63, 29.60, 29.53, 29.47, 25.49. HRMS (-TOF MS): [M-H]- Calc’d for
C17H25D9O3 m/z 294.2995. Found: m/z 294.2982.

Methyl-O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-heptadecanoyl)glycyl)-L-serinate, (35)

N-Hydroxy succinimide (185 mg, 1.61 mmol) and N-(3-dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride (308 mg, 1.61 mmol) were added to a stirring solution of 3hydroxyheptadecanoic acid (34, 401 mg, 1.40 mmol) in 25 mL of dry DCM. The solution was
stirred for 5 h at ambient temperature, filtered, and the filtrate was concentrated in vacuo. The
resulting white solid was dissolved in 25 mL of methanol and this solution was added via cannula
to a solution of methyl N-(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate
(14, 960 mg, 1.75 mmol) and Pd/C (298 mg) in 50 mL of methanol. The reaction vessel was
flushed with H2 and the mixture was stirred overnight, filtered through Celite, and concentrated
under reduced pressure. The crude product was purified via column chromatography (2%
MeOH:DCM) to yield methyl O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-heptadecanoyl)glycyl)L-serinate,

35, as a clear oil (641 mg, 0.938 mmol, 67.0%). 1H NMR (400 MHz, CDCl3) δ 7.58 (t,

J = 7.0 Hz, 4H), 7.50–7.33 (m, 6H), 6.88 (dd, J = 28.7, 8.2 Hz, 1H), 6.39 (dt, J = 42.3, 5.5 Hz, 1H),
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4.67 (dt, J = 7.7, 2.5 Hz, 1H), 4.19–3.76 (m, 5H), 3.75 (s, 3H), 3.43 (dd, J = 38.5, 3.6 Hz, 1H),
2.41 (dt, J = 14.6, 2.2 Hz, 1H), 2.27 (dd, J = 13.9, 9.4 Hz, 1H), 1.52–1.35 (m, 3H), 1.33–1.22 (m,
24H), 1.04 (s, 9H), 0.88 (t, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.80, 172.75, 170.73,
168.71, 168.71, 168.53, 135.56, 135.52, 132.98, 132.93, 132.69, 132.64, 130.08, 127.97, 127.94,
127.90, 127.87, 68.93, 64.31, 64.27, 54.34, 52.63, 43.06, 43.02, 42.93, 42.81, 37.19, 37.15, 31.98,
29.75, 29.72, 29.64, 29.57, 29.42, 26.80, 25.49, 22.75, 19.33, 14.17. HRMS (AccuTOF): [MH]+
Calc’d for C39H62N2O6Si m/z 683.4455. Found: m/z 683.4432.

Methyl O-(tert-butyldiphenylsilyl)-N-((3-hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17d9)glycyl)-L-serinate, (43)

N-Hydroxy succinimide (130 mg, 1.13 mmol) and N-(3-dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride (216 mg, 1.13 mmol) were added to a stirring solution of 3hydroxyheptadecanoic-14,14,15,15,16,16,17,17,17-d9 acid (42, 303 mg, 1.03 mmol) in 10 mL of
dry THF. The solution was stirred for 5 h at ambient temperature, filtered, and the filtrate was
concentrated in vacuo. The resulting white solid was dissolved in 25 mL of methanol and this
solution was added via cannula to a solution of methyl N-(((benzyloxy)carbonyl)glycyl)-O-(tertbutyldiphenylsilyl)-L-serinate (14, 563 mg, 1.03 mmol) and Pd/C (273 mg) in 50 mL of methanol.
The reaction vessel was flushed with H2 and the mixture was stirred overnight, filtered through
Celite, and concentrated under reduced pressure. The crude product was purified via column
chromatography (2%

MeOH:DCM) to

yield methyl
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O-(tert-butyldiphenylsilyl)-N-((3-

hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl)-L-serinate, 43, as a clear oil (555
mg, 0.802 mmol, 78.2%). 1H NMR (400 MHz, CDCl3) δ 7.59 (tt, J = 8.1, 1.6 Hz, 4H), 7.49–7.33
(m, 6H), 6.86 (dd, J = 26.2, 8.2 Hz, 1H), 6.34 (dt, J = 41.6, 5.4 Hz, 1H), 4.67 (dtd, J = 7.6, 2.9, 1.2
Hz, 1H), 4.19–3.78 (m, 5H), 3.75 (s, 3H), 3.41 (dd, J = 35.9, 3.6 Hz, 1H), 2.40 (dt, J = 14.6, 2.5
Hz, 1H), 2.26 (ddd, J = 14.6, 9.5, 2.1 Hz, 1H), 1.53–1.34 (m, 3H), 1.32–1.22 (m, 17H), 1.04 (s,
9H).

13

C NMR (101 MHz, CDCl3) δ 172.78, 172.73, 170.70, 168.66, 168.49, 135.57, 135.52,

132.98, 132.93, 132.70, 132.64, 130.09, 127.96, 127.93, 127.90, 127.87, 68.92, 64.31, 64.26,
54.34, 52.61, 43.05, 43.02, 42.94, 42.82, 37.19, 37.14, 29.72, 29.65, 29.57, 29.47, 26.80, 25.49,
19.33. HRMS (AccuTOF): [MH]+ Calc’d for C39H53D9N2O6 m/z 692.5020. Found: m/z 692.5007.

Methyl (3-hydroxyheptadecanoyl)glycyl-L-serinate

Methyl O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-heptadecanoyl)glycyl)-L-serinate (35,
124 mg, 0.182 mmol) was dissolved in 10 mL of dry THF under nitrogen. The solution was cooled
to 0°C and was treated with 1 M tetrabutylammonium fluoride (TBAF, 0.20 mL, 0.200 mmol).
The reaction was slowly warmed to ambient temperature and stirred for 6 h. The solvent was
removed under reduced pressure, and the resulting oil was purified by column chromatography
(2.5 % MeOH:DCM) to yield methyl (3-hydroxyheptadecanoyl)glycyl-L-serinate as a white solid,
(65 mg, 0.146 mmol, 80.5 %), MP, 104-111 °C. 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 7.8
Hz, 1H), 6.71 (d, J = 5.5 Hz, 1H), 4.66 (dt, J = 7.3, 3.4 Hz, 1H), 4.22–3.80 (m, 6H), 3.79 (s, 3H),
3.55 (d, J = 23.0 Hz, 1H), 2.46 (dt, J = 13.9, 2.8 Hz, 1H), 2.36–2.24 (m, 1H), 1.52–1.36 (m, 3H),
1.32–1.24 (m, 24H), 0.88 (t, J = 6.6 Hz, 3H).

C NMR (101 MHz, CDCl3) δ 173.30, 173.10,
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171.07, 170.89, 169.39, 169.18, 69.59, 69.31, 62.92, 54.87, 54.83, 52.89, 43.69, 43.50, 43.46,
43.32, 37.48, 37.27, 31.98, 29.75, 29.72, 29.65, 29.55, 29.42, 25.61, 25.54, 22.75, 14.17. HRMS
(AccuTOF): [MH]+ Calc’d for C23H44N2O6 m/z 445.3278. Found: m/z 444.3278.

Methyl (3-hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serinate

Methyl

O-(tert-butyldiphenylsilyl)-N-((3-hydroxyheptadecanoyl-

14,14,15,15,16,16,17,17,17-d9)glycyl)-L-serinate, (43, 192 mg, 0.277 mmol) was dissolved in 10
mL of dry THF under nitrogen. The solution was cooled to 0°C and was treated with 1 M
tetrabutylammonium fluoride (TBAF, 0.30 mL, 0.304 mmol). The reaction was slowly warmed
to ambient temperature and stirred for 6 h. The solvent was removed under reduced pressure, and
the resulting oil was purified by column chromatography (2.5 % MeOH:DCM) to yield methyl (3hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serinate as a white solid, (107 mg,
0.236 mmol, 85.1 %), MP, 95-102 °C. 1H NMR (400 MHz, CDCl3) δ 7.47 (dd, J = 30.8, 7.7 Hz,
1H), 6.93 (d, J = 6.2 Hz, 1H), 4.65 (dt, J = 7.4, 3.5 Hz, 1H), 4.23–3.78 (m, 6H), 3.78 (s, 3H), 2.45
(dt, J = 14.0, 2.4 Hz, 1H), 2.36–2.25 (m, 1H), 1.54–1.37 (m, 3H), 1.33–1.23 (m, 17H). 13C NMR
(101 MHz, CDCl3) δ 173.36, 173.21, 171.17, 170.97, 169.54, 169.39, 69.62, 69.30, 62.76, 54.92,
54.87, 52.86, 43.72, 43.57, 43.35, 43.26, 37.49, 37.28, 29.76, 29.73, 29.67, 29.58, 29.47, 25.65,
25.59. HRMS (AccuTOF): [MH]+ Calc’d for C23H35D9N2O6 m/z 454.3843. Found: m/z 454.3814.
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(3-Hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine, (26)

A solution of 1 M LiOH (0.12 mL, 0.12 mmol) was added to a solution of methyl (3hydroxyheptadecanoyl)glycyl-L-serinate (47 mg, 0.11 mmol) in 2 mL of methanol at 0 °C, and 4
mL of THF was subsequently added. The resulting solution was warmed to ambient temperature
and stirred for 2 h. The solution was then neutralized with 10% HCl and diluted with 25 mL of
H2O. The solution was then extracted with EtOAc (3 X 25 mL) and the organic layers were
concentrated in vacuo. The resulting crude material was recrystallized from hot EtOAc to yield (3hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine, 26, as a crystalline solid
(38 mg, 0.088 mmol, 84 %), MP, 119-122 °C. 1H NMR (400 MHz, CDCl3) δ 4.64–4.40 (m, 1H),
4.14–3.69 (m, 5H), 2.43–2.33 (m, 1H), 2.30–2.20 (m, 1H), 1.52–1.20 (m, 26H), 0.83 (t, J = 6.7
Hz, 3H). 13C NMR (101 MHz, DMSO) δ 171.95, 171.25, 168.89, 67.48, 61.38, 54.54, 51.82, 43.63,
41.83, 36.86, 31.27, 29.08, 29.03, 28.98, 28.68, 25.10, 22.07, 13.93. HRMS (-TOF MS): [M-H]Calc’d for C22H42N2O6 m/z 429.2965. Found: m/z 429.2989.

(3-Hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine, (24)

A solution of 1 M LiOH (0.28 mL, 0.28 mmol) was added to a solution of methyl (3hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serinate (117 mg, 0.258 mmol) in
2 mL of methanol at 0 °C, and 4 mL of THF was subsequently added. The resulting solution was
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warmed to ambient temperature and stirred for 2 h. The solution was then neutralized with 10%
HCl and diluted with 25 mL of H2O. The solution was then extracted with EtOAc (3 X 25 mL)
and the organic layers were concentrated in vacuo. The resulting crude material was recrystallized
from hot EtOAc to yield ((3-hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-Lserine, 24, as a crystalline solid (83 mg, 0.19 mmol, 73 %), MP, 118-122 °C. 1H NMR (400 MHz,
CDCl3) δ 4.50 (dt, J = 11.0, 3.4 Hz, 1H), 4.17–3.65 (m, 5H), 2.37 (ddd, J = 13.6, 7.9, 2.8 Hz, 1H),
2.29–2.19 (m, 1H), 1.49–1.16 (m, 20H). 13C NMR (101 MHz, DMSO) δ 171.78, 171.22, 168.96,
67.47, 61.31, 54.51, 51.83, 43.60, 41.75, 36.84, 29.08, 29.04, 28.99, 28.74, 25.10. HRMS
(AccuTOF): [MH]+ Calc’d for C22H33D9N2O6 m/z 440.3686. Found: m/z 440.3689.

(6S)-6-(Methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3silaheptacosan-13-yl 13-methyltetradecanoate, (36)

13-Methyltetradecanoic acid (82 mg, 0.338 mmol) was dissolved in 15 mL of dry DCM
and stirred at 0 °C. To the solution was then treated with DCC (87 mg, 0.423 mmol) and a catalytic
amount of DMAP. After stirring for 15 min, methyl (3-hydroxy-haptadecanoyl)glycyl-L-serine
(35, 231 mg, 0.338 mmol) dissolved in 5 mL of dry DCM was added to the reaction via cannula.
The resulting solution was warmed to ambient temperature and stirred overnight. The solvent was
removed under reduced pressure and the resulting oil was redissolved in 20 mL of diethyl ether.
The resulting precipitate was filtered, and the filtrate washed with satd NaHCO3 (3 X 10 mL). The
organic layer was dried, filtered, and solvents evaporated under reduced pressure. Purification via
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column chromatography (1% MeOH:DCM) yielded (6S)-6-(methoxycarbonyl)-2,2-dimethyl8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-silaheptacosan-13-yl 13-methyltetradecanoate, 36,
as a clear wax (123 mg, 0.136 mmol, 63.4% brsm). 1H NMR (400 MHz, CDCl3) δ 7.58 (t, J = 7.1
Hz, 4H), 7.46–7.37 (m, 6H), 6.54 (t, J = 6.7 Hz, 1H), 6.37 (d, J = 4.9 Hz, 1H), 5.16 (p, J = 6.3 Hz,
1H), 4.66 (d, J = 7.8 Hz, 1H), 4.14–3.82 (m, 5H), 3.74 (s, 3H), 2.55–2.42 (m, 2H), 2.29 (t, J = 7.5
Hz, 2H), 1.50 (hept, J = 6.6 Hz, 1H), 1.31–1.24 (m, 42H), 1.15–1.10 (m, 4H), 1.03 (s, 9H), 0.89–
0.84 (m, 9H).
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C NMR (101 MHz, CDCl3) δ 173.45, 170.47, 169.98, 168.26, 135.56, 135.52,

132.82, 132.64, 130.11, 130.06, 127.97, 127.88, 71.12, 64.15, 54.28, 52.58, 49.26, 42.88, 41.43,
39.12, 34.56, 34.18, 34.00, 31.98, 30.01, 29.75, 29.62, 29.57, 29.42, 29.36, 29.21, 28.03, 27.48,
26.78, 25.67, 25.32, 25.05, 24.99, 22.75, 22.72, 14.17. HRMS (AccuTOF): [MH]+ Calc’d for
C54H90N2O7Si m/z 907.6596. Found: m/z 907.6570.

(6S)-6-(Methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3silaheptacosan-13-yl-24,24,25,25,26,26,27,27,27-d9 13-methyltetradecanoate, (44)

13-Methyltetradecanoic acid (130 mg, 0.535 mmol) was dissolved in 15 mL of dry DCM
and stirred at 0 °C. To the solution was then treated with DCC (110 mg, 0.535 mmol) and a
catalytic amount of DMAP.

After stirring for 15 min, methyl (3-hydroxyheptadecanoyl-

14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine (43, 322 mg, 0.465 mmol) dissolved in 5 mL of dry
DCM was added to the reaction via cannula. The resulting solution was warmed to ambient
temperature and stirred overnight. The solvent was removed under reduced pressure and the
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resulting oil was redissolved in 20 mL of diethyl ether. The resulting precipitate was filtered, and
the filtrate washed with satd NaHCO3 (3 X 10 mL). The organic layer was dried, filtered, and
solvents evaporated under reduced pressure.

Purification via column chromatography (1%

MeOH:DCM) yielded (6S)-6-(methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa7,10-diaza-3-silaheptacosan-13-yl-24,24,25,25,26,26,27,27,27-d9 13-methyltetradecanoate, 44, as
a clear wax (216 mg, 0.236 mmol, 79.6% brsm). 1H NMR (400 MHz, CDCl3) δ 7.63–7.55 (m,
4H), 7.48–7.36 (m, 6H), 6.52 (d, J = 6.8 Hz, 1H), 6.33 (d, J = 5.0 Hz, 1H), 5.20–5.13 (m, 1H), 4.66
(dd, J = 7.6, 3.4 Hz, 1H), 4.13 (dd, J = 10.3, 2.9 Hz, 1H), 4.01–3.81 (m, 3H), 3.75 (s, 3H), 2.54–
2.44 (m, 2H), 2.29 (t, J = 7.5 Hz, 2H), 1.51 (hept, J = 13.2, 6.6 Hz, 1H), 1.39–1.16 (m, 38H), 1.15
(q, J = 6.7 Hz, 2H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.42,
170.44, 170.40, 169.95, 168.21, 135.56, 135.52, 132.83, 132.65, 130.11, 130.06, 127.97, 127.88,
71.10, 64.15, 54.28, 54.26, 52.57, 42.88, 41.43, 39.12, 34.56, 34.18, 30.01, 29.72, 29.62, 29.57,
29.47, 29.42, 29.36, 29.21, 28.03, 27.48, 26.78, 25.32, 25.06, 22.72, 19.31. HRMS (AccuTOF):
[MH]+ Calc’d for C54H81D9N2O7Si m/z 916.7160. Found: m/z 916.7154.

1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-1oxoheptadecan-3-yl 13-methyltetradecanoate

(6S)-6-(Methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3silaheptacosan-13-yl 13-methyltetradecanoate (36, 123 mg, 0.136 mmol) was dissolved in 5 mL
of dry THF under nitrogen. The solution was cooled to 0 °C and was treated with 1 M TBAF (0.15
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mL, 0.15 mmol). The reaction was slowly warmed to ambient temperature and stirred for 1 h.
The solvent was removed under reduced pressure, and the resulting oil was purified by column
chromatography (5% MeOH:DCM) to yield 1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2yl)amino)-2-oxoethyl)amino)-1-oxoheptadecan-3-yl 13-methyltetradecanoate as a white solid (69
mg, 0.103 mmol, 76.1 % brsm) MP 84-92 °C. 1H NMR (400 MHz, CDCl3) δ 7.06 (dd, J = 46.7,
7.5 Hz, 1H), 6.44 (s, 1H), 5.24–5.12 (m, 1H), 4.66 (t, J = 3.4 Hz, 1H), 4.11–3.89 (m, 4H), 3.79 (s,
3H), 3.20 (d, J = 68.5 Hz, 1H), 2.49 (dd, J = 6.0, 3.2 Hz, 2H), 2.31 (td, J = 7.6, 2.1 Hz, 2H), 1.51
(hept, J = 6.6 Hz, 1H), 1.38–1.20 (m, 40H), 1.15 (q, J = 6.8 Hz, 2H), 0.93–0.79 (m, 9H). 13C NMR
(101 MHz, CDCl3) δ 174.55, 174.39, 170.78, 170.71, 170.66, 170.60, 168.97, 168.93, 71.53, 62.96,
55.02, 52.76, 43.43, 42.04, 41.95, 39.12, 34.62, 34.55, 31.99, 30.01, 29.76, 29.71, 29.62, 29.57,
29.42, 29.38, 29.33, 29.21, 28.03, 27.48, 25.32, 25.06, 25.00, 22.76, 22.72, 14.17. HRMS (-TOF
MS): [M-H]- Calc’d for C38H72N2O7 m/z 667.5261. Found: m/z 667.5243.

1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-1oxoheptadecan-3-yl-14,14,15,15,16,16,17,17,17-d9 13-methyltetradecanoate

(6S)-6-(Methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3silaheptacosan-13-yl-24,24,25,25,26,26,27,27,27-d9 13-methyltetradecanoate (44, 192 mg, 0.277
mmol) was dissolved in 5 mL of dry THF under nitrogen. The solution was cooled to 0 °C and
was treated with 1 M TBAF (0.30 mL, 0.15 mmol). The reaction was slowly warmed to ambient
temperature and stirred for 1 h. The solvent was removed under reduced pressure, and the resulting
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oil was purified by column chromatography (5% MeOH:DCM) to yield 1-((2-(((S)-3-hydroxy-1methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-1-oxoheptadecan-3-yl14,14,15,15,16,16,17,17,17-d9 13-methyltetradecanoate as a white solid (107 mg, 0.236 mmol,
85.1 % brsm) MP 82-88 °C. 1H NMR (400 MHz, CDCl3) δ 7.10 (dd, J = 43.2, 7.8 Hz, 1H), 6.48
(d, J = 4.2 Hz, 1H), 5.18 (dt, J = 19.0, 6.4 Hz, 1H), 4.66 (t, J = 3.4 Hz, 1H), 4.14–3.89 (m, 4H),
3.79 (s, 3H), 3.27 (d, J = 65.9 Hz, 1H), 2.49 (dd, J = 6.1, 3.1 Hz, 2H), 2.31 (td, J = 7.6, 2.3 Hz,
2H), 1.50 (t, J = 7.0 Hz, 1H), 1.41–1.18 (m, 34H), 1.15 (q, J = 6.4 Hz, 2H), 0.86 (d, J = 6.6 Hz,
6H).

13

C NMR (101 MHz, CDCl3) δ 174.56, 174.39, 170.79, 170.73, 170.67, 170.61, 168.98,

168.93, 71.53, 62.96, 62.92, 55.02, 52.76, 43.44, 43.40, 42.05, 41.94, 39.12, 34.62, 34.55, 30.01,
29.78, 29.73, 29.62, 29.57, 29.48, 29.38, 29.33, 29.22, 29.19, 28.03, 27.48, 25.32, 25.06, 25.00,
22.71. HRMS (AccuTOF): [MH]+ Calc’d for C38H63D9N2O7 m/z 678.5983. Found: m/z 678.5992.

(3-((13-Methyltetradecanoyl)oxy)heptadecanoyl)glycyl-L-serine, (27)

A stirring solution of 1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2oxoethyl)amino)-1-oxoheptadecan-3-yl 13-methyltetradecanoate (48 mg, 0.078 mmol), in 3 mL
of dry DMF, was cooled to 0 °C. Potassium trimethylsilonoate (11 mg, 0.083 mmol) was added,
and the reaction was stirred on the ice bath for 1.5 h before being warmed to ambient temperature
and stirred for an additional 1.5 h. The solution was diluted with 10 mL of 10 mL of H 2O and
acidified with 10% HCl. The resulting cloudy precipitate was extracted with ethyl acetate (3 X
15mL). The organic layer was dried, filtered, and solvents evaporated under reduced pressure. The
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resulting solid was purified by column chromatography (10% MeOH:DCM) to yield (3-((13methyltetradecanoyl)oxy)heptadecanoyl)glycyl-L-serine, 27, as a white sticky solid (33 mg, 0.050
mmol, 65 % brsm). 1H NMR (500 MHz, CDCl3) δ 7.07 (d, J = 8.4 Hz,0.5H), 6.77 (d, J = 8.2
Hz,0.5H), 5.17–5.07 (m, 1H), 4.26 (s, 1H), 4.11–3.60 (m, 4H), 3.36–3.30 (m, 1H), 2.47 (s, 2H),
2.23 (s, 2H), 1.67–1.41 (m, 6H), 1.21 (s, 41H), 0.82 (t, J = 7.0 Hz, 9H). 13C NMR spectrum could
not be obtained due to liposome formation. HRMS (-TOF MS): [M-H]- Calc’d for C37H70N2O7
m/z 653.5105. Found: m/z 653.5077.

(3-((13-Methyltetradecanoyl)oxy)heptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-Lserine, (25)

A stirring solution of 1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2oxoethyl)amino)-1-oxoheptadecan-3-yl-14,14,15,15,16,16,17,17,17-d9 13-methyltetradecanoate
(98 mg, 0.144 mmol), in 3 mL of dry DMF, was cooled to 0 °C. Potassium trimethylsilonoate (18
mg, 0.144 mmol) was added, and the reaction was stirred on the ice bath for 1.5 h before being
warmed to ambient temperature and stirred for an additional 1.5 h. The solution was diluted with
10 mL of 10 mL of H2O and acidified with 10% HCl. The resulting cloudy precipitate was
extracted with ethyl acetate (3 X 15mL). The organic layer was dried, filtered, and solvents
evaporated under reduced pressure. The resulting solid was purified by column chromatography
(10%

MeOH:DCM)

to

yield

(3-((13-methyltetradecanoyl)oxy)heptadecanoyl-

14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine, 25, as a white sticky solid (55 mg, 0.083 mmol,
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58% brsm). 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 8.1 Hz,0.5H), 6.78 (d, J = 8.4 Hz,0.5H),
5.24–5.08 (m, 1H), 4.30 (s, 1H), 4.14–3.55 (m, 4H), 3.43–3.28 (m, 1H), 2.52 (s, 2H), 2.25 (t, J =
7.4 Hz, 2H), 1.57 (d, J = 13.1 Hz, 4H), 1.51–1.44 (m, 1H), 1.42–1.15 (m, 30H), 1.12 (q, J = 6.8
Hz, 2H), 0.83 (d, J = 6.6 Hz, 6H). 13C NMR spectrum could not be obtained due to liposome
formation. HRMS (-TOF MS): [M-H]- Calc’d for C37H61D9N2O7 m/z 662.5670. Found: m/z
662.5640.
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1.4 NMR Spectra
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Synthesis of Nitroimidazole Indocyanine Green Dye Conjugates for
Targeting Hypoxia in Tumor Cells for Near Infrared Fluorescence
Frequency Domain Optical Tomography

2.1 Introduction
2.1.1 Cancer
In 2016 there is an expected 1.6 million new cases of cancer and nearly 600 thousand
cancer deaths, which contributes to the second most common cause of death in the United States.1
Cancer refers to over a hundred different diseases that are characterized as abnormal and
unregulated cell growth. Cells in the human body are constantly being recycled by programmed
cell death, apoptosis, and then replaced by cellular division. Of the estimated 100 trillion cells in
an average adult, 50-70 billion cells are turned over each day. Within this process there is a
probability of reproductive error, which can develop damaged DNA or gene mutations that leads
to cancer. Some of the main causes include UV/nuclear radiation, carcinogenic chemicals,
infections, internal factors, and poor health.
Commonly, a cell has a mechanism in place to correct mutations by either fixing the
damaged DNA, or triggering apoptosis so the cells cannot multiply. When this fails, defective
genes are passed on and the cells begin to multiply at an uncontrollable rate. These cells form
abnormal growths in tissues called neoplasms, or more often referred to as tumors. Tumors show
“the six hallmarks of cancer”: evading apoptosis, sell-sufficiency in growth signals, insensitivity
to anti-growth signals, tissue invasion and metastasis, limitless replicative potential, and sustained
angiogenesis.2 Over time, the tumor cells develop malignancy and obtain the ability to metastasis
217

to other parts of the body through blood vessels or the lymph system. Once cancer has the ability
to migrate throughout the body, it is considered stage 4 cancer and chances of remission drastically
decrease.3 For this reason, tumor detection and eradication is of utmost concern in the fight against
cancer.

2.1.2 Tumor Hypoxia
Once tumors grow to between 2-3 mm in size, they start to develop a tumor-specific
microenvironment due to quick and uncontrolled growth. The growths are said to be hypoxic as
low oxygen levels, pH, and glucose concentration are observed.4 Tumor hypoxia is a direct result
from the accelerated growth rate of cancer cells not allowing for proper angiogenesis, blood vessel
formation. Without proper blood flow, oxygen levels and nutrient supplies diminish compared to
healthy tissues. Mutated cells have the ability to adapt by altering their metabolism to the
environment but healthy cells do not and will eventually die.
The cancer cells left in the hypoxic region start to exhibit a slow growth rate due to rapidly
proliferating distal cancer cells not allowing the profusion into the tumor. This decrease in
profusion often causes ineffectiveness of common chemotherapy drugs.5 Alternatively, radiation
therapy is used to produce reactive oxygen species within the cells that will damage DNA and lead
to cell death. However, hypoxia decreases the effectiveness due to low oxygen concentration. The
longer a tumor remains, its resistance to anticancer drugs and the probability of the cells gaining
the ability to metastasis will increase. For this reason, determining if a tumor is hypoxic and
monitoring the effectiveness of chemotherapy or radiation treatments is vital to the fight against
cancer.
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2.1.3 Detecting & Imaging Hypoxia
The ineffectiveness of chemotherapy regimens and radiotherapy on hypoxic tumors creates
the demand for safe procedures for detection and monitoring of such growths. Invasive procedures
were among the first diagnostic tools for sampling tissues from infected areas and are still used on
a limited basses today. Polarographic oxygen microelectrodes can be inserted into the tumors to
directly quantify the levels of hypoxia from measuring partial pressure of oxygen.4,6 However,
they are limited only to accessible tumors, mainly on surface areas of the body, such as cervix,
head, and neck tumors.7
Non-invasive procedures offer alternatives to hypoxia imaging and are not limited to depth
of the tumors while also being inherently safe measurements. Magnetic resonance imaging (MRI)
and positron emission tomography (PET) are techniques that allow physicians to visualize tissue
properties. To date, recent advances have allowed for the ability of both PET and MRI imaging to
simultaneously scan for tumors within the body.8 This allows more accuracy in treatment planning,
monitoring, and evaluation of response to radiation therapy.
PET imaging can be used for measuring several metabolic
processes in the body associated with tumor growth.9 Most commonly,
a 3-dimensional detector is used to measure gamma rays that are
emitted by a exogenous tracer. The tracer is injected into the body and
the detector measures its concentration as it localizes in the body. The
structure of the tracer dictates what biological activity or function can
be measured. The most common method for measurement of hypoxic
tissue uses tracers encompassing nitroimidazoles. 2-nitroimidazole is
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known to undergo intracellular metabolism in which a nitroreductase reduces the nitro moiety. The
reduced compound can then bond with proteins within the cell, and as a result increases the
retention time. The reverse reaction is directly dependent on the oxygen concentration and is
minimal in hypoxic environments.10 Examples of the tracers are shown. The F-18 labeled
derivative of EF5 is being studied for its effectiveness to study brain tumors due to its propensity
to cross the blood brain barrier.11 The other two derivatives,

18

F-FAZA and

18

F-FMISO, take

advantage of their high levels of biodiversity that makes it easy to get into tumor cells. As the
metabolism progresses, the compound will concentrate in hypoxic tissue and release positrons that
will build a picture of the tumor with PET imaging.
MRI is a type of imaging that takes advantage of the science of nuclear magnetic resonance
(NMR). When some atomic nuclei are applied to a magnetic field they can absorb and emit distinct
radio frequencies. Based on the frequency, a conclusion can be drawn about the environment of
the atomic nuclei is in. MRI scans take advantage of the abundance of NMR active hydrogen nuclei
in the body. Mostly, the hydrogen atoms in the body exist in water and fat molecules. As a result,
MRIs can image the microanatomy of a tissue and distinguish the density or organization of
intra/extracellular space that is indicative of tumor growth.12 Contrast agents can also be
introduced to the body that can measure blood flow as it relates to permeability and perfusion.
Hypoxic tumors can be indirectly illuminated by such contrast agents due to their poor vascular
network and densely distributed cellular network.
Both non-invasive procedures discussed are widely used, however they do inherently
possess some disadvantages and limitations. Some of these include as unfavorable imaging
characteristics, such as high background counts and limited contrast ratio from hypoxic tumors to
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normal tissues. Also, the high cost of these procedures make in unfeasible for routine imaging and
drives the need for a cheap, safe, and non-invasive alternative.
Optical imaging is a non-invasive, low cost, and extremely safe alternative biological
imaging. Near infrared (NIR) frequency domain optical tomography (FDOT) offers a highly
sensitive technique for imaging targets within the body. A NIR fluorescent probe is administered,
and the irradiation with NIR light
allows for the collection of the emitted
fluorescence

signals

from

the

fluorochrome. PET tracers are limited
to a single decay event per molecule for
imaging. A single fluorescent probe
can produce absorb and emit nearly a
hundred million photons per second for
Figure 5. NIR window for optical imaging13

imaging. The released fluorescence

signals are collected by detectors or a charge coupled device (CCD) camera for construction of the
3D imaging. The near-Infrared window of 650 to 900 nm allows for maximum depth penetration
of light because there is minimal absorbance and high scattering by biological tissue. Hemoglobin
and water are the major contributors of light absorption within the body. Figure 5 demonstrates
the fact that absorbing factors are at a minimum in the NIR range. This technique is capable of
imaging targets at depths up to several centimeters from the skin surface. It is noteworthy that bone
and muscular tissues do slightly diminish the penetration of light. However, several studies
demonstrated the ability of NIR fluorochromes to be coupled with targeting agents to efficiently
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image receptors.13 The main difficulty is developing a fluorescence dye and altering it with
targeting moieties, to effectively image hypoxic tissue.

2.1.4 The Combination of Indocyanine Green Dye and Nitroimidazole for
Optical Imaging
Indocyanine green (ICG) is the only FDA approved fluorescence imaging agent for patient
use. It is used for determining the function of cardiac and hepatic processes as it readily binds to
plasma in the blood. The application of ICG is hindered slightly by the problems of a low quantum
yield and quick loss of fluorescence after binding to proteins in circulating blood.14 However, its
low toxicity and easy wash out rates gives ICG
the ability to be a suitable scaffold for a
fluorescence probe to be tailored towards
targeting hypoxic tumors.
Nitroimidazole derivatives have been used as common moieties when targeting hypoxic
cells of an organism since its potential was discovered by Varghese et al.15 Specifically, 2nitroimidazole has been incorporated into several
radiosensitizers and hypoxia targeting prodrugs.16 The
sensitivity towards hypoxic cells is attributed to an
enzyme mediated reduction of the nitro group by
nitroreductase enzymes in the absence of oxygen. The

Figure 6. Reduction Potentials of
Nitroimidazoles

reduction potentials for nitroimidazoles are shown in figure 6. 2-Nitroimidazole inherently has the
highest reduction potential and therefore is the most widely used to target hypoxic cells. This
222

reduced imidazole ring is susceptible to nucleophilic addition from cellular macromolecules to
form long lasting binding adducts. The proposed mechanism for hypoxia specificity is shown in
part a of figure 7.

Figure 7. Mechanism proposed for 2-nitroimidaze selectivity towards hypoxic cells.17

Studies in vivo reveal the sensitivity towards hypoxia of 2-nitroimidazole is due to the
bioactive reduction is dependent on oxygen concentration. In a normoxia environment the initial
one electron activation reduction to a nitro radical is in competition with reverse reaction of O2
oxidation. The reaction is highly reversible and high oxygen concentrations dictates the
equilibrium between the two reactions making further reduction impossible because oxidation
back to the parent nitro compound is inevitable. In Hypoxia, nitro radicals are further reduced by
a nitroreductase to the nitroso derivative, and eventually to the hydroxyl-amine. Acid catalyzed
dehydration creates a cyclic imine that is susceptible towards binding of certain nucleophilic
proteins and locking the compound within the cell. A specific enzyme for the reductions is
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unknown, however one-electron reductases such as NADPH–nitroreductases, NADPH–
cytochrome P450 reductase, cytochrome b5 reductase, aldehyde dehydrogenase, and xanthine
oxidase, and two-electron reductases such as DT-diaphorase have been acciociated.18
With a suitable fluorophore, nitroimidazole can be used to deliver and retain a fluorescent
probe in hypoxic cells. ICG lacks a reactive functional group that can efficiently couple with
targeting agents. Fortunately the development of ICG bis-carboxylic acid (1) has been achieved,
while retaining all desirable characteristics of the parent ICG dye.19 Figure 8 shows how the
carboxylic acid derivative can be built upon to increase its sensitivity towards hypoxic cells.

Figure 8. Proposed Structure for Fluoresence Hypoxia Probe
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2.1.5 Development of ICG Dye Conjugates
The Smith group has developed a method for coupling nitoimidazoles to ICG biscarboxylic acid 1. Connecting the two fragments together with an appropriate linker was of the
first priority. The first-generation protocol involved the incorporation of an ethanolamine linker in
route to synthesizing dye conjugate (2).20

The first generation targeted fluorophores showed great sensitivity in breast cancer cells
treated under hypoxic conditions in vitro.21 The cells fluorescence intensities were integrated to
revealed a ratio between hypoxia per normoxia conditions are 2.5 for 2-nitroimidazole (2) treated
cells and 1.2 for ICG (1) treated cells. These results were also verified in vivo using a murine
model, which involved 4TI mammary cancer cells grown in balb/c mice.22 The targeted dye 2
displayed a two-fold higher fluorescence at the hypoxic tumor site when compared to normal sites.
Hypoxic sights showed no difference in flouresence when treated with the untargeted dye 1. It is
also noteworthy for later discussion that the 4-nitroimidazole derivative of 2 revealed minimal
differences in fluorescence at the tumor when compared to the nomoxia tissues. An attempt to
increase the bioavailability of the dye lead to the development of a “2nd generation dye conjugate”
(3).23
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The linker of 3 was changed to a piperazine ring instead of the presumed to be labile
ethanolamine linker used previously. The new linker is not believed to exhibit any direct influence
on the targeting of hypoxia. However, the more robust piperazine moiety is presumed to be more
metabolically stable because of the two secondary amide linkages. Increasing the number of
carbon atoms and diminishing the polarity slightly, leads to greater solubility in tissue. We
presume that for these reasons, the bioavailability is greatly increased. This increased
bioavailability leads to a higher probability of the 2-nitroimidazole dye conjugate to perfuse into
hypoxic cells, undergoing enzymatic reduction, and irreversibly binding to macromolecule
nucleophiles. Since the reduction is selective towards hypoxia, this leads to an enhanced
fluorescence intensity in cancerous tumors compared to other tissues. When compared in vivo, the
fluorescence intensity of 3 was measured to be twice that of 2 in the tumor tissue (figure 9).23

226

Figure 9. Fluoresence Intensity of 1st and 2nd Generation Dyes in Hypoxic Tumors

This work has demonstrated the effectiveness of coupling the fluorophore ICG with a
known hypoxia-targeting agent to optically image cancerous tumors. Table 1 displays the optical
properties of the synthesized dyes and comparison to the parent FDA approved ICG. The
wavelengths of absorbance and emission all fall into the desired window for imaging human tissue.
However the quantum yield, the ratio of emitted photons to absorbed photons, is considered very
low in all cases. The introduction of the piperazine linker did slightly increase the quantum yield,
but the dye conjugate is still low. This diminished florescent yield leads to the requirement of
higher doses of dye for proper imaging. In addition, the toxicity of the dye conjugate is unknown.
The depth at which the dye conjugates can image will also be effected since the dye itself
will inherently lose a large percentage of photons. For these reasons, there is a need for
improvement upon the system.
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Dye
FDA approved ICG

λabs (nm)

λem (nm)

Extinction Coefficient
(M-1cm-1)

Quantum
Yield (Φ)

780

807

115,000

0.0120

755

790

220,920

0.0728

760

790

159,141

0.0420

760

790

229,543

0.0825

ICG bis-carboxylic acid (1)
2-Nitroimidazoleethanolamine-ICG (2a)
2-Nitroimidazolepiperazine-ICG (3)

Table 1. Optical Properties of ICG, ICG bis-carboxylic acid, and 1st & 2nd Generation Dye Conjugates
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2.2 Results & Discussion
2.2.1 Synthesis of Nitroimidazole Piperazine ICG Dye Conjugates
With the aim of optically imaging hypoxic tissues that are indicative of cancerous tumors,
our lab set out a goal of linking nitroimidazole, a known hypoxia targeting agent, to an indocyanine
green (ICG) dye, which is a FDA approved fluorophore used as a medical diagnostic tool. Using
a targeting moiety on a dye allows for selective imaging of desired regions while avoiding healthy
tissues. The main priorities of the project include: (1) coupling the two compounds together with
a linker that is stable in a biological system, (2) insure that the fluorescence properties of the dye
remain useful, and (3) the nitroimidazole moiety is still efficient in targeting hypoxic cells.
To achieve the first priority, our lab identified ICG bis-carboxylic acid (1) as a suitable
candidate to link with the targeting agent. It was first synthesized by Lindsey et al and the dyeconjugate showed great retention of optical properties, with a 5-fold increase of quantum yield,
when compared to its parent compound ICG.19a The two carboxylic acid groups give a worthy
branching point to which the targeting agent can be coupled. Our synthesis is shown in scheme 10.
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Scheme 10. Synthesis of ICG bis-carboxylic Acid (1)

Compound 1 was prepared by a straightforward synthesis as it was previously reported by
Lindsey et al.19a Starting with commercially available p-hydrazinobenzoic acid (4), treatment with
3-methyl-2-butanone gave indole 5, via a Fischer indole synthesis. Subsequent heating at reflux
with butanesultone in 1,2-dichlorobenzene gave a zwitterion 6. The assembly of dye 1 was
completed by condensation of two equivalents of 6 with the commercially available glutacondianil
hydrochloride (7). The synthesis of ICG bis-carboxylic acid (1) has a 55% overall yield through 3
steps and is routinely completed in gram scale.
To produce the target dye we envisioned a convergent synthesis in which the targeting
agent is connected to the linker and then coupled together with dye 1. The preparation of the
targeting agent portion is shown in scheme 11.
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Scheme 11. Synthesis of 2-nitroimidazole Piperazine Fragment (10)

When designing this portion of the synthesis the main concern was to carry the expensive
2-nitroimidazole through as few synthetic steps as possible. Building upon the linker was therefore
a logical plan compared to linearly from the imidazole ring. Stoichiometric protection of
piperazine with di-tert-butyl dicarbonate gave half protected Boc-piperazine via a literature
protocol.24 Subsequent acyl substitution of the free amine with bromoacetyl bromide gave 8.
Coupling the 2-nitroimidazole linker was achieved via SN2 of the primary halide to produce
compound 9. Deprotection of the Boc protected amine was achieved by stirring with trifluoroacetic
acid, followed by crystallization to produce TFA salt 10 in a 27% yield from piperazine.25
The TFA salt 10 was coupled to ICG dye 1 using PyBOP as the coupling reagent. BOP
reagents have demonstrated great efficiency when coupling secondary amino groups to acids and
ByBOP is specifically used to minimize the amount of hazardous biproducts.26 The synthesis is
shown in scheme 12, producing 2-nitroimidazole-piperazine-ICG (3) in 28% yield.27
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Scheme 12. Synthesis of 2-Nitroimidazole Piperazine ICG (3)

The low yield of the coupling procedure is due to the production of half loaded dye (single
equivalence of 10 coupling to 1) and the extreme difficulty of purification. Both the half loaded
and fully loaded dyes exist in a mixture of rotational isomers that elute off of reverse phase
columns in a wide overlapping range. For this reason multiple purification attempts are needed in
small scales to achieve pure material. This is a problem that has yet to be solved. With an extreme
amount of effort we managed to purify a large quantity of mostly pure material for toxicity testing.
The results are expected in the near future, however stress tests did show minimal discomfort in
mice injection experiments.
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With the costly price of 2-nitroimidazole, $354.00 per gram (Sigma-Aldrich CAS=527-731), and the low yields in mind, our lab set out to try and produce the cheaper fluorescence dye 13.
Using 4-nitroimidazole, $1.86 pure gram (Sigma-Aldrich CAS=3034-38-6), should greatly
decrease the cost. A literature search revealed that the 4-nitro does still retain hypoxia targeting
properties with a minimal decrease in efficiency, but there is some concern of increased toxicity.28
Scheme 13 displays the synthesis of 4-Nitroimidazole Piperazine ICG (12).

Scheme 13. Synthesis of 4-Nitroimidazole Piperazine ICG (12)

Dye Conjugate 12 was synthesized in the identical straight forward manner as known targeting dye
3 with similar yields.29 The only difference is the incorporation of 4-nitroimidazole instead of 2nitroimidasole. The two dyes used for in vivo studies to test the hypothesis that 4-nitroimidazole will still
target hypoxic cells. For good measure, a control dye, a derivative with just imidazole linked to ICG, was
synthesized to analyze the effect of having no targeting moiety on our synthetic dyes. The lack of a nitro
group would create a unsuitable substrate for macromolecule binding within the cell. Scheme 14 shows the
synthesis of imidazole-piperazine-ICG (14), a non-targeting second generation dye.
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Scheme 14. Synthesis of imidazole-piperazine-ICG (14)

Again the synthesis followed identical synthetic methodology with just the substitution of
imidazole to couple with the linker.29 The only modification in the procedure was the duration of
time and stoichiometry in which we allowed the substitution reaction of imidazole with
intermediate 8. The absence of a nitro moiety on the imidazole ring displayed a higher reactivity
of the second nitrogen and yielded undesired di-substituted imidazole. Stirring the reaction for a
shorter amount of time and increased equivalence of imidazole gave the proper substitution.
Coupling of 13 with synthetic 1 produced ICG dye conjugate 14 to be used as a control for optical
imaging experiments.

2.2.2 Hypoxia Targeting Evaluation of Nitroimidazole Piperazine ICG Dye
Conjugates
Upon completion of the synthesis of the second generation dyes, in vivo testing was done
in mice with hypoxic tumors.29 The protocol used a murine model, which involved 4TI mammary
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cancer cells grown in balb/c mice. The tumors were grown on top of the right leg until diameter
was approximately 7-8 mm. All injections were administered intravenously through retro-orbital
venous sinus. The tumor was then imaged at designated time intervals and the measured
fluorescence intensity for each imaging experiment were averaged and compared.

Figure 10. In vivo Fluorescence of 2-Nitroimidazole-Piperazine-ICG (3)

Figure 11. In vivo Fluorescence of 4-Nitroimidazole-Piperazine-ICG (12)
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Figure 12. In vivo Fluorescence of Imidazole-Piperazine-ICG (14)

Figures 10, 11, and 12 shows images obtained over 48 h post injection of ICG dye
conjugates 3, 12, and 14 respectively. Each image is averaged fluorescence distribution of a mouse
injected with 100 μL of a 25 μM concentration of designated dye. The images show rapid uptake of
the dye-conjugates in the tumor, as well as widespread distribution in the mouse. Washout rates in each
case are rapid throughout the body, however 3 and 12 are retained in the tumor for a prolonged time relative
to 14. This is indicative of the need for a nitroimidazole moiety to target and irreversibly bind to hypoxic
cells. Interestingly with identical injection concentrations, 12 appears to accumulate and retain in the tumor
at higher concentrations for longer amount of time compared to 3. Figure 13 is a graphical example of the
maximum radiant efficiency for 3, 12, and 14 within the tumors vs. time. This is an aim to demonstrate the
wash out rates of the three dye conjugates.
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Figure 13. Graphical Representation of Maximum Radiant Efficiencies for 2 nd Generation Dye Conjugates Over
Time

The in vivo imaging reveals that all three dye conjugates go into the tumors extremely fast,
therefore displaying a high level of biodiversity. The maximum intensity for imaging is around 15
minutes. Non-targeted dye 14 washes out of the tumor extremely fast as expected due to a lack of
a binding potential. Targeted dyes 3 and 12 seem to wash out of the tumors at similar rates. This
is most likely due to the cellular metabolism being identical for bound ICG dye conjugates. 4Nitroimidazole-piperazine-ICG (12) has a higher fluorescence intensity in the tumor with the same
injection volume and concentration when compared to 2-nitroimidazole-piperazine-ICG (3). Since
the quantum yield of 12 is slightly lower then 3, it implies that the 4-nitro derivative is actually
slightly better at targeting hypoxia in our fluorescence probe system. The optical properties of all
three second generation dyes are shown in Table 2.
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Dye
FDA approved ICG

λabs (nm)

λem (nm)

Extinction Coefficient
(M-1cm-1)

Quantum
Yield (Φ)

780

807

115,000

0.0120

755

790

220,920

0.0728

755

790

204,100

0.0610

755

790

229,543

0.0825

755

790

207,519

0.0711

ICG bis-carboxylic acid (1)
Nitroimidazolepiperazine-ICG (14)
2-Nitroimidazolepiperazine-ICG (3)
4-Nitroimidazolepiperazine-ICG (12)

Table 2. Optical Properties of 2nd Generation Dye Conjugates

2.2.3 Synthesis of Rigid ICG Dye Conjugate

In an attempt to rigidify the dye conjugates and potentially increase the optical properties,
Mohammad et al synthesized several ICG derivatives by altering the polyene chain.30 The theory
was that an introduction of a ring into the chain or shortening it would decrease the rotation around
the C-C bonds. The rotational isomers of ICG derivatives can quench absorbed energy and
diminish the release of fluorescence. The result is a probe with a low quantum yield and a poor
tool for fluorescence imaging. Only one of the newly synthesized dyes revealed a large increase
in quantum yield and was worth exploring further. This gave birth to the idea of a “3rd generation
dye conjugate” (15). The deletion of 2 carbons to a pentamethine polyene chain is only difference
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between the 2nd and 3rd generation of dye conjugates. This minor difference leads to a restriction
of rotation around the polyene chain due to an increased steric clash between the sulfate side
chains. The synthesis of 15 and its precursor bis-carboxylic acid 18 is shown in figure 14.31
The production of the shorten anilide 17 was achieved via condensation reaction of the
bis(dimethyl acetal) of propanedial (16) with aniline in the presence of aqueous HCl. Reacting 2
equivalence of indole 6 with 17 produced “rigid ICG di-acid” (18). Coupling the di-acid with

Scheme 15. Synthesis of 3rd Generation Dye Conjugate

targeting agent 10 synthesized 2-nitroimidazole-piperazine-rigid-ICG (15). Brief stability studies
with UV light radiation showed nearly a 4-fold slower degradation half-life compared to the ICG
counterparts. A small negative is that the max absorbance and fluorescence wavelengths displayed
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a slight blue shift, however still fall in the ideal window for tissue imaging. The quantum yield of
15 and 18 greatly improved and are shown in table 3 with ICG comparisons.31

Dye
FDA approved ICG
ICG bis-carboxylic acid (1)
2-Nitroimidazolepiperazine-ICG (3)
Rigid bis-carboxylic acid
(18)
2-Nitroimidazolepiperazine-rigid (15)

λabs (nm)

λem (nm)

Extinction Coefficient
(M-1cm-1)

Quantum
Yield (Φ)

780

807

115,000

0.0120

755

790

220,920

0.0728

755

790

229,543

0.0825

655

672

262,000

0.403

653

670

268,000

0.467

Table 3. Optical Properties of 3rd Generation Dye Conjugate

2.2.4 Hypoxia Targeting Evaluation of Rigid ICG Dye Conjugates
Evaluation of third generation dye’s hypoxia imaging capabilities was done the same way
as the previous in vivo studies.31 Figure 15 shows the graphical representation of fluorescence
intensity in the tumor over the course of a 48 hour period. The rigid dyes 15 and 18 were compared
to second generation 3 and ICG bis-carboxylic acid (1). As expected the rigid analogs showed a
superior fluorescence detectability for hypoxic tumors in vivo. This was expected due to the nearly
5-fold increase in quantum yield when compared to previous generation. Targeted dye conjugate
15 showed a slower diminishment of fluorescence when compared to 3. This is likely the effect of
increased stability of the rigid dyes.
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Figure 14. In vivo Fluoresence Efficiency of 3rd Generation Dyes

2.2.5 Synthesis of Biotin Derivative
It is important in our work to demonstrate proof that our dye conjugates are binding to targets in
the cell and possibly understand the identity of that protein. Immunoprecipitation is a technique in which
isolation of a protein is attained by selectively binding an antigen to the target protein. An antibody can
bind the antigen and be used to separate the protein from others. An avidin-biotin pull down is a specific
version of this.32 Bioactive molecules can be labeled with a biotin moiety (biotinylation) and bound to their
respective proteins. Avidin then attaches to the biotin and easily co-purified with the targeted protein.
Applying this chemistry to the nitroimidazole dye conjugates could elucidate the specific protein binding
of the compounds. For this reason biotinylated unsymmetrical dye conjugate 16 was designed.
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An unsymmetrical dye conjugate’s synthesis is not as straight forward as the symmetrical
targeted dye conjugates. Coupling bis-carboxylic acid ICG (1) with just one equivalence of
targeting agent leads to a mixture of fully loaded (two targeting agents attached) and half loaded
(one targeting agent attached). The mixtures are difficult to separate and deems the synthetic
strategy useless. A way around this is by the production half methyl ester ICG 18. Treatment of
indole acid 6 with oxalyl chloride in methanol produced indole methyl ester 17. One equivalence
of each 6 and 17 can be coupled together to produced 18 with stepwise introduction of each indole.
Then coupling the free acid with targeting agent 10 would produce half loaded dye 19.
Unfortunately all attempts at saponification of the methyl ester failed due to the degradation of the
dye. One idea that was not tried is the use of an esterase. Without easy accessibility to a library of
enzymes, we changed routes to synthesis biotinylated 16.
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Scheme 16. Attempted Synthesis of Biotinylated ICG Dye Conjugate via Half Methyl Ester ICG di-acid

Attaching a biotin moiety to an earlier intermediate of the dye synthesis was a successful
strategy. Biotin compound 21 was coupled to indole 5 to produce biotin-indole 22.33 Reaction with
1,4-butane sultone produced 23, that could be linked to indole 6 with anilide 7 through a stepwise
addition of each indole. This produced biotinylated dye 24 in an easily purified fashion. Final
coupling with targeting agent 10 gave biotin dye conjugate 16. This product has been verified and
awaits being applied to tumor cells for the “avidin pull down” experiment.
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Scheme 17. Successful Synthesis of Biotinylated Dye Conjugate

2.2.6 Present Research & Future Work
Our current efforts are aimed towards the once again restrict the rotation around the polyene
unit of our dye conjugates. The rigid dyes showed an excellent increase in quantum yield, however
the blue shift fluorescence is a negative effect that may decrease tissue penetration. An SAR study
has begun on the effects of the dye’s optical properties by increasing the steric bulk attached to the
indole rings. This would be in the form of increasing the size of the methyl groups on compound
1 (circled in red in figure 18). Preliminary studies are producing derivatives of the ethyl, pentyl
and benzyl variety by incorporating them into the fisher indole synthesis. One possible structure
that is highly interesting is macrocycle 26. The bridged bicyclic ring system is thought to be
possible through ring closing metathesis of 25 or a derivative aimed towards a different ring
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construction. Shown is just a generic olefin coupling, but this could be envisioned through other
completely different derivatives for ring closer. The aim is to try and lock the polyene unit into as
strict of a formation as possible and increase the dyes quantum yield.

Figure 15. Current SAR Study towards a New Generation of Dye Conjugates
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2.3 Experimental
All glassware was oven-dried, and all reactions were performed under a nitrogen
atmosphere. All chemicals were purchased from the Sigma-Aldrich Chemical Co., and used
without further purification unless otherwise noted. Tetrahydrofuran (THF) was distilled from
sodium benzophenone ketyl, methylene chloride (dichloromethane, DCM) was distilled from
calcium hydride, and dimethylformamide (DMF) was distilled in vacuo from calcium hydride.
Ethyl acetate (EtOAc), methanol (MeOH), and diethyl ether were used as obtained from the
vendor.
Thin-layer chromatography was done on Sorbent Technologies aluminum-backed TLC
plates with fluorescent indicator and 0.2 mm silica gel layer thickness, and p-anisaldehyde or
phosphomolybdic acid were used as developing agents. Column chromatography was done using
60 Å porosity, 32-63 µm silica gel. 1H and
(300.13 MHz 1H, 75.48 MHz

13

13

C NMR were collected on a Bruker Avance 300

C), Bruker DRX-400 (400.144 MHz 1H, 100.65 MHz

Bruker Avance 500 (500.13 MHz 1H, 125.65 MHz

13

13

C) or a

C). Chemical shifts are reported in ppm

downfield from tetramethylsilane (TMS) in the following format chemical shift, multiplicity
(s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet). Coupling constants are reported in Hz.
Mass spectrometry data was collected on a HP 5870B GC/MSD mass spectrometer with an HP-1
column, and high resolution MS and MS/MS spectra were obtained by direct infusion into a QTOF
mass spectrometer, QSTAR Elite from Sciex (Foster City, CA) or directly by using AccuTOF™
DART, JEOL (Peabody, MA). Multiple reaction monitoring (MRM) transitions were selected
based the MS/MS spectra. IR spectra were taken on FT/IR-410/C031560585 JASCO and Nexus
670 FT-IR E.S.P, neat, unless otherwise stated. All melting points to an upper limit of 270 °C
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were obtained using a Uni-melt capillary melting point apparatus or Digimelt MPA160. For
products described as waxy solid or semi-solids, melting points could not be obtained.
Repeated efforts to obtain the 13C NMR of dye conjugates failed to give a spectrum. We
examined the possibility of aggregation, rotamers, relaxation time, and low concentration due to
solubility issues. All of these issues can lead to poor

13

C NMR spectra. Attempts to obtain

13

C

NMR spectra at 25 °C failed, and we heated the samples to 55 °C to promote deaggregation. We
also explored different solvents, including CD3OD, (CD3)2CO, D2O. We examined extended delay
(relaxation) times up to 10 to 15 s, as well as long acquisition times (up to 24 hours). None of these
experiments led to a 13C NMR. We have attempted indirect

13

C experiments, including HSQC,

HMBC, and CIGAR. The problem is likely due to low solubility, coupled with the low isotope
percentage of 13C relative to 12C versus the high percentage of 1H, but we do not have a definitive
answer to this problem. No experiments have been successful, so only 1H NMR data is provided.
It is noted that the commercial ICG obtained from SigmaAldrich, as well as derivatives
prepared in our laboratory is a mixture of isomers as determined by high-performance liquid
chromatography analysis. This mixture is undoubtedly a mixture of E/Z isomers of the polyene
linker. No attempt was made to separate this mixture into the component stereoisomers, and in all
cases, the mixture was used for in vivo studies. To the best of our knowledge, such mixtures are
used in all biological studies that involve ICG.
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2,3,3-Trimethyl-3H-indole-5-carboxylic acid, (5)

A 100 mL round-bottumed flask was charged with 4-hydrazinobenzoic acid (4.892 g, 32.2 mmol),
3-methylbutan-2-one (4.82 g, 45.1 mmol), sodium acetate (5.28 g, 64.4 mmol), and glacial acetic
acid (50 mL). The mixture was stirred for 1 h and then heated at reﬂux overnight. The solvent was
removed under reduced pressure to a sludge and then crystalized from 10% MeOH (80mL). The
resulting precipitate was ﬁltered and dried to yield 5 (3.66 g, 18.0 mmol, 55.9%) as a tan solid.20
1

H NMR (400 MHz, Chloroform-d) δ 8.13 (dd, J = 8.1, 1.7 Hz, 1H), 8.04 (d, J = 1.7 Hz, 1H), 7.63

(d, J = 8.1 Hz, 1H), 2.36 (s, 3H), 1.36 (s, 6H). 13C NMR (101 MHz, Chloroform-d) δ 192.5, 171.0,
158.1, 145.9, 131.0, 126.4, 123.4, 119.9, 54.1, 23.0, 15.8.

5-Carboxy-1-(d-sulfobutyl)-2,3,3-trimethyl-3H-indolium betaine, (6)

A mixture of 5 (3.66 g, 18.0 mmol) and 1,4-butanesultone (10.1 mL, 99.0 mmol) in 1,2dichlorobenzene (80 mL), was created under a nitrogen atmosphere. The mixture was heated at
reﬂux overnight. The reaction solution was cooled to room temperature and the red precipitate was
ﬁltered, rinsed with acetone, and dried to give 6 (4.90 g, 14.4 mmol, 80.2 %).20 1H NMR (400
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MHz, CD3OD) δ 8.40 (d, J = 1.3 Hz, 1H), 8.34 (dd, J = 8.4 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 4.63
(t, J = 7.8 Hz, 2H), 4.43 (s, 3H), 2.93 (t, J = 7.1 Hz, 2H), 2.24-2.16 (m, 2H), 2.02-1.95 (m, 2H),
1.68 (s, 6H).

13

C NMR (101 MHz, CD3OD) δ 201.1, 167.9, 145.3, 143.6, 133.7, 132.3, 125.6,

116.8, 56.2, 51.0, 27.3, 23.2, 22.6.

N-(2-Hydroxyethyl)-2-(4-nitro-1H-imidazol1-yl)acetamido-ICG, (1)

Indolium salt 6 (3.85 g, 11.3 mmol) and N-[5-(Phenylamino)-2,4-pentadienylidene]aniline
monohydrochloride (1.79 g, 6.29 mmol) was added to a 100 mL round-bottomed flask. Then acetic
anhydride (60 mL) and glacial acetic acid (36 mL) were added and stirred at room temperature.
This solution was treated with sodium acetate (1.64 g) and then heated to reflux for 45 min. The
blue solution was then cooled to room temperature before being poured into hot anhydrous ether
(150 mL). The solution was cooled in the refrigerator overnight, and the green precipitate was
vacuum filtrated and washed with ether. The product was recrystallized from a 1:4 mixture of
water and propanol to yield 1 (2.94 g, 3.85 mmol, 68 %) as a green powder.20 1H NMR (400 MHz,
DMSO-d6) δ 12.96 (bs, 1H), 8.08 (d, J = 7.3 Hz, 2H), 7.97 (d, J = 7.3, 2H), 7.84 (m, 2H), 7.52 (d,
J = 9.1 Hz, 2H), 7.47 (s, 1H), 6.48 (m, 4H), 4.15-4.06 (m,4H), 3.86 (s, 3H), 1.73 (s, 8H), 1.63 (s,
12H). 13C NMR (101 MHz, DMSO-d6) δ 167.7, 166.6, 147.1, 142.0, 131.3, 125.6, 124.0, 123.8,
52.8, 51.4, 49.4, 41.8, 27.7, 26.8, 23.2.
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Tert-butyl piperazine-1-carboxylate

A solution of di-tert-butyl dicarbonate (3.80 g, 17.4 mmol) in CH2Cl2 (50 mL) was added dropwise
to a stirring solution of piperazine (3.00 g, 34.8 mmol) in CH2Cl2 (60 mL) at room temperature
and stirred for 16 h. The solvent were removed under reduced pressure and the residue dissolved
in water (50 mL). The aqueous solution was extracted with methylene chloride (4 × 75 mL) and
all the organic extractions were combined, dried over anhydrous magnesium sulfate, and
concentrated to get tert-butyl piperazine-1-carboxylate as a white solid (1.5 g, 8.05 mmol, 34.7
%).24 1H NMR (400 MHz, CDCl3) δ 3.37 (m, 2 H), 2.79 (m, 2 H), 1.72 (bs, 1 H), 1.44 (s, 9 H)
ppm. 13C NMR (101 Hz, CDCl3) δ 154.3, 79.8, 45.6, 44.5, 28.8 ppm.

Tert-butyl 4-(2-bromoacetyl) piperazine-1-carboxylate, (8)

Triethylamine (2.8 mL, 20.3 mmol) was added to a stirring solution of tert-butyl piperazine-1carboxylate (3.44 g, 18.4 mmol) in dry dichloromethane (100 mL) at 0°C and stirred for 15 min.
Bromoacetyl bromide (1.8 mL, 20.3 mmol) was added dropwise at 0°C, and the resulting mixture
was stirred at room temperature overnight. Reaction progress was monitored by TLC, and after
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disappearance of the starting material, the mixture was concentrated and purified via column
chromatography (hexanes:ethyl acetate 20%) to give tert-butyl 4-(2-bromoacetyl) piperazine-1carboxylate (8, 3.36 g, 10.9 mmol, 59.3%) as a white solid. Mp: 95-97°C.24 1H NMR (400 MHz,
Chloroform-d) δ 3.86 (s, 2H), 3.63–3.56 (m, 2H), 3.56–3.46 (m, 4H), 3.46–3.41 (m, 2H), 1.47 (s,
9H). 13C NMR (101 MHz, Chloroform-d) δ 165.6, 154.6, 80.6, 46.7, 42.1, 28.5, 25.7.

Tert-butyl 4-(2-(2-nitro-1 H-imidazol-1-yl)acetyl) piperazine-1-carboxylate, (9)

Commercially available 2-nitroimidazole (0.100 g, .885 mmol) was dissolved in 2 mL of freshly
distilled DMF, under N2, and cooled to 0°C. Sodium hydride (0.042 g, .106 mmol) was added to
the reaction and stirred for 30 min before a dropwise addition of tert-butyl 4-(2bromoacetyl)piperazine-1-carboxylate (8, 0.272 g, .885 mmol) dissolved in 2 mL of DMF. The
mixture was slowly warmed to room temperature and stirred overnight. The reaction was
concentrated under reduced pressure and then addition of 10 mL of water caused a white
precipitate to form. The solid was filtered and dried under reduced pressure overnight to afford
tert-butyl 4-(2-(4-nitro-1Himidazol-1-yl)acetyl)piperazine-1-carboxylate (9, 0.280 g, .825 mmol,
93%). Mp: 197-199°C.27 1H NMR (400 MHz, Chloroform-d) δ 7.20 (s, 1H), 7.07 (s, 1H), 5.23 (s,
2H), 3.65–3.55 (m, 4H), 3.54–3.44 (m, 4H), 1.48 (s, 9H). 13C NMR (101 MHz, Chloroform-d) δ
163.5, 154.5, 145.3, 128.3, 127.2, 80.7, 50.9, 45.1, 42.5, 28.5.
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tert-Butyl 4-(2-(4-nitro-1H-imidazol-1-yl)acetyl)piperazine-1- carboxylate

Commercially available 4-nitroimidazole (0.55 g, 4.9 mmol) was dissolved in 2 mL of freshly
distilled DMF, under N2, and cooled to 0°C. Sodium hydride (0.14 g, 5.9 mmol) was added to the
reaction and stirred for 30 min before a dropwise addition of tert-butyl 4-(2bromoacetyl)piperazine-1-carboxylate (1.50 g, 4.9 mmol) dissolved in 2 mL of DMF. The mixture
was slowly warmed to room temperature and stirred overnight. Addition of 10 mL of water caused
a white precipitate to form. The solid was filtered and dried under reduced pressure overnight to
afford tert-butyl 4-(2-(4-nitro-1Himidazol-1-yl)acetyl)piperazine-1-carboxylate (1.26 g, 3.7
mmol, 76%).29 Mp: 197-199 °C. 1H NMR (400 MHz, CDCl3) δ 7.82-7.81 (d, J = 1.5 Hz, 1H),
7.45-7.44 (d, J = 1.4 Hz, 1H), 4.86 (s, 2H), 3.65-3.63 (m, 2H), 3.56-3.54 (m, 2H), 3.50-3.47 (m,
4H), 1.48 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 163.1, 154.6, 148.2, 137.1, 120.9, 81.1, 48.8,
45.0, 42.5, 28.5. HRMS (ESI-TOF): [M+H] Calc'd for C14H22N5O5 m/z 340.1621. Found m/z
340.1607.29
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tert-Butyl 4-(2-(1H-imidazol-1-yl)acetyl)piperazine-1- carboxylate

Commercially available imidazole (0.33 g, 4.9 mmol) was dissolved in 2 mL of freshly distilled
DMF, under N2, and cooled to 0°C. Sodium hydride (0.14 g, 5.9 mmol) was added to the reaction
and stirred for 30 min before a dropwise addition of tert-butyl 4- (2-bromoacetyl)piperazine-1carboxylate (1.50 g, 4.9 mmol) dissolved in 2 mL of DMF. The mixture was slowly warmed to
room temperature and stirred overnight. Addition of 10 mL of water caused a white precipitate to
form. The solid was filtered and dried under reduced pressure overnight to afford tert-butyl 4-(2(1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (0.97 g, 3.3 mmol, 67%).29 Mp: 147-149°C. 1H
NMR (400 MHz, Chloroform-d) δ 7.50 (s, 1H), 7.10 (s, 1H), 6.95 (s, 1H), 4.78 (s, 2H), 3.61 (d, J
= 5.3 Hz, 2H), 3.49–3.39 (m, 6H), 1.47 (s, 9H).

13

C NMR (101 MHz, Chloroform-d) δ 164.9,

154.5, 138.1, 129.9, 120.1, 80.8, 48.2, 45.1, 42.2, 28.5. HRMS (ESI þ TOF): [M þ H] þ Calc'd for
CH23N4O3 m/z 295.1770. Found, m/z 295.1751.
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4-(2-(2-Nitro-1H-imidazole-1-yl)acetyl)piperazin-1-ium trifluoroacetate, (10)

A solution of trifluoroacetic acid (1 mL) and chloroform (6 mL) was cooled to 0°C under a nitrogen
atmosphere. tert-Butyl 4-(2-(2-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (0.280 g,
0.823 mmol) dissolved in 3 mL of chloroform was added dropwise via cannula. The solution was
slowly warmed to room temperature and stirred overnight. The reaction was concentrated in vacuo
to a crude oil that was crystalized from ethyl acetate. The product was isolated by vacuum filtration
and dried under reduced pressure to yield 4-(2-(2-nitro-1H-imidazole-1-yl)acetyl)piperazin-1-ium
tri-fluoroacetate (10, 0.214 g, 0.636 mmol, 77%).27 1H NMR (400 MHz, D2O) δ7.58 (s, 1 H), 7.40
(s, 1 H), 5.68 (s, 2 H), 4.08 (t, J ¼ 4 Hz, 2 H), 4.03 − 4.00 (m, 2 H), 3.59 (t, J ¼ 4 Hz, 2 H), 3.503.47 (m, 2 H); 13C NMR (100 MHz, D2O) δ166.9, 163.3, 162.9, 162.6, 149.0, 129.2, 128.4, 121.0,
118.1, 115.2, 112.2, 51.3, 43.3, 42.2, 39.6; HRMS Calcd C10H14F3N5O5 240.1096, found
240.1149.
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4-(2-(4-Nitro-1H-imidazole-1-yl)acetyl)piperazin-1-ium trifluoroacetate, (11)

A solution of trifluoroacetic acid (1 mL) and chloroform (6 mL) was cooled to 0 C under a nitrogen
atmosphere. tert-Butyl 4-(2-(4- nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (0.250 g,
0.73 mmol) dissolved in 3 mL of chloroform was added dropwise via cannula. The solution was
slowly warmed to room temperature and stirred overnight. The reaction was concentrated in vacuo
to a crude oil that was crystalized from ethyl acetate. The product was isolated by vacuum filtration
and dried under reduced pressure to yield 4-(2-(4-nitro-1H-imidazole-1-yl)acetyl)piperazin-1-ium
tri- fluoroacetate 9b (0.193 g, 0.55 mmol, 74%).29 mp: 228e229 C; 1 H NMR (400 MHz, D2O) d
8.20 (bs, 1H), 7.79 (bs, 1H), 5.32 (s, 2H), 3.92e3.89 (m, 4H), 3.47e3.37 (m, 4H); 13C NMR (100
MHz, CDCl3) d 166.6, 163.4, 163.0, 162.5, 162.0, 146.7, 138.7, 123.5, 118.7, 49.0, 42.9, 41.7,
39.2; HRMS (ESI-TOF): [M þ H] þ Calc'd for C9H14N5O3 m/ z 240.1096. Found, m/z 240.1100.
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4-(2-(1H-Imidazole-1-yl)acetyl)piperazin-1-ium trifluoroacetate, (13)

A solution of trifluoroacetic acid (1 mL) and chloroform (6 mL) was cooled to 0 C under a nitrogen
atmosphere. tert-Butyl 4-(2- (1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (0.250 g, 0.85
mmol) dissolved in 3 mL of chloroform was added dropwise via cannula. The reaction mixture
was slowly warmed to room temperature, stirred overnight, and concentrated in vacuo to a crude
oil that was crystalized from ethyl acetate. The product was isolated by vacuum filtration and dried
under reduced pressure to yield 4-(2-(1H-imidazole-1-yl)acetyl)piperazin-1-ium trifluoroa cetate
9a (0.161 g, 0.52 mmol, 61%).29 mp: 129e130 C; 1 H NMR (400 MHz, D2O) d 8.76 (s, 1H), 7.53
(s, 1H), 7.46 (s, 1H), 5.43 (s, 2H), 3.90e3.87 (m, 4H), 3.44e3.41 (m, 2H), 3.36e3.34 (m, 2H); 13C
NMR (100 MHz, CDCl3) d 166.0, 163.4, 163.0, 136.5, 123.6, 119.8, 118.0, 115.1, 50.1, 42.9,
41.8, 41.7, 39.3; HRMS (ESI þ TOF): [MCF3COO þ H] Calc'd for C9H15N4O m/z 195.1246.
Found, m/z 195.1231.
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Sodium

4-((Z)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(4-(2-(2-nitro-

yl)acetyl)cyclo-hexane-1-carbonyl)-1-(4trien-1-ylidene)-

1H-imidazol-1-

sulfonatobutyl)-3H-indol-1-ium-2-yl)hepta-2,4,6-

3,3-dimethyl-5-(4-(2-(2-nitro-1H-imidazol-1-yl)acetyl)

cyclohexane-1-

carbonyl)indolin-1-yl)butane-1-sulfonate, (3)

A stirred solution of ICG bis (carboxylic acid) (1, 0.139 g, 0.182 mmol) in dry DMF (2 mL) at
0°C was treated with benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
(0.208 g, 0.400 mmol), 1-hydroxybenzotriazole (0.054 g, 0.400 mmol), and diisopropylethylamine
(69.9 μL, 0.400 mmol) in that order, and stirred at 0°C for 15 min. At this time, 2-(2-nitro-1Himidazol-1-yl)-1-(piperazin-1-yl)ethanone, TFA salt (10, 0.135 g, 0.400 mmol) was added and the
resulting mixture stirred at room temperature for 48 h. The DMF was evaporated and the resulting
solid was purified using C18 reverse phase column chromatography to yield compound 3 as an
amorphous green solid (0.044 g, 0.037 mmol, 20.0%).27 1H NMR (400 MHz, D2O): δ7.84 (t, J ¼
12 Hz, 2 H), 7.57 (s, 2 H), 7.45 (bs, 5 H), 7.35–7.33 (m, 2 H), 7.27 (s, 2 H), 6.57 (t, J ¼ 12 Hz, 2
H), 6.29 (d, J ¼ 12 Hz, 2 H), 5.57 − 5.51 (m, 4 H), 4.15 (bs, 4 H), 3.86 − 3.52 (m, 16 H), 2.97 (t,
J ¼ 8 Hz, 4 H), 1.99 − 1.97 (m, 4 H), 1.91 − 1.87 (m, 4 H), 1.61 (bs, 12 H). HRMS Calcd protonated
formula C55H67N12O14S2 1183.4341, found 1183.4399.
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Sodium

4-((Z)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(4-(2-(4-nitro-

yl)acetyl)cyclo-hexane-1-carbonyl)-1-(4trien-1-ylidene)-

1H-imidazol-1-

sulfonatobutyl)-3H-indol-1-ium-2-yl)hepta-2,4,6-

3,3-dimethyl-5-(4-(2-(4-nitro-1H-imidazol-1-yl)acetyl)

cyclohexane-1-

carbonyl)indolin-1-yl)butane-1-sulfonate, (12)

A total of (0.150 g, 0.197 mmol) of 2 was dissolved in 1 mL freshly distilled DMF under N2 and
cooled to 0 C. The reaction was then charged with pyBop (0.220 g, 0.0423 mmol), HOBt (0.065
g, 0.423 mmol), DIPEA (0.074 mL, 0.423 mmol) and stirred for 15 min before the addition 4nitroimidazole piperazine TFA (0.149 g, 0.423 mmol). The solution was warmed to room
temperature and let stir overnight. The solvent extensively removed and the resulting sold was
washed with EtOAc (15 mL), chloroform (15 mL), and acetonitrile (15 mL) before being
recrystallized from methanol/ diethyl ether. The crude material was purified by C18 reverse phase
chromatography to yield 6 as a green solid (0.049 g, 0.041 mmol, 21%).29 mp: decomposed >250
C; 1 H NMR (400 MHz, D2O) d 8.26 (s, 2H), 7.92 (t, J ¼ 12 Hz, 2H), 7.81 (s,2H), 7.75 (s, 2H),
7.69 (s, 2H), 7.72e7.48 (m, 4H), 6.65e6.59 (m, 2H), 6.51 (d, J ¼ 8 Hz, 2H), 5.21 (bs, 4H), 4.11
(m, 4H), 3.58 (m, 16H), 1.80e1.71 (m, 8H), 1.68 (s, 12H); HRMS (ESI-TOF): [M-Na]- Calc'd for
C55H65N12O14S2 m/z 1181.4185. Found, m/z 1181.4174.
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Sodium 4-((Z)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(4-(2-(1Himidazol-1-yl)acetyl)cyclohexane1-carbonyl)-1-(4-

sulfonatobutyl)-3H-indol-1-ium-2-yl)hepta-2,4,6-trien-1-ylidene)-

dimethyl-5-(4-(2-(1H-imidazol-1-yl)acetyl)cyclohexane-1-

3,3-

carbonyl)indolin-1-yl)butane-1-

sulfonate, (14)

A total of (0.301 g, 0.39 mmol) of 2 was dissolved in 1 mL freshly distilled DMF under N2 and
cooled to 0 C. The reaction was then charged with pyBop (0.45 g, 0.86 mmol), HOBt (0.117 g,
0.86 mmol), DIPEA (0.200 mL, 0.1.18 mmol) and stirred for 15 min before the addition imidazole
piperazine TFA (0.266 g, 0.86 mmol). The solution was warmed to room temperature and let stir
overnight. The solvent extensively removed and the resulting sold was washed with EtOAc (15
mL), chloroform (15 mL), and acetonitrile (15 mL) before being recrystallized from
methanol/diethyl ether. The crude material was purified by C18 reverse phase chromatography to
yield 5 as a green solid (0.065 g, 0.0058 mmol, 15%).29 mp: decomposed >250 C; 1 H NMR (400
MHz, D2O) d 7.92 (t, J ¼ 12 Hz, 2H), 7.69 (s,2H), 7.51 (d, J ¼ 16 Hz, 6H), 7.06 (s, 2H), 7.05e6.95
(m, 1H), 6.87 (s, 2H), 6.62 (t, J ¼ 12 Hz, 2H), 6.50 (d, J ¼ 12, 2H), 5.06 (s, 4H), 4.10 (bs, 4H),
3.57 (bs, 16H), 1.77 (m, 8H), 1.67 (s, 12H); HRMS (ESITOF): [M-Na]- Calc'd for
C55H67N10O10S2 m/z 1091.4483. Found, m/z 1091.4456.
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Sodium 4-[2-[(1E,3E,5Z)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)- indol-2-ylidene]penta-1,3dienyl]-1,1-dimethylindol-3-ium-3-yl]- butane-1-sulfonate, (18)

A vigorously stirred solution of 3-(5-carboxy-2,3,3-trimethyl-3H-indolium-1-yl)propane-1sulfonate (6, 0.14 g, 0.41 mmol) and 7 (0.05 g, 0.19 mmol) in acetic anhydride (1 mL) and acetic
acid (0.5 mL) was treated with sodium acetate (0.054 g, 0.66 mmol) and heated at reflux (120 °C)
for 45 min. The reaction mixture was cooled to ambient temperature and anhydrous diethyl ether
(5 mL) was added. The resulting precipitate was isolated by vacuum filtration to give a crude solid
that was recrystallized (methanol : water) to give 8 as a blue solid (0.09 g, 0.12 mmol, 63%);22
mp: decomposition at 287 °C; 1 H NMR (400 MHz, CD3OD) δ 12.92 (bs, 2H), 8.43 (t, J = 13 Hz,
2H), 8.17 (s, 2H), 8.00 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 6.71 (t, J = 12.4 Hz, 1H), 6.50
(d, J = 13.7 Hz, 2H), 4.15 (bs, 4H), 1.18–1.76 (m, 8H), 1.73 (s, 12H).31 13C NMR (100 MHz,
CD3OD) δ 175.7, 169.2, 156.8, 147.4, 142.8, 132.3, 128.7, 128.6, 124.6, 112.0, 106.0, 51.7, 50.4,
45.1, 27.9, 27.2, 23.5; 13C NMR (100 MHz, MeOD) d 175.7, 169.2, 156.8, 147.4, 142.8, 132.3,
128.7128.6, 124.6, 112.0, 106.0, 51.7, 50.4, 45.1, 27.9, 27.2, and 23.5 ppm. HRMS (TOF): [M +
H]+ Calc’d for C35H43N2O10S2 m/z 715.2359. Found, m/z 715.2321.
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Sodium

4-((Z)-2-((2E,4E)-5-(3,3-dimethyl-5-(4-(2-(2-nitro-1Himidazol-1-yl)acetyl)-

piperazine-1-carbonyl)-1-(4-sulfonatobutyl)ylidene)-3,3-dimethyl-5-

3H-indol-1-ium-2-yl)penta-2,4-dien-1-

(4-(2-(2-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-

carbonyl)indolin- 1-yl)butane-1-sulfonate, (15)

A total of 78 mg (0.149 mmol) of PyBOP was added to a stirring solution of bis-(carboxylic acid)
8 (50 mg, 0.0068 mmol) in dry DMF (2 mL) at 0 °C. This solution was subsequently treated with
HOBt (hydroxybenzotriazole, 20 mg, 0.149 mmol), followed by diisopropylethylamine (DIPEA,
0.026 mL, 0.149 mmol). This mixture was stirred for 15 min before the addition of 2nitroimidazole piperazine 11 (54 mg, 0.149 mmol) followed by stirring at room temperature for
48 h in the dark. The DMF was removed by air-drying to yield a thick blue oil and further
concentrated in vacuo overnight. The crude mixture was recrystallized from methanol (15 mL) via
the dropwise addition of diethyl ether (50 mL), and the resulting blue solid was washed with
acetonitrile (2 × 25 mL), ethyl acetate (2 × 25 mL), and chloroform (2 × 25 mL). The crude was
purified by C18 reverse phase column chromatography (H2O : MeOH) to yield 12 (25 mg, 0.021
mmol, 31%) as a blue solid.31 mp: decomposed to black residue >250 °C; 1 H NMR (400 MHz,
D2O) d 8.17 (m, 3H), 7.71 (s, 2H), 7.63 (d, J = 8 Hz, 2H), 7.55 (s, 2H), 7.50 (d, J = 8, 1H), 7.38
(s, 1H), 6.76 (t, 2H), 6.47 (d, 2H), 5.64 (bs, 4H), 4.27 (bs, 4H), 3.66–4.05 (bs, 16H), 3.06 (t, 4H),
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2.10 (m, 4H), 1.97 (m, 2H), 1.80 (bs, 9H), 1.44 (m, 3H); HRMS (ESI-TOF): [M − Na]− Calc’d for
m/z C53H63N12O14S2 1155.4034. Found, m/z 1155.4028.
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